documents incorporated reference specified portions registrant 's proxy statement filed commission pursuant regulation connection registrant 's annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrant 's common stock held executive officers directors stockholders whose ownership exceeds registrant 's common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrantgilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ii item market registrant 's common equity related stockholder matters issuer purchases equity securities item selected financial data item management 's discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences sovaldi truvada harvoni complera eviplera stribild viread letairis ranexa ambisome zydelig emtriva tybost hepsera vitekta cayston volibris rapiscan atripla registered trademark belonging bristolmyers squibb gilead sciences llc lexiscan registered trademark belonging astellas us llc macugen registered trademark belonging eyetech inc sustiva registered trademark bristolmyers squibb pharma company tamiflu registered trademark belonging hoffmannla roche inc report also includes trademarks service marks trade names companiesthis annual report including section entitled management 's discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forward looking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forwardlooking statements various reasons including identified risk factors beginning given risks uncertainties cautioned place undue reliance forward looking statements forwardlooking statements included report made date hereof except required federal securities laws rules regulations securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise part item business overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world gilead 's primary areas focus include human immunodeficiency virus hiv liver diseases chronic hepatitis c virus hcv infection chronic hepatitis b virus hbv infection oncology inflammation serious cardiovascular respiratory conditions operations countries worldwide headquarters foster city california continue add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategy highlights past year brought bestinclass drugs market advanced standard care offering enhanced modes delivery convenient treatment regimens improved resistance profiles reduced side effects greater efficacy liver diseases area received approval us food drug administration fda european commission harvoni first oncedaily single tablet regimen treatment hcv genotype infection adults harvoni combines nsa inhibitor ledipasvir nucleotide analog polymerase inhibitor sofosbuvir approved tradename sovaldi december approval harvoni represents significant improvement treatment paradigm majority hcv genotype infected patients eliminates need pegylated interferon pegifn injections ribavirin rbv clinical studies harvoni demonstrated high cure rates eight twelve weeks hiv area submitted new drug application nda oncedaily single tablet regimen containing elvitegravir mg cobicistat mg emtricitabine mg tenofovir alafenamide taf mg ecftaf treatment hiv infection adults also received approval united states tybost cobicistat vitekta elvitegravir mg mg component stribild oncology area received approval zydelig idelalisib firstinclass targeted oral inhibitor pik delta combination rituximab treatment certain patients chronic lymphocytic leukemia cll small lymphocytic lymphoma sll follicular lymphoma fl common type indolent nonhodgkin 's lymphoma inhl also advanced research development pipeline active clinical studies end phase clinical trials addition advancing treatment options across therapeutic areas also enabled access medications people need around world signed nonexclusive license agreements seven indiabased generic drug companies manufacture sovaldi harvoni distribution developing countries also announced agreement medicines patent pool mpp mpp sublicense taf generic drug companies india china manufacturing distribution developing countries efforts extend ongoing programs enable access people resourcelimited parts world diseases like hiv hcv affect highest numbers individuals hiv program goal ensure hiv patients choose single tablet regimen right single tablet regimens allow patients adhere fully suppressive course therapy easily consistently critical successful management disease focused development new hiv medicines coformulations products complete regimens launch stribild united states europe compleraeviplera emtricitabine mgrilpivirine mgtenofovir disoproxil fumarate mg atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg three single tablet regimens available treatment hiv advanced development new single tablet regimen ecftaf treatment hiv infection adults marketing applications ecftaf pending united states european union fda established target review date prescription drug user fee act november phase clinical studies demonstrated patients taking ecftaf experienced favorable renal bone safety compared stribild patients also conducting phase clinical trials fixeddose coformulation taf emtricitabine agreement janssen rd ireland janssen formerly tibotec pharmaceuticals evaluating single tablet regimen taf cobicistat darunavir emtricitabine treatment hiv infection also amended agreement janssen collaborate single tablet regimen rilpivirine emtricitabine taf received fda approval tybost pharmacokinetic enhancer boosts blood levels certain hiv medicines tybost indicated boosting agent hiv protease inhibitors atazanavir mg daily darunavir mg daily part antiretroviral combination therapy adults hiv infection fda also approved vitekta integrase inhibitor treatment hiv infection adults without known mutations associated resistance elvitegravir vitekta indicated use part hiv treatment regimens include ritonavirboosted protease inhibitor liver diseases goal advance treatment options standard care underserved hcv market received approval sovaldi treatment hcv component combination antiviral treatment regimen sovaldis efficacy established patients hcv genotypes infection united states europe genotypes infection europe including hepatocellular carcinoma meeting milan criteria awaiting liver transplantation hcvhiv coinfection compared prior standard care weeks sovaldi shortened duration treatment weeks reduced completely eliminated need pegifn injections certain viral genotype populations received fda european commission approval harvoni first oncedaily single tablet regimen treatment hcv genotype infected patients prevalent genotype united states harvoni combines nsa inhibitor ledipasvir sofosbuvir indicated eight week treatment duration depending prior treatment history cirrhosis status baseline viral load eliminates need pegifn rbv challenging take tolerate marketing applications sofosbuvir fixeddose combination ledipasvir sofosbuvir pending japan long term goal develop oral therapy hcv patients across genotypes fixeddose combination sofosbuvir gs pangenotypic nsa inhibitor currently phase clinical trials also evaluating single tablet regimen gs gs sofosbuvir phase trials potential treatment hcv genotype infected patients four six weeks evaluating taf treatment hbv completed enrollment phase clinical trials also conducting phase clinical studies gs tarmogen cell immunity stimulator gs oral tlr agonist evaluated potential cure hbv evaluating simtuzumab nonalcoholic steatohepatitis nash phase clinical trials december also entered agreement phenex pharmaceuticals ag phenex acquired phenexs farnesoid x receptor fxr program comprised small molecule fxr agonists treatment liver diseases including nash oncology inflammation oncology area received fda european commission approval zydelig idelalisib firstinclass pik delta inhibitor combination rituximab treatment patients certain blood cancers fourth quarter also initiated phase clinical studies evaluate idelalisib treatment patients inhl frontline treatment patients cll december entered exclusive license agreement ono pharmaceutical co ltd development commercialization ono known gs oral brutons tyrosine kinase inhibitor treatment bcell malignancies diseases cardiovascular released positive results ambition study randomized doubleblind multicenter study firstline combination therapy letairis ambrisentan tadalafil patients pulmonary arterial hypertension conducted collaboration glaxosmithkline plc ambition firstline treatment pulmonary arterial hypertension combination ambrisentan mg tadalafil mg reduced risk clinical failure percent compared pooled ambrisentan tadalafil monotherapy arm combination also statistically significant versus individual ambrisentan tadalafil monotherapy groups primary endpoint filed supplemental nda united states cover use ambrisentan combination tadalafil products hiv stribild oral formulation dosed day treatment hiv infection treatmentnaive adults stribild third complete single tablet regimen treatment hiv fixeddose combination antiretroviral medications vitekta tybost viread emtriva emtricitabine stribild approved fda august european commission may compleraeviplera oral formulation dosed day treatment hiv infection adults product marketed united states complera europe eviplera second complete single tablet regimen treatment hiv fixeddose combination antiretroviral medications viread emtriva janssen 's nonnucleoside reverse transcriptase inhibitor edurant rilpivirine atripla oral formulation dosed day treatment hiv infection adults atripla first single tablet regimen hiv intended standalone therapy combination antiretrovirals fixeddose combination antiretroviral medications viread emtriva bristolmyers squibb company 's bms 's nonnucleoside reverse transcriptase inhibitor sustiva efavirenz truvada emtricitabine tenofovir disoproxil fumarate oral formulation dosed day part combination therapy treat hiv infection adults fixeddose combination antiretroviral medications viread emtriva fda also approved truvada combination safer sex practices reduce risk sexually acquired hiv infection adults high risk strategy called preexposure prophylaxis prep viread oral formulation nucleotide analog reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection patients two years age older european commission approved use viread combination antiretroviral agents treatment hiv infected adolescent patients aged two less years nucleoside reverse transcriptase inhibitor resistance toxicities precluding use firstline pediatric agents viread also approved treatment chronic hbv emtriva oral formulation nucleoside analog reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults united states europe emtriva also available oral solution approved part combination therapy treat hiv infection children tybost pharmacokinetic enhancer dosed day boosts blood levels certain hiv medicines tybost indicated boosting agent hiv protease inhibitors atazanavir darunavir part antiretroviral combination therapy adults hiv infection vitekta oral formulation integrase inhibitor dosed day part combination therapy treat hiv infection adults without known mutations associated resistance elvitegravir active ingredient vitekta vitekta indicated use part hiv treatment regimens include ritonavirboosted protease inhibitor liver diseases harvoni oral formulation nsa inhibitor nucleotide analog polymerase inhibitor dosed day treatment hcv genotype infection adults harvoni approved fda october european commission november europe harvoni also indicated certain patients hcv genotype infection hcv genotype infection cirrhosis andor prior treatment failure hcvhiv coinfection sovaldi oral formulation nucleotide analog polymerase inhibitor dosed day treatment hcv component combination antiviral treatment regimen sovaldi approved fda december european commission january sovaldis efficacy established patients hcv genotypes infection united states europe genotypes infection europe including hepatocellular carcinoma meeting milan criteria awaiting liver transplantation hcvhiv coinfection viread oral formulation nucleotide analog reverse transcriptase inhibitor dosed day treatment chronic hbv adults compensated decompensated liver disease licensed glaxosmithkline inc gsk rights commercialize viread treatment chronic hbv china japan saudi arabia european commission approved use viread treatment chronic hbv infection adolescent patients aged less years compensated liver disease evidence immune active disease viread also approved treatment hiv infection hepsera adefovir dipivoxil oral formulation nucleotide analog polymerase inhibitor dosed day treat chronic hbv patients years age older licensed gsk rights commercialize hepsera treatment chronic hbv asia pacific latin america certain territories oncology zydelig firstinclass pik delta inhibitor combination rituximab treatment certain blood cancers july fda approved zydelig relapsed cll fl sll september european commission approved zydelig cll fl cardiovascular letairis ambrisentan oral formulation endothelin receptor antagonist era indicated treatment pulmonary arterial hypertension pah world health organization group patients class ii iii symptoms improve exercise capacity delay clinical worsening sublicensed gsk rights ambrisentan marketed gsk volibris ambrisentan pah territories outside united states ranexa ranolazine extendedrelease tablet treatment chronic angina licensed menarini international operations luxembourg sa rights ranexa territories outside united states lexiscanrapiscan regadenoson injection indicated use pharmacologic stress agent radionuclide myocardial perfusion imaging mpi test detects characterizes coronary artery disease patients unable undergo adequate exercise stress astellas us llc astellas exclusive rights manufacture sell regadenoson name lexiscan united states rapidscan pharma solutions inc rps holds exclusive right manufacture sell regadenoson name rapiscan europe certain territories outside united states receive royalties astellas rps sales territories respiratory cayston aztreonam inhalation solution inhaled antibiotic treatment respiratory systems cystic fibrosis cf patients seven years age older pseudomonas aeruginosa p aeruginosa tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approved treatment influenza children adults countries including united states japan european union tamiflu also approved prevention influenza children adults united states japan european union developed tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us royalties based percentage net sales tamiflu ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat serious invasive fungal infections caused various fungal species adults corporate partner astellas pharma us inc promotes sells ambisome united states canada promote sell ambisome europe australia new zealand macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelated macular degeneration macugen developed eyetech inc eyetech using technology licensed us promoted united states valeant pharmaceuticals inc valeant acquired eyetech valeant holds exclusive rights manufacture sell macugen united states pfizer inc pfizer holds exclusive right manufacture sell macugen rest world receive royalties valeant pfizer based worldwide sales macugen sales antiviral products include products hiv liver diseases areas described billion billion billion represented total revenues total revenues total revenues sales products billion billion billion represented total revenues total revenues see item management 's discussion analysis item note segment information consolidated financial statements included annual report commercialization distribution us international commercial sales operations marketing subsidiaries argentina australia austria belgium brazil canada czech republic denmark finland france germany greece hong kong india ireland israel italy japan malaysia mexico netherlands new zealand norway panama poland portugal russia singapore slovakia south africa south korea spain sweden switzerland taiwan turkey united arab emirates united kingdom united states products marketed commercial teams andor conjunction thirdparty distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant thirdparty distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory sell distribute sovaldi atripla truvada harvoni complera stribild viread emtriva ranexa zydelig tybost hepsera united states exclusively wholesale channel product sales three large wholesalers cardinal health inc mckesson corp amerisourcebergen corp accounted total revenues years ended december combined basis wholesalers accounted approximately product sales united states approximately total worldwide revenues letairis cayston distributed exclusively specialty pharmacies specialty pharmacies dispense medications complex chronic conditions require high level patient education ongoing counseling sell distribute stribild eviplera atripla truvada sovaldi harvoni viread hepsera emtriva vitekta tybost ambisome europe countries outside united states product approved either commercial teams thirdparty distributors corporate partners us patient access make priority increase access medicines people benefit regardless ability pay united states us patient assistance programs help make therapies accessible uninsured individuals need financial assistance also support programs unable afford copayments associated health insurance programs half patients taking hiv medicines united states already receive federal state programs substantially discounted prices long history working state aids drug assistance programs adaps provide lower pricing hiv medicines price freeze instituted adaps extended end providing important support critical programs evolve changing us healthcare environment access developing world gilead access program established certain products treatment hiv hbv hcv visceral leishmaniasis available substantially reduced prices developing world deliver medicines countries working regional business partners distribute brand name truvada viread prices based country 's ability pay represent little profit us also partnerships indiabased companies expand access generic versions hiv hcv medications leastdeveloped countries world see work closely world health organization nongovernmental organizations provide ambisome treatment leishmaniasis preferential price resource limited settings support numerous clinical studies investigating role ambisome treat visceral cutaneous leishmaniasis developing countries collaborations organizations drugs neglected diseases initiative mdecins sans frontires also support clinical research studies aimed identifying best treatment course visceral leishmaniasis donated ambisome support clinical studies assessing combination therapies costeffectiveness multiple visceral leishmaniasis treatment interventions december signed partnership agreement world health organization donate vials ambisome five years donation used treat patients resource limited countries also support many clinical studies donation products help define best treatment strategies developing world countries example donated tenofovir centre aids programme research south africa caprisa microbicide trial assessed effectiveness safety tenofovirbased microbicide gel prevention hiv infection south african women also provide drugs number innovative international studies investigating whether viread truvada prevent hiv transmission among atrisk uninfected adults hiv prevention strategy called preexposure prophylaxis prep fda approval prep truvada became first agent indicated uninfected individuals reduce risk acquiring hiv sex also entered number collaborations related access products developing world include pharmachem acquisition company ltd pharmachem pharmachem one commercial manufacturing partners established facility bahamas manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients atripla truvada including resource limited countries cooperative effort pharmachem grand bahama port authority aspen pharmacare holdings ltd aspen entered nonexclusive manufacturing distribution agreement aspen providing manufacture distribution truvada viread treatment hiv infection certain developing world countries included gilead access program amended agreement aspen amended agreement aspen retained right manufacture distribute truvada viread treatment hiv infection developing world countries aspen right purchase truvada viread unlabeled bottles us distribution countries also right manufacture truvada viread using active pharmaceutical ingredient purchased aspen suppliers approved us aspen also granted right manufacture distribute generic versions emtricitabine tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen required pay us royalties net sales truvada viread well royalties net sales generic versions tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination generic versions emtricitabine manufactured distributed aspen licenses generic manufacturers entered nonexclusive license agreements indian generic manufacturers granting rights produce distribute generic versions tenofovir disoproxil fumarate treatment hiv infection low income countries around world include india many countries gilead access program agreements require generic manufacturers meet certain national international regulatory quality standards include technology transfers enable expeditious production large volumes high quality generic versions tenofovir disoproxil fumarate addition agreements allow manufacture commercial quantities active pharmaceutical ingredient finished product expanded nonexclusive license agreements increase number countries included license also include rights cobicistat elvitegravir including generic versions combination product containing four active ingredients cobicistat elvitegravir tenofovir disoproxil fumarate emtricitabine also included nonexclusive license agreements ability manufacture distribute generic versions tenofovir disoproxil fumarate treatment hbv countries authorized sell generic versions tenofovir disoproxil fumarate hiv announced new collaborations indian partners produce distribute generic emtricitabine developing world including single tablet regimens containing emtricitabine fixeddose combinations emtricitabine co formulated hiv medicines granted certain indian partners direct licenses produce distribute generic tenofovir alafenamide developing world including single tablet regiments containing emtricitabine fixeddose combinations tenofovir alafenamide emtricitabine coformulated hiv medicines also entered eight new collaborations indian partners produce distribute generic versions sofosbuvir fixeddose combination ledipasvirsofosbuvir distribution developing countries early expanded collaborations allow indian partners manufacture gs single tablet regimen sofosbuvirgs approved merck co inc merck entered agreement affiliate merck pursuant merck provide atripla substantially reduced prices hiv infected patients developing countries africa caribbean latin america southeast asia agreement manufacture atripla using efavirenz supplied merck merck handles distribution product countries covered agreement also entered agreement merck commercialize atripla lowmiddle income countries including brazil egypt mexico international partnership microbicides ipm conrad entered agreement granted rights ipm conrad cooperating agency us agency international development committed improving reproductive health expanding contraceptive choices women men develop manufacture proven efficacious arrange distribution resource limited countries certain formulations tenofovir use topical microbicide prevent hiv infection medicines patent pool mpp entered agreement mpp organization established united nations increase global access highquality lowcost antiretroviral therapy sharing patents granted mpp nonexclusive license identify generic pharmaceutical manufacturers india specialize highquality production generic medicines granted sublicenses indian manufacturers manufacture distribute generic versions antiretrovirals developing world sublicensees mpp free develop combination products pediatric formulations hiv medicines also granted mpp right grant sublicenses generic versions single tablet regimen consisting elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine product candidates elvitegravir cobicistat generic pharmaceutical manufacturers india distribution developing world entered new agreement mpp expand access taf hiv hbv developing countries contingent medicines us regulatory approval agreement mpp sublicense generic drug companies india china right manufacture generic versions products containing taf including fixeddose combinations taf coformulated certain hiv medicines distribute generic versions developing countries janssen expanded agreement janssen provide distribution compleraeviplera treatment hiv less developed countries agreement amended include product clinical development containing janssens rilpivirine emtricitabine taf competition marketed products target number areas including viral cardiovascular respiratory fungal diseases many commercially available products treatment diseases many companies institutions making substantial investments developing additional products treat diseases products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv products hiv landscape becoming competitive complex treatment trends continue evolve growing number hiv drugs currently sold advanced stages clinical development competition current expected competitors may erode revenues receive sales hiv products branded hiv drugs available united states products primarily compete fixeddose combination products nucleotidenucleoside reverse transcriptase inhibitors nrti class including combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sold viiv healthcare viiv products compete stribild compleraeviplera atripla truvada tybost compete ritonavir marketed abbvie inc abbvie hiv products also compete broadly hiv products abbvie boehringer ingelheim gmbh merck roche janssen addition tivicay dolutegravir integrase inhibitor launched viiv triumeq dolutegravirabacavirlamivudine single tablet antiretroviral regimen launched third quarter viiv could adversely impact sales hiv products also face competition generic hiv products bms 's videx ec didanosine ddi became first generic hiv product united states gsk 's retrovir zidovudine faces competition united states result launch generic zidovudine bms 's zerit stavudine faces competition united states result launch generic stavudine epivir lamivudine marketed viiv competitive emtricitabine active pharmaceutical ingredient emtriva component atripla truvada compleraeviplera stribild may compound patent covering epivir lamivudine expired united states generic lamivudine available united states spain portugal italy expect generic versions lamivudine launched countries within european union may generic version combivir lamivudine zidovudine approved recently launched united states addition late generic tenofovir also became available turkey resulted increase rebate viread turkey generic efavirenz active pharmaceutical ingredient sustiva component atripla available canada europe expect competition generic efavirenz united states december may put pricing pressure hiv products liver diseases products hcv products sovaldi harvoni compete abbvie 's viekira pak janssen 's olysio simeprevir united states hbv products viread hepsera face significant competition existing expected therapies treating patients hbv may erode revenues receive sales hbv products hbv products face competition baraclude entecavir oral nucleoside analog developed bms well generic entecavir hbv products also compete tyzekasebivo telbivudine oral nucleoside analog developed novartis pharmaceuticals corporation novartis epivirhbvzeffix lamivudine developed gsk collaboration shire plc viread hepsera treatment hbv also compete established immunomodulatory therapies including introna interferon alfab sold merck major countries throughout north south america europe asia pegasys pegylated interferon alfaa injectable drug similar introna sold roche treatment hbv cardiovascular products letairis competes directly tracleer bosentan opsumit macitentan drugs sold actelion pharmaceuticals us inc letairis also competes adcirca tadalafil united therapeutics corporation ranexa competes predominantly generic compounds three distinct classes drugs treatment chronic angina united states including generic andor branded betablockers calcium channel blockers longacting nitrates addition surgical treatments interventions coronary artery bypass grafting percutaneous coronary intervention another option angina patients may perceived healthcare practitioners preferred methods treat cardiovascular disease underlies causes angina numerous marketed generic andor branded pharmacologic stress agents compete lexiscanrapiscan respiratory products cayston competes primarily tobi tobramycin inhalation solution inhaled medication sold novartis treatment cf patients whose lungs contain p aeruginosa bacterial infection tamiflu competes relenza zanamivir antiinfluenza drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder generic competitors include amantadine rimantadine oral tablets inhibit replication influenza virus biocryst pharmaceuticals inc developing injectable formulations peramivir influenza neuraminidase inhibitor treatment influenza currently approved japan south korea products zydelig competes imbruvica ibrutinib marketed pharmacyclics inc treatment relapsed cll ambisome faces strong competition several current expected competitors ambisome faces competition vfend voriconazole developed pfizer caspofungin product developed merck marketed cancidas united states caspofungin elsewhere ambisome also competes lipidbased amphotericin b products including abelcet amphotericin b lipid complex injection sold enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sold three rivers pharmaceuticals llc worldwide anfogen amphotericin b liposomal sold genpharma sa argentina bms numerous generic manufacturers sell conventional amphotericin b also competes ambisome aware least three lipid formulations claim similarity ambisome becoming available outside united states including possible entry formulations taiwan formulations may reduce market demand ambisome manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association macugen competes primarily visudyne verteporfin injection sold novartis used connection photodynamic therapy lucentis ranibizumab sold genentech inc united states novartis territories outside united states number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs collaborative relationships part business strategy establish collaborations companies universities medical research institutions assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies universities medical research institutions information regarding certain relationships including ongoing financial accounting impact business see item note collaborative arrangements consolidated financial statements included annual report commercial collaborations although currently number collaborations corporate partners manufacture sale distribution andor marketing products various territories worldwide following commercial collaborations significant us financial statement perspective significant ongoing collaboration activity exists bms entered collaboration arrangement bms develop commercialize single tablet regimen containing truvada bms 's sustiva efavirenz united states combination approved use united states sold brand name atripla bms structured collaboration joint venture operates limited liability company named bristolmyers squibb gilead sciences llc consolidate bms granted royaltyfree sublicenses joint venture use respective company owned technologies return granted license joint venture use intellectual property results collaboration bms amended joint venture 's collaboration agreement allow joint venture sell atripla canada economic interests joint venture held us bms including share revenues outofpocket expenses based portion net selling price atripla attributable efavirenz truvada since net selling price truvada may change time relative net selling price efavirenz bms 's respective economic interests joint venture may vary annually bms shared marketing sales efforts starting except limited number activities jointly managed parties longer coordinate detailing promotional activities united states parties reduced joint promotional efforts since launched complera august stribild august agreement continue terminated mutual agreement parties addition either party may terminate party 's participation collaboration within days launch least one generic version party 's single agent products double agent products terminating party right continue sell atripla become continuing party obligated pay terminated party certain royalties threeyear period following effective date termination gilead sciences ireland unlimited company whollyowned subsidiary formerly known gilead sciences limited bms entered collaboration agreement bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bms 's estimated net selling price efavirenz european territory starting except limited number activities jointly managed parties longer coordinate detailing promotional activities region december efavirenz purchased bms bms 's estimated net selling price efavirenz european territory included inventories consolidated balance sheets agreement terminate upon expiration lasttoexpire patent affords market exclusivity atripla one components european territory addition starting december either party may terminate agreement reason termination effective two calendar quarters notice termination nonterminating party right continue sell atripla become continuing party obligated pay terminating party certain royalties threeyear period following effective date termination event continuing party decides sell atripla effective date termination date atripla withdrawn country date third party assumes distribution atripla whichever earlier janssen entered collaboration agreement janssen develop commercialize fixeddose combination truvada janssen 's rilpivirine agreement amended combination approved united states european union sold brand name complera united states eviplera european union amendment expanded collaboration include another single tablet regimen containing janssens rilpivirine emtricitabine tenofovir alafenamide rftaf agreement janssen granted us exclusive license compleraeviplera rftaf worldwide right distribute combination products countries including mexico russia japan neither party restricted combining drugs drug products except similar components compleraeviplera rftaf december recorded million approximately million reimbursable research development rd expenses incurred janssen development rilpivirine represented maximum amount reimbursable terms agreement responsible manufacturing compleraeviplera rftaf lead role registration distribution commercialization products except countries janssen distributes janssen exercised right codetail combination product countries gilead selling party selling party sets price products parties share revenues based ratio net selling prices partys components subject certain restrictions adjustments retain specified percentage janssens share revenues major markets either party may terminate collaboration agreement respect product country product withdrawn market country respect product countries party materially breaches agreement respect product agreement parties obligation share revenues expire productbyproduct countrybycountry basis janssen patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement without cause respect countries sell products case janssen right become selling party country product launched market fewer years japan tobacco entered licensing agreement japan tobacco japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retains rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize elvitegravircontaining products treatment hiv infection bear costs expenses associated commercialization efforts terms agreement paid upfront license fee million total milestone payments million achievement certain clinical regulatory commercial objectives additionally obligated pay royalties based net sales products containing elvitegravir territories market agreement obligation pay royalties japan tobacco terminate productbyproduct basis patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement reason case license granted japan tobacco us would terminate either party may terminate agreement response material breach party research collaborations also number collaborations partners rd certain compounds drug candidates none research collaborations rose level significant us financial statement perspective significant ongoing collaboration activity exists research development rd philosophy strategy develop bestinclass drugs improve safety efficacy unmet medical needs intend continue committing significant resources rd opportunities business development activity product development efforts cover wide range medical conditions including hivaids liver diseases hbv hcv inflammationoncology serious cardiovascular respiratory conditions research scientists foster city fremont san dimas oceanside california branford connecticut seattle washington alberta canada engaged discovery development new molecules technologies hope lead approval new medicines addressing unmet needs development product candidates subject various risks uncertainties risks uncertainties include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain regulatory approvals result product candidates may never successfully commercialized drug development inherently risky many product candidates fail drug development process summary key product candidates corresponding current stages development additional information development pipeline visit website wwwgileadcom product candidates treatment hiv product candidates description marketing application pending single tablet regimen elvitegravir cobicistat single tablet regimen elvitegravir cobicistat emtricitabine taf evaluated treatment emtricitabine taf hiv infection products phase fixeddose coformulation emtricitabine fixeddose coformulation emtricitabine taf evaluated treatment hiv infection taf single tablet regimen emtricitabine rilpivirine agreement janssen single tablet regimen emtricitabine rilpivirine taf evaluated taf treatment hiv infection product candidates treatment liver diseases product candidates description products phase fixeddose combination sofosbuvir gs fixeddose combination sofosbuvir gs nucleotide nsb inhibitorpangenotypic nsa inhibitor evaluated treatment hcv taf taf nucleotide reverse transcriptase inhibitor evaluated treatment hbv products phase fixeddose combination gs sofosbuvir gs pangenotypic ns protease inhibitor evaluated combination sofosbuvir gs gs treatment hcv gs gs tarmogen cell immunity stimulator evaluated treatment hbv gs gs oral tlr agonist evaluated potential cure hbv simtuzumab simtuzumab monoclonal antibody evaluated treatment liver fibrosis nash primary sclerosing cholangitis products phase gs gs ask inhibitor evaluated treatment diabetic nephropathy nash gs gs aldh inhibitor evaluated treatment drug addiction product candidates treatment oncology inflammation product candidates description products phase idelalisib idelalisib pik delta inhibitor evaluated treatment inhl frontline relapsed refractory cll momelotinib momelotinib jak inhibitor evaluated treatment myelofibrosis products phase gs gs spleen tyrosine kinase syk inhibitor evaluated hematological malignancies idelalisib idelalisib also evaluated treatment frontline inhl momelotinib momelotinib also evaluated treatment pancreatic cancer products phase gs gs brutons tyrosine kinase inhibitor evaluated bcell malignancies gs gs mmp mab inhibitor evaluated treatment solid tumors ulcerative colitis gs gs pik delta inhibitor evaluated treatment hematological malignancies product candidates treatment cardiovascular diseases product candidates description products phase ranolazine ranolazine late sodium current inhibitor approved treatment chronic angina evaluated treatment incomplete revascularization postpercutaneous coronary intervention gs gs late sodium current inhibitor evaluated treatment lqt syndrome products phase fixeddose combination ranolazine fixeddose combination ranolazine dronedarone evaluated treatment paroxysmal atrial dronedarone fibrillation gs gs also evaluated treatment pulmonary arterial hypertension gs gs late sodium current inhibitor evaluated treatment lqt syndrome hypertrophic cardiomyopathy product candidates treatment respiratory diseases product candidates description products phase gs gs inhalable small molecule antiviral fusion inhibitor evaluated treatment respiratory syncytial virus simtuzumab simtuzumab also evaluated treatment idiopathic pulmonary fibrosis total rd expenses billion compared billion billion addition internal discovery clinical development programs seek add portfolio products product acquisitions licenses collaborations december entered exclusive license agreement ono pharmaceutical co ltd development commercialization ono known gs oral brutons tyrosine kinase inhibitor treatment bcell malignancies diseases december entered agreement phenex pharmaceuticals ag phenex acquired phenexs farnesoid x receptor program comprised small molecule fxr agonists treatment liver diseases including nash patents proprietary rights us european patent expiration number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows estimated expiration dates including patent term extension supplementary protection certificates andor pediatric exclusivity granted united states europe primary typically compound patents phase product candidates patents cover ranolazine compound active ingredient ranexa instead discovered sustainedrelease formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve product candidates single tablet regimens estimated patent expiration date provided corresponds latest expiring compound patent one active ingredients single tablet regimen phase product candidates patent expiration product candidates treatment hiv us eu single tablet regimen elvitegravir cobicistat emtricitabine taf single tablet regimen emtricitabine taf single tablet regimen darunavir cobicistat emtricitabine taf single tablet regimen emtricitabine rilpivirine taf product candidates treatment liver diseases single tablet regimen sofosbuvir gs treatment hcv single agent taf treatment hbv product candidates treatment oncologyinflammation idelalisib treatment inhl frontline relapsed refractory cll momelotinib treatment myelofibrosis product candidates treatment cardiovascular diseases ranolazine treatment incomplete revascularization postpercutaneous coronary intervention treatment type ii diabetes gs treatment lqt syndrome dates parentheses reflect estimated expiration date patents may issue currently pending applications estimated expiration dates include potential additional exclusivity eg patent term extension supplementary protection certificates pediatric exclusivity yet granted following table shows actual estimated expiration dates including patent term extension supplementary protection certificates andor pediatric exclusivity granted united states europe primary typically compound patents marketed products product single tablet regimens eg truvada atripla compleraeviplera stribild estimated patent expiration dates provided correspond latest expiring compound patent one active ingredients single tablet regimen products patent expiration us eu hepsera ambisome macugen tamiflu letairis viread ranexa atripla cayston emtriva truvada lexiscan compleraeviplera vitekta zydelig sovaldi stribild tybost harvoni dates parentheses reflect estimated expiration date patents may issue currently pending applications estimated expiration dates include potential additional exclusivity eg patent term extension supplementary protection certificates pediatric exclusivity yet granted gilead teva pharmaceuticals teva reached agreement principle settle ongoing patent litigation concerning four patents protect tenofovir disoproxil fumarate viread truvada atripla products agreement teva allowed launch generic version viread december gilead lupin limited lupin reached agreement settle patent litigation prior issuance courts decision agreement lupin allowed launch generic version ranexa february patent protection certain challenges patents proprietary rights important business properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology patents covering certain active pharmaceutical ingredients atripla truvada compleraeviplera stribild letairis emtriva hepsera vitekta held third parties acquired exclusive rights patents agreements parties patents cover ranolazine compound active ingredient ranexa instead discovered sustainedrelease formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve patents cover active ingredients ambisome may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions supplementary protection certificates countries example extensions patents supplementary protection certificates many products granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain countries also important infringe valid patents third parties infringe valid patents third parties may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware body patents may relate operation letairis education access program leap restricted distribution program designed support letairis aware patents patent applications owned parties may claim cover use sofosbuvir use combination sofosbuvir ledipasvir patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate interferencederivation proceedings litigation determine right patent litigation interferencederivation proceedings unpredictable expensive even ultimately successful results operations may adversely affected events patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation proceedings regarding enforcement validity existing patents future patents could result invalidation patents substantially reduce protection time time certain individuals entities may challenge patents pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products closely related developed developing addition certain countries south america africa asia including brazil china provide effective enforcement patents thirdparty manufacturers may able sell generic versions products countries litigation regarding sofosbuvir january acquired pharmasset inc pharmasset acquisition acquired sofosbuvir nucleotide analog acts inhibit replication hcv december received fda approval sofosbuvir known commercially sovaldi october also received approval fixeddose combination ledipasvir sofosbuvir known commercially harvoni received number intellectual property claims regarding sofosbuvir carefully considered claims prior following acquisition believe without merit patents patent applications claim sofosbuvir sovaldi chemical entity metabolites fixeddose combination ledipasvir sofosbuvir harvoni third parties may may obtain rights patents allegedly could used prevent attempt prevent us commercializing sovaldi harvoni example aware patents patent applications owned parties may alleged parties cover use sovaldi harvoni predict ultimate outcome intellectual property claims related sovaldi harvoni spent continue spend significant resources defending claims parties successfully obtain valid enforceable patents successfully prove infringement patents sovaldi andor harvoni could prevented selling products unless able obtain license patents license may available commercially reasonable terms interference proceedings litigation idenix pharmaceuticals inc idenix february received notice us patent trademark office uspto declared interference first idenix interference us patent patent idenix 's pending us patent application interference administrative proceeding uspto designed determine first invent subject matter claimed parties patent covers metabolites sofosbuvir idenix attempting patent class compounds including metabolites purpose first idenix interference determine first invent compounds therefore entitled patent claiming compounds march uspto patent trial appeal board board determined idenix entitled benefit early application filing dates none patent applications including application granted idenixs us patent patent taught make compounds dispute board also determined entitled filing date earliest application first file patent application compounds dispute therefore senior party first idenix interference january board determined pharmasset idenix first invent compounds dispute accordingly gilead prevailed first idenix interference decision board held idenix failed prove first conceive compounds dispute specifically idenix failed prove idenix inventors identified structure method making use disputed compounds board went conclude idenix failed work diligently toward making testing compounds dispute relevant time period idenix appealed boards decisions us district court district delaware december receiving request uspto declared interference second idenix interference pending us patent application patent patent includes claims directed methods treating hcv nucleoside compounds similar involved first idenix interference second idenix interference determine first invent claimed methods treating hcv january board issued decision favor gilead first phase second idenix interference board decided first file patent application disputed methods treating hcv designated gilead senior party second idenix interference invalidated patent claims idenix patent involved second idenix interference senior party presumed first invented disputed methods treating hcv idenix failed teach make use invention patent board invalidated idenix claims involved second idenix interference lack enablement board also placed idenix order show cause requiring idenix explain judgment entered second idenix interference based upon decision board first idenix interference decision second idenix interference consistent boards earlier rulings march january first idenix interference gilead declared senior party first invent certain fluoro methyl nucleoside compounds compounds relevant methods treating hcv issue second idenix interference believe idenix claims involved first second idenix interferences similar us foreign patents claiming compounds metabolites uses thereof invalid result filed impeachment action federal court canada invalidate idenix canadian patent patent canadian patent corresponds patent idenix patent application subject first idenix interference idenix asserted commercialization sovaldi canada infringe patent canadian patent corresponding patent involved first idenix interference invalid trial issues commenced january filed similar legal action norway oslo district court seeking invalidate idenix 's norwegian patent corresponding patent september idenix filed invalidation action norwegian proceedings norwegian patent patent corresponds patent march norwegian court found claims idenix norwegian patent invalid upheld validity claims challenged gilead patent april idenix appealed march decision norwegian court appeal idenixs obligation pay attorneys fees stayed pendency appeal appeal march decision scheduled commence february august april idenix filed two separate requests invalidation chinese patent office chinese patent cn zl corresponds ' patent august idenix withdrew invalidation requests chinese proceedings terminated challenged patent remaining valid enforceable january filed legal action federal court australia seeking invalidate idenixs australian patent corresponding patent april idenix asserted commercialization sovaldi australia infringe australian patent corresponding patent trial issues scheduled commence september sydney march european patent office epo granted idenix european patent patent corresponds patent day patent granted filed opposition epo seeking revoke patent also day idenix initiated infringement proceedings gilead united kingdom uk germany france alleging commercialization sovaldi countries would infringe respective national counterparts patent united kingdom trial held october determine issues infringement validity idenix uk patent december high court justice england wales uk court invalidated claims patent multiple grounds specifically uk court held patent lacked novelty earlier filed patent application teaching compounds patent lacked inventive step add anything knowledge existing time disclosure idenixs patent application insufficient teach make compounds show claimed compounds would activity viruses like hepatitis c virus january uk court held hearing court ordered idenix pay gileads costs interim payment due within days hearing uk court granted idenix permission appeal december judgment february german court dsseldorf held hearing determine issue infringement idenix german patent expect decision mid march trial date french lawsuit idenix awarded patents corresponding patent japan china event patents issue expect challenge proceedings similar invoked countries december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringe patent interference exists patent us patent also december idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringe us patent nos june court massachusetts granted request transferred massachusetts litigation us district court district delaware believe idenixs patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir district court set trial dates october december resolution issues decision district court appealed either party us court appeals federal circuit cafc idenix acquired merck august acquisition change view lack merit claims made idenix merck greater resources idenix may therefore choose fund litigation higher levels idenix litigation merck august merck contacted us requesting pay royalties sales sofosbuvir obtain license us patent nos coowns isis pharmaceuticals inc believe mercks patents invalid infringed commercialization sofosbuvir sole right commercialize sofosbuvir august filed lawsuit us district court northern district california seeking declaratory judgment merck patents invalid infringed mercks us patent nos cover compounds include may relate sofosbuvir patent prosecution merck amended patent application attempt cover compounds related sofosbuvir apparent goal ultimately extracting royalty payments sofosbuvirs commercialization eliminating competition excluding market court determines mercks patents valid infringed claims may required obtain license pay royalties merck commercialize sofosbuvir either party appeal decision district court cafc court set trial date march lawsuit litigation abbvie inc abbvie abbvie obtained us patent nos abbvie patents purport cover use combination ledipasvirsofosbuvir harvoni treatment hcv gilead aware abbvie pending patent applications united states countries published pending patent applications directed use combinations treatment hcv specifically combination ledipasvir sofosbuvir certain applications filed abbvie patents reason others believe abbvie patents invalid accordingly december filed lawsuit us district court district delaware seeking declaratory judgment abbvie patents invalid unenforceable well relief believe abbott laboratories inc abbvie conspired eliminate competition hcv market falsely representing uspto gilead invented methods treating hcv using combination ledipasvirsofosbuvir february march abbvie responded lawsuit filing two lawsuits also us district court district delaware alleging fixeddose combination ledipasvirsofosbuvir infringe patents lawsuits consolidated single action united states either party appeal decision district court cafc abbvie patents blocked delayed commercialization combination product united states europe expect foreign patents block delay commercialization around world court determines abbvie patents valid infringed claims may required obtain license pay royalties abbvie commercialize sofosbuvir combination products litigation generic manufacturers part approval process products fda granted us new chemical entity nce exclusivity period manufacturers ' applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug tenofovir disoproxil fumarate emtricitabine fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz received notices teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version truvada april teva reached agreement settle ongoing patent litigation concerning patents protect tenofovir disoproxil fumarate atripla truvada viread agreement teva allowed launch generic version viread december april teva entered agreement settle ongoing patent litigation concerning emtricitabine patents protect atripla truvada terms settlement confidential november received notice teva submitted ands canadian minister health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate notice teva alleges three patents associated truvada invalid unenforceable andor infringed teva 's manufacture use sale generic version truvada january filed lawsuit teva federal court canada seeking order prohibition approval ands december received notice teva submitted ands canadian minister health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva alleges three patents associated atripla two merck 's patents associated atripla invalid unenforceable andor infringed teva 's manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz february filed lawsuit teva federal court canada seeking order prohibition approval ands august received notice teva submitted ands canadian minister health requesting permission manufacture market generic version viread notice teva alleges two patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed teva 's manufacture use sale generic version viread truvada atripla september filed lawsuit teva federal court canada seeking order prohibition approval ands also august teva filed impeachment action federal court canada seeking invalidation two canadian patents associated viread currently defending impeachment action requests orders prohibition connection three tevas ands filings tevas generic versions viread truvada atripla consolidated december court issued requested order prohibiting canadian minister health issuing notice compliance tevas generic versions viread truvada atripla products expiry patent july teva appealed decision decision rule validity patents accordingly issue appeal whether minister health prohibited issuing notices compliance tevas products separately court determine validity patents pending impeachment action trial impeachment action scheduled september teva successful invalidating patents teva may able launch generic versions viread truvada atripla products canada prior expiry patents received notice lupin limited lupin submitted anda fda requesting permission manufacture market generic versions truvada viread may lupin amended andas certify longer seeking approval market generic versions truvada viread prior expiration four patents associated tenofovir disoproxil fumarate january including pediatric exclusivity september reached agreement lupin settle lawsuit related emtricitabine patents protect truvada atripla terms settlement confidential july received notice cipla ltd cipla submitted anda fda requesting permission manufacture market generic versions emtriva viread july cipla reached agreement settle lawsuits terms settlement confidential april received notice mylan inc mylan submitted anda fda requesting permission manufacture market generic version truvada notice mylan alleges two patents associated emtricitabine one patents associated fixeddose combination emtricitabine tenofovir disoproxil fumarate invalid unenforceable andor infringed mylan 's manufacture use sale generic version truvada june filed lawsuit mylan us district court northern district west virginia infringement patents june received notice mylan inc submitted petitions inter partes review ipr board alleging four patents associated tenofovir disoproxil fumarate invalid opposed mylans petitions december uspto patent trial appeal board ptab issued decisions denying mylans petitions ipr tenofovir disoproxil fumarateassociated patents grounds mylan established reasonable likelihood success would prevail challenge patents mylan requested rehearing basis believes ptab decision wrong june received notice apotex inc apotex submitted ands canadian minister health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate separate ands requesting permission manufacture market generic version viread notice apotex alleges three patents associated truvada two patents associated viread invalid unenforceable andor infringed apotex 's manufacture use sale generic version truvada viread august filed lawsuit apotex federal court canada seeking order prohibition approval ands ranolazine received notice lupin submitted anda fda requesting permission manufacture market generic version sustainedrelease ranolazine august parties reached agreement settle patent litigation prior issuance courts decision agreement lupin allowed launch generic version ranexa february tamiflu february received notice natco pharma ltd natco submitted anda fda requesting permission manufacture market generic version tamiflu notice natco alleges one patents associated oseltamivir phosphate invalid unenforceable andor infringed natco 's manufacture use sale generic version tamiflu march roche filed lawsuit natco us district court district new jersey infringement one patents associated tamiflu december court issued ruling favor gilead roche patent invalid reason stated natco 's notice letter natco appealed decision cafc issued decision april allowing natcos patent invalidity challenge proceed remanding district court new jersey full trial merits june filed petition rehearing en banc cafc subsequently denied filed petition certiorari supreme court united states concurrently proceeding district court letairis august natco filed complaint u district court district minnesota gilead express scripts holding co specialty pharmacy distributes letairis product distribute letairis pursuant fdamandated risk evaluation mitigation strategies rems program natco alleges gilead independently together express scripts denied natco access samples letairis natco claims needs order conduct bioequivalence testing file anda according natco conduct therefore violates antitrust laws natco seeking damages order restraining gilead limiting distribution letairis natco use rems program november zydus pharmaceuticals usa inc zydus cadila healthcare limited cadila filed complaint us district court district new jersey us relating letairis sales distribute letairis pursuant rems program zydus cadila allege denied access samples letairis claim need order conduct bioequivalence testing file anda according zydus cadila conduct therefore violates antitrust laws zydus cadila seeking damages order enjoining gilead provide zydus samples letairis february received notice watson laboratories inc watson submitted anda fda requesting permission manufacture market generic version letairis notice watson alleges one patents associated ambrisentan tablets invalid unenforceable andor infringed watson 's manufacture use sale generic version letairis currently evaluating watson 's notice file patent infringement lawsuit necessary protect exclusivity product lexiscan december astellas informed us received notice apotex submitted anda fda requesting permission manufacture market generic version lexiscan notice apotex alleges one patents associated regadenoson invalid unenforceable andor infringed apotexs manufacture use sale generic version lexiscan apotex challenged several patents associated regadenoson apotex product would eligible final approval expiry patents challenged astellas opportunity file patent infringement lawsuit apotex future decide necessary protect exclusivity product predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits claims patents may narrowed invalidated patent protection truvada viread lexiscan tamiflu united states atripla truvada viread canada could substantially shortened patents covering one products invalidated fda canadian minister health could approve requests manufacture generic version products united states canada respectively prior expiration date patents sale generic versions products earlier patent expiration would significant negative effect revenues results operations trade secrets also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions manufacturing raw materials manufacturing strategy contract third parties manufacture majority active pharmaceutical ingredients solid dose products also rely corporate partners manufacture certain products additionally lease manufacturing facilities foster city san dimas oceanside california edmonton alberta canada cork ireland manufacture certain products active pharmaceutical ingredients clinical commercial uses manufacturing products contract third parties manufacture certain products clinical commercial purposes including sovaldi atripla truvada harvoni compleraeviplera stribild viread emtriva hepsera tybost vitekta ranexa ambisome zydelig cayston generally use multiple thirdparty contract manufacturers manufacture active pharmaceutical ingredients products exclusive manufacturer idelalisib active pharmaceutical ingredient zydelig ambrisentan active pharmaceutical ingredient letairis although another supplier qualified make active pharmaceutical ingredient letairis also rely thirdparty contract manufacturers manufacture tablet capsule products example use multiple thirdparty contract manufacturers tablet sovaldi atripla truvada harvoni compleraeviplera stribild viread hepsera tybost vitekta letairis zydelig ranexa emtriva encapsulation also completed thirdparty contract manufacturers also manufacturing agreements many corporate partners roche third parties responsible manufacturing tamiflu agreement roche joint manufacturing committee composed representatives roche gilead opportunity review roche 's existing manufacturing capacity tamiflu global plans manufacturing tamiflu astellas us llc corporate partner lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan future products continue develop additional manufacturing capabilities establish additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future products ability conduct large scale clinical trials meet customer demand commercial products adversely affected addition rely thirdparty contract manufacturers manufacture aseptic products ambisome cayston manufacturing facilities san dimas california manufacturing facility package label solid dosage oral form products including sovaldi atripla truvada harvoni compleraeviplera stribild viread ranexa zydelig emtriva label hepsera facilities san dimas manufacture ambisome cayston san dimas facility depend single supplier high quality cholesterol active pharmaceutical ingredient used manufacture ambisome exclusive supplier key drug product intermediates ambisome event disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome meet market needs utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral products well product packaging activities package label drug product sovaldi atripla truvada harvoni compleraeviplera stribild viread tybost vitekta label hepsera emtriva facilities cork ireland also perform quality control testing final labeling secondary packaging ambisome cayston final release many products european union elsewhere facility distribute products european union international markets dublin ireland site edmonton alberta facility canada carry process research scaleup clinical development candidates manufacture active pharmaceutical ingredients investigational commercial products conduct chemical development activities improve existing commercial manufacturing processes also manufacture active pharmaceutical ingredients letairis hepsera exclusively edmonton site although another supplier qualified make active pharmaceutical ingredient letairis oceanside california facility designed equipped produce biologic compounds toxicological phase phase clinical studies use facility process development manufacture simtuzumab investigational monoclonal antibody candidate development treatment certain cancers respiratory diseases biologics thirdparty manufacturers thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval may writeoff costs manufacturing batch fails pass quality inspection meet regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected addition thirdparty manufacturers corporate partners may able produce products one limited number facilities therefore limited manufacturing capacity certain products example due unexpected delays qualifying two new external sites expanding cayston manufacturing san dimas unable supply enough cayston fulfill projected demand february september suspended access patients new prescriptions cayston subject certain exceptions specific medical need existed result inability manufacture sufficient cayston meet demand amount revenues received sale cayston reduced believe technology use manufacture products proprietary products manufactured thirdparty contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements thirdparty manufacturers intended restrict manufacturers using revealing technology certain thirdparty manufacturers comply restrictions addition thirdparty manufacturers could develop technology related work perform us may need manufacture products could required enter additional agreements thirdparty manufacturers want use technology allow another manufacturer use technology thirdparty manufacturer could refuse allow us use technology could demand terms use technology acceptable us regulation manufacturing process manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations thirdparty manufacturers corporate partners subject current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda european medicines agency ema similar regulations effect countries manufacturing operations subject routine inspections regulatory agencies example april fda conducted inspection foster city facility issued form inspectional observations noted deficiencies documentation validation certain quality testing procedures methods result observations fda delivered complete response letters notifying us unable approve ndas elvitegravir cobicistat standalone agents midoctober fda completed sofosbuvir preapproval inspection foster city facility following inspection fda issued additional form inspectional observations citing deficiencies related testing reconciliation stability samples testing protocols testing shipping samples procedures calibrating test equipment completed filed responses observations fda received letter fda related extent method revalidations conducted stability program oversight audit trail reviewdata management quality management system gaps filed responses observations fda unable remedy deficiencies cited fda inspections currently marketed products timing regulatory approval products development could adversely affected risk regulatory agencies countries marketing applications pending undertake similar additional reviews apply heightened standard review could delay regulatory approvals products countries approval product candidates delayed production marketed products interrupted anticipated revenues stock price would adversely affected access supplies materials need access certain supplies products manufacture products unable purchase sufficient quantities materials find suitable alternate materials timely manner development efforts product candidates may delayed ability manufacture products would limited would limit ability generate revenues example significant portion raw materials intermediates used manufacture antiviral products sovaldi atripla truvada harvoni compleraeviplera stribild viread emtriva tybost vitekta supplied chinabased companies result international trade dispute china united states actions chinese government would limit prevent chinese companies supplying materials would adversely affect ability manufacture supply hiv hcv products meet market needs material adverse effect operating results seasonal operations backlog worldwide product sales reflect significant degree seasonality part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states countries united states drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming fda must approve drug sold united states general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidate 's potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous phase clinical trials phase drug candidate appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data clinical trials show adequate level safety efficacy submit appropriate filing usually form nda supplemental nda fda seeking approval sell drug candidate particular use fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety efficacy particular use allow us sell drug candidate united states use unusual however fda reject application believes drug candidate safe enough efficacious enough believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california including oceanside san dimas facilities also must licensed state california compliance local regulatory requirements manufacturing facilities located canada including edmonton alberta facility facilities located near dublin cork ireland also must obtain local licenses permits compliance local regulatory requirements drugs treat serious life threatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track candidates fda may eligible accelerated priority review drugs treatment hiv infection designated use us president 's emergency plan aids relief may also qualify expedited priority review sovaldi atripla truvada harvoni viread complera stribild viread zydelig received accelerated approval priority reviews drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union includes major countries europe centralized approval procedure used approval one country european union used obtain approval another country european union one two simplified application processes mutual recognition procedure decentralized procedure rely principle mutual recognition receiving regulatory approval european registration procedures separate pricing reimbursement approvals also required countries european union also requirements approval manufacturing facilities products approved sale european regulatory authorities pricing reimbursement successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services resulted lower average selling prices united states significant portion sales majority products subject significant discounts list price rebate obligations hcv area experienced increased pricing pressure certain cases provided significant discounts rebates private public payers order obtain formulary status change formulary coverage reimbursement levels discounts rebates offered hcv products payers may impact anticipated revenues also expect pricing pressure hcv market continue addition state adaps purchase significant portion hiv products rely federal supplemental federal state funding help fund purchases products past experienced shift payer mix hiv patients previously covered private insurance move public reimbursement programs require rebates discounts us patients previously covered one public reimbursement program move another public reimbursement program requires greater rebates discounts us federal state funds available amounts sufficient support number patients rely adaps sales hiv products could negatively impacted would reduce revenues prior quarters insufficiency federal state funds many states reduced eligibility criteria saw increase number patients state adap waitlists may see similar increases future periods result reduction federal state adap support resulting sequestration patients enrolled adap generally receive product industrysupported patient assistance programs unable access treatment increased emphasis managed healthcare united states put additional pressure product pricing reimbursement usage may adversely affect product sales profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid healthcare reform pharmaceutical reimbursement policies pricing general july received letter us senate committee finance requesting information supporting documentation us related sovaldi pricing sovaldi united states letter raised concerns approach pricing sovaldi affordability impact federal government spending public health cooperating inquiries costly timeconsuming us comply inquiries predict outcome possible inquiries could result negative publicity negative actions could harm reputation reduce demand sovaldi harvoni sofosbuvir containing products andor reduce coverage sovaldi harvoni sofosbuvir containing products including federal health care programs medicare medicaid events occur business stock price could materially adversely affected countries outside united states success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices certain governmental authorities delay commercialization months reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates revenuerelated taxes tenders profit control expect prices prescription pharmaceuticals decline life product volumes increase recently many countries european union increased level discounting required products efforts could continue countries attempt manage healthcare expenditures especially light severe fiscal debt crises experienced many countries european union countries instituted clawbacks enacted taxes specific products generic drugs come market may face price decreases products countries european union cost containment pressures european union especially southern europe could lead delays treatment patients also delay pricing approval could negatively impact commercialization new products government agencies also issue regulations guidelines directly applicable us products addition time time professional societies practice management groups private healthscience foundations organizations publish guidelines recommendations directed certain health care patient communities recommendations guidelines may relate matters product usage dosage route administration use related competing therapies consequently result increased decreased usage products united states healthcare reform legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions march healthcare reform legislation adopted united states requiring us rebate discount products reimbursed paid various public payers including medicaid entities eligible purchase discounted products b drug pricing program public health service act adaps result legislation discounts rebates fees impacted us include minimum base rebate amount owed medicaid products reimbursed medicaid increased discounts rebates owe adaps public health service entities reimburse purchase products also increased required extend rebates patients receiving products medicaid managed care organizations required provide discount products sold patients medicare part donut hole along pharmaceutical manufacturers branded drug products required pay portion new industry fee also known branded prescription drug fee bpd fee billion calculated based select government sales calendar year percentage total industry government sales amount annual industry fee imposed pharmaceutical industry whole billion increase billion increase peak billion decrease billion thereafter expect portion bpd fee increase revenues grow amount annual industry fee increases drug patents expire major drugs companies addition third quarter internal revenues service irs issued final regulations indicated manufacturers obligation pay portion bpd fee given calendar year triggered qualifying sales previous year instead first qualifying sale current calendar year result final irs regulations required recognize fee million fee million consolidated statement income bpd fees approximately million million million respectively bpd fee tax deductible even though addressed healthcare reform legislation discussions continue federal level legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare part pricing addition state medicaid programs could request additional supplemental rebates products result increase federal base medicaid rebate private insurers could also use enactment increased rebates exert pricing pressure products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules health care fraud abuse laws antibribery laws subject various federal state laws pertaining health care fraud abuse including antikickback laws false claims laws antikickback laws make illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions increasing attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws generally prohibit anyone knowingly presenting causing presented false fraudulent claim payment federal certain state payers including medicare medicaid knowingly making using causing made used false record statement material false fraudulent claim sales marketing medical activities may subject scrutiny laws addition us foreign corrupt practices act similar worldwide antibribery laws generally prohibit companies intermediaries making improper payments purpose obtaining retaining business policies mandate compliance antibribery laws operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different local custom despite training compliance program internal control policies procedures may protect us reckless criminal acts committed employees agents violations fraud abuse laws antibribery laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid violations also lead imposition corporate integrity agreement similar government oversight program government allege convict us violating laws could disruption business material adverse effect results operations compulsory licenses number developing countries government officials interested groups suggested pharmaceutical companies make drugs hcv hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example growing attention availability hcv therapies activists advocating increased availability hcv therapies means including compulsory licenses past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread addition concerns cost availability tamiflu related potential avian flu pandemic hn influenza generated international discussions compulsory licensing tamiflu patents example canadian government considered allowing canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canada 's access medicines regime furthermore roche issued voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense india 's hetero drugs limited india certain developing countries compulsory licenses permit generic manufacturing override product patents sovaldi harvoni hiv products tamiflu required grant compulsory licenses products could reduce earnings cash flows harm business addition certain countries permit enforcement patents thirdparty manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales employees january approximately fulltime employees believe good relations employees environment health safety evaluated current level environmental impact identified ways reduce energy consumption factors contribute environmental impact include greenhouse gas emissions produced employee commutes energy water consumed facilities use hazardous materials chemicals viruses radioactive compounds rd facilities pursuant evaluation taken initial measures address impacts example established employee commuter programs evaluated energy efficiency buildings installed lowflow water fixtures also implemented proactive programs minimize occurrence hazardous materials incidents reduce risk accidental environmental contamination worker injury subject number laws regulations require compliance federal state local regulations regarding workplace safety protection environment anticipate additional regulations near future laws regulations implemented consideration mitigate effects climate change mainly caused greenhouse gas emissions business energy intensive therefore anticipate subject cap trade system mitigation measure would materially impact capital expenditures operations competitive position based current information subject finalization proposed regulations believe primary risk related climate change increased energy costs use hazardous materials chemicals viruses various radioactive compounds rd activities eliminate risk accidental contamination injury materials misuse accidents involving hazardous materials could lead significant litigation fines penalties information subject information requirements exchange act therefore file periodic reports proxy statements information sec reports proxy statements information may obtained visiting public reference room sec f street ne washington dc calling sec sec sending electronic message sec publicinfosecgov sending fax sec addition sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section make available following filings soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act filings available free charge upon request transactions iran transactions iran would require disclosure annual report item risk factors evaluating business carefully consider following risks addition information annual report manifestation following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider following risks complete statement potential risks uncertainties face substantial portion revenues derived sales products treat hcv hiv unable maintain continue increasing sales products results operations may adversely affected year ended december sales sovaldi harvoni treatment hcv accounted approximately total product sales since sovaldi harvoni recently launched certain sales hcv products indicative future sales approval competitors hcv product december potential entry competitive products predict whether extent hcv revenues may adversely affected future result launch competing regimen experienced may continue experience increased pricing pressure certain cases provided significant discounts rebates public private payers order obtain formulary status expand access patients hcv products addition future sales sovaldi harvoni difficult estimate demand depends part extent reimbursement hcv products private public payers united states countries outside united states light continued fiscal debt crises experienced several countries european union several governments announced implemented measures manage healthcare expenditures continue experience pricing pressure increases amount discounts required products delayed reimbursement could negatively impact future product sales results operations also private public payers choose exclude sovaldi harvoni formulary limit types patients coverage provided would negatively impact demand revenues sovaldi harvoni change formulary coverage reimbursement levels discounts rebates offered hcv products payers may impact anticipated revenues expect pricing pressure hcv market continue unable maintain current expected future sales levels sovaldi harvoni obtain approval reimbursement hcv product candidates currently anticipated timelines results operations stock price could negatively affected receive substantial portion revenue sales products treatment hiv infection particularly single tablet regimen products atripla compleraeviplera stribild year ended december sales hiv products accounted total product sales hiv products contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutics treatment paradigm hiv changes causing nucleosidebased therapeutics fall favor unable maintain continue increasing hiv product sales results operations would likely suffer would likely need scale back operations including spending research development rd efforts may able sustain increase growth rate sales hiv products especially atripla compleraeviplera stribild number reasons including limited following hiv products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings contraindications labels narrow approved indications halt sales product could reduce revenues hiv products mature private insurers government payers often reduce amount reimburse patients products increases pressure us reduce prices large part market hiv products consists patients already taking hiv drugs physicians see benefit hiv products sales hiv products limited generic hiv products introduced major markets ability maintain pricing market share may affected example generic versions sustiva efavirenz component atripla available canada europe anticipate competition generic efavirenz united states december observed pricing pressure related sustiva component atripla sales fail commercialize new products expand indications existing products prospects future revenues may adversely affected introduce new products market increase sales existing products able increase maintain total revenues continue expand rd efforts drug development inherently risky many product candidates fail drug development process example recently announced results phase study simtuzumab treatment pancreatic cancer myelofibrosis colorectal cancer showing product candidate provide clinical benefit june submitted nda japans pharmaceutical medical devices agency pmda approval sofosbuvir treatment hcv september submitted nda pmda approval fixeddose combination ledipasvir sofosbuvir fourth quarter filed marketing applications approval single tablet regimen elvitegravir cobicistat emtricitabine taf treatment hiv infection adults united states european union marketing applications may approved regulatory authorities timely basis even marketing approval granted products may significant limitations use may unable file marketing applications new products inability accurately predict demand products uptake new products timing fluctuations inventories maintained customers makes difficult us accurately forecast sales may cause revenues earnings fluctuate could adversely affect financial results stock price may unable accurately predict demand products including uptake new products demand dependent number factors example hcv products sovaldi harvoni represent significant change treatment paradigm hcvinfected patients due shortened duration treatment reduction elimination need pegylated interferon injection ribavirin certain patient populations products new therapeutic area us product demand dependent number factors revenues products beyond difficult us investors estimate demand sovaldi harvoni depend part extent reimbursement hcv products private public payers united states countries outside united states private public payers choose exclude sovaldi harvoni formulary limit types patients coverage provided would negatively impact demand revenues sovaldi harvoni also hcv products represent significant change treatment paradigm hcv infection light launch competitors regimen sales levels prescription growth rates early launch may indicative future sales result launch competing regimen experienced increased pricing pressure united states certain cases provided significant discounts private public payers order obtain formulary status expand access patients hcv products change formulary coverage reimbursement levels discounts rebates offered hcv products payers may negatively impact anticipated revenues expect pricing pressure hcv market continue hcvrelated revenues difficult predict investors may widely varying expectations may materially higher lower actual revenues extent hcv product revenues exceed fall short expectations stock price may experience significant volatility year ended december approximately product sales united states three wholesalers amerisourcebergen corp mckesson corp cardinal health inc us wholesalers entered inventory management agreements make estimates determine end user demand may completely effective matching inventory levels actual end user demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand addition inventory held retail pharmacies nonwholesaler locations inventory management agreements control buying patterns adverse changes economic conditions factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers ' orders us even end user demand changed example fourth quarter strong wholesaler subwholesaler purchases hiv products resulted inventory drawdown wholesalers subwholesalers first quarter inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues addition nonretail sector united states includes government institutions including state aids drug assistance programs adaps correctional facilities large health maintenance organizations tends even less consistent terms buying patterns often causes quarter quarter fluctuations necessarily mirror patient demand products federal state budget pressures including sequestration well annual grant cycles federal state adap funds may cause adap purchasing patterns reflect patient demand hiv products example first quarters certain prior years observed large nonretail purchases hiv products number state adaps exceeded patient demand believe purchases driven grant cycle federal adap funds expect continue experience fluctuations purchasing patterns nonretail customers may result fluctuations product sales revenues earnings future light global economic downturn budget crises faced many european countries observed variations purchasing patterns induced cost containment measures europe believe measures caused government agencies purchasers reduce inventory products distribution channels decreased revenues caused fluctuations product sales earnings may continue see trend future results operations may adversely affected current potential future healthcare reforms legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions march healthcare reform legislation adopted united states requiring us rebate discount products reimbursed paid various public payers including medicaid entities eligible purchase discounted products b drug pricing program public health service act adaps result legislation discounts rebates fees impacted us include minimum base rebate amount owed medicaid products reimbursed medicaid increased discounts rebates owe adaps public health service entities reimburse purchase products also increased required extend rebates patients receiving products medicaid managed care organizations required provide discount products sold patients medicare part donut hole along pharmaceutical manufacturers branded drug products required pay portion new industry fee also known branded prescription drug bpd fee billion calculated based select government sales calendar year percentage total industry government sales amount annual industry fee imposed pharmaceutical industry whole billion increase billion increase peak billion decrease billion thereafter expect portion bpd fee increase revenues grow amount annual industry fee increases drug patents expire major drugs companies addition third quarter internal revenues service irs issued final regulations indicated manufacturers obligation pay portion bpd fee given calendar year triggered qualifying sales previous year instead first qualifying sale current calendar year result final irs regulations required recognize fee million fee million consolidated statement income bpd fees approximately million million million respectively bpd fee tax deductible even though addressed healthcare reform legislation discussions continue federal level legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare part pricing addition state medicaid programs could request additional supplemental rebates products result increase federal base medicaid rebate private insurers could also use enactment increased rebates exert pricing pressure products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services resulted lower average selling prices significant portion sales majority products subject significant discounts list price rebate obligations united states state adaps purchase significant portion hiv products rely federal supplemental federal state funding help fund purchases products past experienced shift payer mix hiv patients previously covered private insurance move public reimbursement programs require rebates discounts us patients previously covered one public reimbursement program move another public reimbursement program requires greater rebates discounts us federal state funds available amounts sufficient support number patients rely adaps sales hiv products could negatively impacted would reduce revenues prior quarters insufficiency federal state funds many states reduced eligibility criteria saw increase number patients state adap waitlists may see similar increases future periods result reduction federal state adap support resulting sequestration patients enrolled adap generally receive product industrysupported patient assistance programs unable access treatment increased emphasis managed healthcare united states country regional pricing reimbursement controls european union put additional pressure product pricing reimbursement usage may adversely affect product sales profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid healthcare reform pharmaceutical reimbursement policies pricing general also experienced increased pricing pressure united states certain cases provided discounts private payers order obtain formulary status expand access patients hcv products see also risk factor substantial portion revenues derived sales products treat hcv hiv unable maintain continue increasing sales products results operations may adversely affected july received letter us senate committee finance requesting information supporting documentation us related sovaldi pricing sovaldi united states letter raised concerns approach pricing sovaldi affordability impact federal government spending public health cooperating inquiries costly timeconsuming us comply inquiries predict outcome possible inquiries could result negative publicity negative actions could harm reputation reduce demand sovaldi harvoni sofosbuvir containing products andor reduce coverage sovaldi harvoni sofosbuvir containing products including federal health care programs medicare medicaid events occur business stock price could materially adversely affected countries outside united states success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices certain governmental authorities delay commercialization months reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates revenuerelated taxes tenders profit control expect prices prescription pharmaceuticals decline life product volumes increase recently many countries european union increased level discounting required products efforts could continue countries attempt manage healthcare expenditures especially light severe fiscal debt crises experienced many countries european union countries instituted clawbacks enacted taxes specific products generic drugs come market may face price decreases products countries european union cost containment pressures european union especially southern europe could lead delays treatment patients also delay pricing approval could negatively impact commercialization new products government agencies also issue regulations guidelines directly applicable us products addition time time professional societies practice management groups private healthscience foundations organizations publish guidelines recommendations directed certain health care patient communities recommendations guidelines may relate matters product usage dosage route administration use related competing therapies consequently result increased decreased usage products approximately product sales occur outside united states currency fluctuations hedging expenses may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates us dollar strengthens foreign currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increases overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business use foreign currency exchange forward option contracts hedge percentage forecasted international sales primarily denominated euro also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid predict future fluctuations foreign currency exchange rate us dollar us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation results operations adversely affected stock price may decline additionally expenses recognize relation hedging activities also cause earnings fluctuate level hedging expenses recognize particular period impacted changes interest rate spreads foreign currencies hedge us dollar face significant competition face significant competition large global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers hcv products sovaldi harvoni compete product marketed abbvie inc abbvie janssen rd ireland 's olysio simeprevir united states hiv products compete primarily products viiv healthcare viiv markets fixeddose combination products compete stribild compleraeviplera atripla truvada example lamivudine marketed joint venture competes emtricitabine active pharmaceutical ingredient emtriva component compleraeviplera atripla truvada tybost compete ritonavir marketed abbvie addition tivicay dolutegravir integrase inhibitor launched fourth quarter viiv triumeq singletablet triplecombination antiretroviral regimen launched third quarter viiv could adversely impact sales hiv products also face competition generic hiv products may compound patent covering epivir lamivudine expired united states generic lamivudine available united states spain portugal italy expect generic versions lamivudine launched countries within european union may generic version combivir lamivudine zidovudine approved recently launched united states addition late generic tenofovir also became available turkey resulted increase rebate viread turkey generic versions sustiva efavirenz component atripla available canada europe anticipate competition generic efavirenz united states december observed pricing pressure related sustiva component atripla sales viread hepsera treatment chronic hepatitis b virus hbv infection face competition baraclude entecavir marketed bristolmyers squibb company well generic entecavir hbv products also compete tyzekasebivo telbivudine marketed novartis pharmaceuticals corporation novartis ambisome competes predominantly vfend voriconazole developed pfizer caspofungin product developed merck marketed cancidas united states caspofungin elsewhere addition aware least three lipid formulations claim similarity ambisome becoming available outside united states including possible entry formulations taiwan formulations may reduce market demand ambisome furthermore manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association letairis competes directly tracleer bosentan opsumit macitentan produced actelion pharmaceuticals us inc also adcirca tadalafil united therapeutics corporation pfizer ranexa competes predominantly generic compounds three distinct classes drugs betablockers calcium channel blockers longacting nitrates treatment chronic angina united states cayston competes tobi tobramycin inhalation solution marketed novartis tamiflu competes relenza zanamivir sold gsk products sold generic competitors relapsed chronic lymphocytic leukemia zydelig competes imbruvica ibrutinib marketed pharmacyclics inc addition number companies pursuing development technologies competitive existing products research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs competitors gain market share products could adversely affect results operations stock price significant safety issues arise marketed products product candidates future sales may reduced would adversely affect results operations data supporting marketing approvals products forming basis safety warnings product labels obtained controlled clinical trials limited duration cases postapproval use products used longer periods time many patients underlying health problems taking numerous medicines expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings contraindications labels narrow approved indications could reduce market acceptance products product letairis approved us food drug administration fda june member class compounds called endothelin receptor antagonists pose specific risks including serious risks birth defects risks letairis available letairis education access program leap restricted distribution program intended help physicians patients learn risks associated product assure appropriate use product product used additional patients may discover new risks associated letairis may result changes distribution program additional restrictions use letairis may decrease demand product regulatory authorities moving towards active transparent pharmacovigilance making greater amounts standalone safety information clinical trial data directly available public websites means eg periodic safety update report summaries risk management plan summaries various adverse event data safety information without appropriate context expertise may misinterpreted lead misperception legal action may potentially cause product sales stock price decline serious safety resistance drug interaction issues arise marketed products sales products could limited halted us regulatory authorities results operations would adversely affected operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda ema comparable regulatory agencies countries continuing clinical trials sovaldi atripla truvada harvoni compleraeviplera stribild viread emtriva hepsera tybost vitekta letairis ranexa cayston zydelig currently approved additional uses anticipate file marketing approval additional countries additional indications products next several years products may fail receive marketing approvals timely basis marketed products manufacture sell products subject extensive regulation review discovery previously unknown problems marketed products problems manufacturing promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements including related promotion manufacturing could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution example fda rules often required conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk implement risk evaluation mitigation strategy products could include medication guide patient package insert communication plan healthcare providers elements fda deems necessary assure safe use drug could include imposing certain restrictions distribution use product failure comply requirements imposed sponsor fda could result significant civil monetary penalties operating results may adversely affected results anticipated timelines clinical trials uncertain may support continued development product candidate would adversely affect prospects future revenue growth required demonstrate safety efficacy products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products product candidates fails achieve primary endpoint clinical trials safety issues arise results clinical trials otherwise inadequate support regulatory approval product candidates commercialization product candidate could delayed halted example recently announced results phase study simtuzumab treatment pancreatic cancer myelofibrosis colorectal cancer showing product candidate provide clinical benefit addition may also face challenges clinical trial protocol design clinical trials product candidates pipeline delayed terminated prospects future revenue growth would adversely impacted example face numerous risks uncertainties product candidates including fixeddose combination sofosbuvir gs hcv fixeddose combination emtricitabine taf hiv idelalisib treatment indolent nonhodgkin lymphoma frontline relapsed refractory chronic lymphocytic leukemia momelotinib treatment myelofibrosis ranolazine treatment incomplete revascularization post percutaneous coronary intervention gs treatment lqt taf standalone agent currently phase clinical trials could prevent completion development product candidates risks include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain fda regulatory body approvals result product candidates may never successfully commercialized may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs others pipeline completed timely basis prospects future revenue growth may adversely impacted addition clinical trials involving commercial products could raise new safety issues existing products could turn decrease revenues harm business due reliance thirdparty contract research organizations conduct clinical trials unable directly control timing conduct expense quality clinical trials extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent third party contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management bioanalytical analysis many important aspects services performed us cros direct control dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros ' processes methodologies results determined invalid inadequate clinical data results related regulatory approvals could adversely affected depend relationships companies sales marketing performance development commercialization product candidates revenues failure maintain relationships poor performance companies disputes companies could negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance certain territories include collaborations bms atripla united states europe canada f hoffmannla roche ltd together hoffmannla roche inc roche tamiflu worldwide gsk ambrisentan territories outside united states countries rely international distributors sales truvada viread hepsera emtriva ambisome relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us particularly light current economic conditions given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline addition letairis cayston distributed thirdparty specialty pharmacies pharmacies specializing dispensing medications complex chronic conditions may require high level patient education ongoing counseling use specialty pharmacies requires significant coordination sales marketing medical affairs regulatory affairs legal finance organizations involves risks including limited risks specialty pharmacies provide us accurate timely information regarding inventories patient data safety complaints effectively sell support letairis cayston devote resources necessary sell letairis cayston volumes within time frames expect able satisfy financial obligations us others cease operations also rely third party administer leap restricted distribution program designed support letairis third party provides information education prescribers patients risks letairis confirms insurance coverage investigates alternative sources reimbursement assistance ensures fulfillment risk management requirements mandated letairis fda coordinates controls dispensing patients third party specialty pharmacies failure third party specialty pharmacies distribute letairis perform expected may result regulatory action fda decreased letairis sales either would harm business cayston may taken patients using specific inhalation device delivers drug lungs patients ongoing distribution cayston entirely reliant upon manufacturer device manufacturer could encounter issues regulatory agencies related device unable supply sufficient quantities device addition manufacturer may able provide adequate warranty support device distributed patients respect distribution drug device patients reliant capabilities specialty pharmacies example distribution channel drug device complicated requires coordination reimbursement approval processes associated drug device similarly complex device manufacturer unable obtain reimbursement approval receives approval lowerthanexpected price sales cayston may adversely affected previously described issues may limit sales cayston would adversely affect financial results success depend significant degree ability defend patents intellectual property rights domestically internationally may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology patents proprietary rights important business success depend significant degree ability obtain patents licenses patent rights preserve trade secrets defend infringement efforts invalidate patents operate without infringing intellectual property others properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents patent applications confidential period time patent issued result may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate litigation interference proceedings determine right patent litigation interference proceedings unpredictable expensive even ultimately successful results operations may adversely affected events patents cover ranolazine compound active ingredient ranexa instead discovered sustainedrelease formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve patents cover active ingredients ambisome addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hbv indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions supplementary protection certificates countries generic manufacturers sought may continue seek fda approval market generic versions products abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug see description anda litigation legal proceedings beginning risk factor entitled litigation generic manufacturers increased expenses may continue reduce earnings unsuccessful lawsuits claims patents may narrowed invalidated generic versions products could launched prior patent expiry beginning success depends large part ability operate without infringing upon patents proprietary rights third parties infringe valid patents third parties may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents may relate operation leap restricted distribution program designed support letairis aware patents patent applications owned parties may claim cover use sofosbuvir see description litigation regarding sofosbuvir risk factor entitled party successful establishing exclusive rights sovaldi andor harvoni expected revenues earnings sale sovaldi andor harvoni could adversely affected beginning furthermore also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions trade secrets confidential information become known independently discovered competitors enter disputes ownership inventions business results operations could adversely affected party successful establishing exclusive rights sovaldi andor harvoni expected revenues earnings sale sovaldi andor harvoni could adversely affected patents patent applications claim sofosbuvir sovaldi chemical entity metabolites fixeddose combination ledipasvir sofosbuvir harvoni third parties may may obtain rights patents allegedly could used prevent attempt prevent us commercializing sovaldi harvoni example aware patents patent applications owned parties may alleged parties cover use sovaldi harvoni predict ultimate outcome intellectual property claims related sovaldi harvoni spent continue spend significant resources defending claims parties successfully obtain valid enforceable patents successfully prove infringement patents sovaldi andor harvoni could prevented selling sofosbuvir unless able obtain license patents license may available commercially reasonable terms interference proceedings litigation idenix pharmaceuticals inc idenix february received notice us patent trademark office uspto declared interference first idenix interference us patent patent idenix 's pending us patent application interference administrative proceeding uspto designed determine first invent subject matter claimed parties patent covers metabolites sofosbuvir idenix attempting patent class compounds including metabolites purpose first idenix interference determine first invent compounds therefore entitled patent claiming compounds march uspto patent trial appeal board board determined idenix entitled benefit early application filing dates none patent applications including application granted idenixs us patent patent taught make compounds dispute board also determined entitled filing date earliest application first file patent application compounds dispute therefore senior party first idenix interference january board determined pharmasset idenix first invent compounds dispute accordingly gilead prevailed first idenix interference decision board held idenix failed prove first conceive compounds dispute specifically idenix failed prove idenix inventors identified structure method making use disputed compounds board went conclude idenix failed work diligently toward making testing compounds dispute relevant time period idenix appealed boards decisions us district court district delaware december receiving request uspto declared interference second idenix interference pending us patent application patent patent includes claims directed methods treating hcv nucleoside compounds similar involved first idenix interference second idenix interference determine first invent claimed methods treating hcv january board issued decision favor gilead first phase second idenix interference board decided first file patent application disputed methods treating hcv designated gilead senior party second idenix interference invalidated patent claims idenix patent involved second idenix interference senior party presumed first invented disputed methods treating hcv idenix failed teach make use invention patent board invalidated idenix claims involved second idenix interference lack enablement board also placed idenix order show cause requiring idenix explain judgment entered second idenix interference based upon decision board first idenix interference decision second idenix interference consistent boards earlier rulings march january first idenix interference gilead declared senior party first invent certain fluoro methyl nucleoside compounds compounds relevant methods treating hcv issue second idenix interference believe idenix claims involved first second idenix interferences similar us foreign patents claiming compounds metabolites uses thereof invalid result filed impeachment action federal court canada invalidate idenix canadian patent patent canadian patent corresponds patent idenix patent application subject first idenix interference idenix asserted commercialization sovaldi canada infringe patent canadian patent corresponding patent involved first idenix interference invalid trial issues commenced january filed similar legal action norway oslo district court seeking invalidate idenix 's norwegian patent corresponding patent september idenix filed invalidation action norwegian proceedings norwegian patent patent corresponds patent march norwegian court found claims idenix norwegian patent invalid upheld validity claims challenged gilead patent april idenix appealed march decision norwegian court appeal idenixs obligation pay attorneys fees stayed pendency appeal appeal march decision scheduled commence february august april idenix filed two separate requests invalidation chinese patent office chinese patent cn zl corresponds ' patent august idenix withdrew invalidation requests chinese proceedings terminated challenged patent remaining valid enforceable january filed legal action federal court australia seeking invalidate idenixs australian patent corresponding patent april idenix asserted commercialization sovaldi australia infringe australian patent corresponding patent trial issues scheduled commence september sydney march european patent office epo granted idenix european patent patent corresponds patent day patent granted filed opposition epo seeking revoke patent also day idenix initiated infringement proceedings gilead united kingdom uk germany france alleging commercialization sovaldi countries would infringe respective national counterparts patent united kingdom trial held october determine issues infringement validity idenix uk patent december high court justice england wales uk court invalidated claims patent multiple grounds specifically uk court held patent lacked novelty earlier filed patent application teaching compounds patent lacked inventive step add anything knowledge existing time disclosure idenixs patent application insufficient teach make compounds show claimed compounds would activity viruses like hepatitis c virus january uk court held hearing court ordered idenix pay gileads costs interim payment due within days hearing uk court granted idenix permission appeal december judgment february german court dsseldorf held hearing determine issue infringement idenix german patent trial date french lawsuit idenix awarded patents corresponding patent japan china event patents issue expect challenge proceedings similar invoked countries december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringe patent interference exists patent us patent also december idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringe us patent nos june court massachusetts granted request transferred massachusetts litigation us district court district delaware believe idenixs patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir district court set trial dates october december resolution issues decision district court appealed either party us court appeals federal circuit cafc idenix acquired merck august acquisition change view lack merit claims made idenix merck greater resources idenix may therefore choose fund litigation higher levels idenix litigation merck august merck contacted us requesting pay royalties sales sofosbuvir obtain license us patent nos coowns isis pharmaceuticals inc believe mercks patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir accordingly august filed lawsuit us district court northern district california seeking declaratory judgment merck patents invalid infringed mercks us patent nos cover compounds include may relate sofosbuvir patent prosecution merck amended patent application attempt cover compounds related sofosbuvir ultimately extract royalty payments sofosbuvirs commercialization exclude market court determines mercks patents valid infringed claims may required obtain license pay royalties merck commercialize sofosbuvir either party appeal decision district court cafc court set trial date march litigation litigation abbvie abbvie obtained us patent nos abbvie patents purport cover use combination ledipasvirsofosbuvir harvoni treatment hcv aware abbvie pending patent applications countries published pending patent applications directed use combinations treatment hcv specifically combination ledipasvir sofosbuvir certain applications filed abbvie patents reason others believe abbvie patents invalid accordingly december filed lawsuit us district court district delaware seeking declaratory judgment abbvie patents invalid unenforceable well relief believe abbott laboratories inc abbvie conspired eliminate competition hcv market falsely representing uspto gilead invented methods treating hcv using combination ledipasvirsofosbuvir february march abbvie responded lawsuit filing two lawsuits also us district court district delaware alleging fixeddose combination ledipasvirsofosbuvir infringe patents lawsuits consolidated single action either party appeal decision district court cafc abbvie patents blocked delayed commercialization combination product united states expect foreign patents block delay commercialization around world court determines abbvie patents valid infringed claims may required obtain license pay royalties abbvie commercialize sofosbuvir combination products manufacturing problems including thirdparty manufacturers corporate partners could cause inventory shortages delay product shipments regulatory approvals may adversely affect results operations order generate revenue products must able produce sufficient quantities products satisfy demand many products result complex manufacturing processes manufacturing process pharmaceutical products also highly regulated regulators may shut manufacturing facilities believe comply regulations products either manufactured facilities thirdparty manufacturers corporate partners depend third parties perform manufacturing activities effectively timely basis majority solid dose products addition roche either third parties responsible manufacturing tamiflu thirdparty manufacturers corporate partners subject good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda ema similar regulations effect countries thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval may writeoff costs manufacturing batch fails pass quality inspection meet regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected addition thirdparty manufacturers corporate partners may able produce products one limited number facilities therefore limited manufacturing capacity certain products example due unexpected delays qualifying two new external sites expanding cayston manufacturing san dimas unable supply enough cayston fulfill projected demand february september suspended access patients new prescriptions cayston subject certain exceptions specific medical need existed result inability manufacture sufficient cayston meet demand amount revenues received sale cayston reduced manufacturing operations subject routine inspections regulatory agencies example april fda conducted inspection foster city facility issued form inspectional observations noted deficiencies documentation validation certain quality testing procedures methods result observations fda delivered complete response letters notifying us unable approve ndas elvitegravir cobicistat standalone agents midoctober fda completed sofosbuvir preapproval inspection foster city facility following inspection fda issued additional form inspectional observations citing deficiencies related testing reconciliation stability samples testing protocols testing shipping samples procedures calibrating test equipment completed filed responses observations fda received letter fda related extent method revalidations conducted stability program oversight audit trail reviewdata management quality management system gaps filed responses observations fda unable remedy deficiencies cited fda inspections currently marketed products timing regulatory approval products development could adversely affected risk regulatory agencies countries marketing applications pending undertake similar additional reviews apply heightened standard review could delay regulatory approvals products countries approval product candidates delayed production marketed products interrupted anticipated revenues stock price would adversely affected may able obtain materials supplies necessary conduct clinical trials manufacture sell products would limit ability generate revenues need access certain supplies products conduct clinical trials manufacture products unable purchase sufficient quantities materials find suitable alternate materials timely manner development efforts product candidates may delayed ability manufacture products would limited would limit ability generate revenues suppliers key components materials must named nda filed fda ema regulatory authority product candidate seeking marketing approval significant delays occur qualification new supplier required even manufacturer qualified regulatory authority manufacturer must continue expend time money effort area production quality control ensure full compliance gmp manufacturers subject regular periodic inspections regulatory authorities following initial approval result inspections regulatory authority determines equipment facilities laboratories processes comply applicable regulations conditions product approval regulatory authority may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand would turn decrease revenues harm business addition delivery material suppliers interrupted reason may unable ship certain products commercial supply supply products development clinical trials addition products materials utilize operations made one facility example manufacture certain drug product intermediates utilized ambisome exclusively facilities san dimas california event disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome meet market needs addition depend single supplier highquality cholesterol active pharmaceutical ingredient used manufacture ambisome also rely single source active pharmaceutical ingredient zydelig letairis astellas us llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problems single suppliers depend may negatively impact development commercialization efforts significant portion raw materials intermediates used manufacture antiviral products sovaldi atripla truvada harvoni compleraeviplera stribild viread emtriva tybost supplied chinabased companies result international trade dispute china united states actions chinese government would limit prevent chinese companies supplying materials would adversely affect ability manufacture supply antiviral products meet market needs material adverse effect operating results litigation generic manufacturers increased expenses may continue reduce earnings unsuccessful lawsuits claims patents may narrowed invalidated generic versions products could launched prior patent expiry part approval process products fda granted us new chemical entity nce exclusivity period manufacturers ' applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug anda application form typically used manufacturers seeking approval generic drug current legal proceedings significance generic manufacturers include mylan april received notice mylan inc mylan submitted anda fda requesting permission manufacture market generic version truvada notice mylan alleges two patents associated emtricitabine one patents associated fixeddose combination emtricitabine tenofovir disoproxil fumarate invalid unenforceable andor infringed mylan 's manufacture use sale generic version truvada june filed lawsuit mylan us district court northern district west virginia infringement patents june received notice mylan inc submitted petitions inter partes review ipr board alleging four patents associated tenofovir disoproxil fumarate invalid opposed mylans petitions december ptab issued decisions denying mylans petitions ipr tenofovir disoproxil fumarateassociated patents grounds mylan established reasonable likelihood success would prevail challenge patents mylan requested rehearing basis believes ptab decision wrong apotex june received notice apotex inc apotex submitted abbreviated new drug submission ands canadian minister health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate separate ands requesting permission manufacture market generic version viread notice apotex alleges three patents associated truvada two patents associated viread invalid unenforceable andor infringed apotex 's manufacture use sale generic version truvada viread august filed lawsuit apotex federal court canada seeking order prohibition approval ands natco march f hoffmannla roche ltd roche filed lawsuit natco pharma ltd natco us district court district new jersey infringement one patents associated tamiflu december court issued ruling favor gilead roche patent invalid reason stated natcos notice letter natco appealed decision cafc april cafc issued decision allow natcos patent invalidity challenge proceed case remanded district court full trial merits june filed petition rehearing en banc cafc subsequently denied submitted request extension time submit petition certiorari supreme court united states concurrently proceeding district court teva august teva pharmaceuticals teva filed impeachment action federal court canada seeking invalidation two canadian patents associated viread september hearing consolidated requests orders prohibition connection three tevas ands filings canadian minister health tevas generic versions viread truvada atripla took place december court issued requested order prohibiting canadian ministry health issuing notice compliance tevas generic versions viread truvada atripla products expiry patent july teva appealed decision court prohibiting minister heath issuing notices compliance expiry patent july decision rule validity patents accordingly issue appeal whether minister health prohibited issuing notices compliance tevas products separately court determine validity patents pending impeachment action trial impeachment action scheduled september teva successful invalidating patents teva may able launch generic versions viread truvada atripla products canada prior expiry patents watson february received notice watson laboratories inc watson submitted anda fda requesting permission manufacture market generic version letairis notice watson alleges one patents associated ambrisentan tablets invalid unenforceable andor infringed watson 's manufacture use sale generic version letairis currently evaluating watson 's notice file patent infringement lawsuit necessary protect exclusivity product astellasapotex december astellas informed us received notice apotex submitted anda fda requesting permission manufacture market generic version lexiscan notice apotex alleges one patents associated regadenoson invalid unenforceable andor infringed apotexs manufacture use sale generic version lexiscan apotex challenged several patents associated regadenoson apotex product would eligible final approval expiry patents challenged astellas opportunity file patent infringement lawsuit apotex future decide necessary protect exclusivity product predict ultimate outcome foregoing actions litigation generic manufacturers may spend significant resources enforcing defending patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection truvada viread tamiflu united states atripla truvada viread canada could substantially shortened patents covering one products invalidated fda canadian minister health could approve requests manufacture generic version products united states canada respectively prior expiration date patents sale generic versions products earlier patent expiration would significant negative effect revenues results operations face credit risks emerging market southern european customers may adversely affect results operations exposure customer credit risks emerging markets southern europe southern european product sales governmentowned supported customers southern europe specifically spain italy portugal greece historically continue subject significant payment delays due government funding reimbursement practices resulted may continue result days sales outstanding significantly higher countries due average length time accounts receivable remain outstanding december accounts receivable countries totaled approximately million million past due greater days million past due greater days historically receivable balances certain publiclyowned hospitals accumulate period time subsequently settled large lump sum payments pattern also experienced pharmaceutical companies sell directly hospitals significant changes occur reimbursement practices european governments government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected revenues gross margin could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly truvada viread agreed make available substantially reduced prices countries participating gilead access program atripla merck distributes substantially reduced prices hiv infected patients developing countries agreement revenues would adversely affected addition established partnerships indiabased generic manufacturers distribute generic versions tenofovir disoproxil fumarate developing world countries including india expanded agreements include rights stribild tybost vitekta also entered agreements certain indiabased generic manufacturers produce distribute generic emtricitabine developing world including single tablet regimens containing emtricitabine fixeddose combinations emtricitabine coformulated hiv medicines september entered licensing agreements indiabased generic manufacturers produce distribute generic sofosbuvir fixeddose combination ledipasvirsofosbuvir developing countries generic versions hiv hcv medications licenses reexported united states europe markets outside countries revenues would adversely affected part commitment make sovaldi available developing world discounted prices entered agreement make sovaldi available egypt country among highest hcv prevalence world discounted sovaldi reexported developing countries united states higher price markets revenues could adversely affected addition purchases products countries selling prices relatively low resale countries selling prices relatively high may adversely impact revenues gross margin may cause sales fluctuate quarter quarter example european union required permit products purchased one country sold another country purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter quarterly fluctuations may impact earnings could adversely affect stock price harm business expensive litigation government investigations increased expenses may continue reduce earnings involved number litigation investigation disputerelated matters require us expend substantial internal financial resources expect matters continue require high level internal financial resources foreseeable future matters reduced continue reduce earnings please see description litigation regarding sofosbuvir litigation generic manufacturers legal proceedings beginning outcome lawsuits lawsuits may brought us investigation investigations may initiated inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us could significantly reduce earnings cash flows harm business countries may required grant compulsory licenses products patents may enforced number developing countries government officials interested groups suggested pharmaceutical companies make drugs hcv hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example growing attention availability hcv therapies activists advocating increased availability hcv therapies means including compulsory licenses past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread addition concerns cost availability tamiflu related potential avian flu pandemic hn influenza generated international discussions compulsory licensing tamiflu patents example canadian government considered allowing canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canada 's access medicines regime furthermore roche issued voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense india 's hetero drugs limited india certain developing countries compulsory licenses permit generic manufacturing override product patents sovaldi harvoni hiv products tamiflu required grant compulsory licenses products could reduce earnings cash flows harm business addition certain countries permit enforcement patents thirdparty manufacturers able sell generic versions products countries example july brazilian patent authority rejected patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread highest level appeal available us within brazilian patent authority currently patent brazil brazilian government purchases supply tenofovir disoproxil fumarate generic manufacturers sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others recent years coverage availability costeffective product liability insurance decreased may unable maintain sufficient coverage product liabilities may arise addition cost defend lawsuits pay damages product liability claims may exceed coverage unable maintain adequate coverage claims exceed coverage financial condition ability clinically test product candidates market products adversely affected addition negative publicity associated claims regardless merit may decrease future demand products impair financial condition business disruptions natural manmade disasters may harm future revenues worldwide operations could subject business interruptions stemming natural manmade disasters may selfinsured corporate headquarters fremont locations together house majority rd activities san dimas oceanside manufacturing facilities located california seismically active region carry earthquake insurance significant recovery time could required resume operations financial condition operating results could materially adversely affected event major earthquake dependent information technology systems infrastructure data dependent upon information technology systems infrastructure data multitude complexity computer systems make inherently vulnerable service interruption destruction malicious intrusion random attack likewise data privacy security breaches employees others may pose risk sensitive data including intellectual property trade secrets personal information employees patients customers business partners may exposed unauthorized persons public cyberattacks increasing frequency sophistication intensity cyberattacks could include deployment harmful malware denialofservice social engineering means affect service reliability threaten data confidentiality integrity availability business partners face similar risks security breach systems could adversely affect security posture invested continue invest protection data information technology infrastructure assurance efforts prevent service interruptions identify breaches systems could adversely affect business operations andor result loss critical sensitive information could result financial legal business reputational harm us addition liability insurance may sufficient type amount cover us claims related security breaches cyberattacks related breaches changes effective income tax rate could reduce earnings subject income taxes united states various foreign jurisdictions including ireland due economic political conditions various countries actively considering changes existing tax laws predict form timing potential legislative changes could material adverse impact results operations addition significant judgment required determining worldwide provision income taxes various factors may favorable unfavorable effects income tax rate including limited changes forecasted demand hcv products portion nontax deductible bpd fee also known pharmaceutical excise tax accounting stock options sharebased awards mergers acquisitions ability manufacture product cork ireland facility amortization certain acquisition related intangibles receive tax benefit expiration federal research tax credit future levels rd spending changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact consolidated results operations income tax returns audited federal state foreign tax authorities currently examination internal revenue service tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions resolution one exposures reporting period could material impact results operations period fail attract retain highly qualified personnel may unable successfully develop new product candidates conduct clinical trials commercialize product candidates future success depend large part continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization face competition personnel companies universities public private research institutions government entities organizations competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit may able attract retain quality personnel acceptable terms unsuccessful recruitment retention efforts business may harmed assurance pay dividends continue repurchase stock february announced board directors authorized dividend program intend pay quarterly dividends per share beginning second quarter subject quarterly declarations board directors board directors also approved repurchase additional billion common stock declaration amount timing dividends andor amount timing stock repurchases subject capital availability determinations board directors cash dividends andor stock repurchases best interest stockholders compliance respective laws agreements applicable declaration payment cash dividends repurchase stock ability pay dividends andor repurchase stock depend upon among factors cash balances potential future capital requirements strategic transactions including acquisitions debt service requirements results operations financial condition factors beyond control board directors may deem relevant reduction elimination dividend payments dividend program andor stock repurchases could negative effect stock price item b unresolved staff comments applicable item properties corporate headquarters located foster city california house administrative manufacturing rd activities also rd facilities oceanside fremont california seattle washington branford connecticut alberta canada manufacturing facilities san dimas california cork ireland global commercial operations include offices throughout europe seven asia one south america one north america believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings litigation regarding sofosbuvir january acquired pharmasset inc pharmasset acquisition acquired sofosbuvir nucleotide analog acts inhibit replication hcv december received fda approval sofosbuvir known commercially sovaldi october also received approval fixeddose combination ledipasvir sofosbuvir known commercially harvoni received number contractual intellectual property claims regarding sofosbuvir carefully considered claims prior following acquisition believe without merit patents patent applications claim sofosbuvir sovaldi chemical entity metabolites fixeddose combination ledipasvir sofosbuvir harvoni third parties may may obtain rights patents allegedly could used prevent attempt prevent us commercializing sovaldi harvoni example aware patents patent applications owned parties may alleged parties cover use sovaldi harvoni predict ultimate outcome intellectual property claims related sovaldi harvoni spent continue spend significant resources defending claims parties successfully obtain valid enforceable patents successfully prove infringement patents sovaldi andor harvoni could prevented selling products unless able obtain license patents license may available commercially reasonable terms interference proceedings litigation idenix pharmaceuticals inc idenix february received notice us patent trademark office uspto declared interference first idenix interference us patent patent idenix 's pending us patent application interference administrative proceeding uspto designed determine first invent subject matter claimed parties patent covers metabolites sofosbuvir idenix attempting patent class compounds including metabolites purpose first idenix interference determine first invent compounds therefore entitled patent claiming compounds march uspto patent trial appeal board board determined idenix entitled benefit early application filing dates none patent applications including application granted idenixs us patent patent taught make compounds dispute board also determined entitled filing date earliest application first file patent application compounds dispute therefore senior party first idenix interference january board determined pharmasset idenix first invent compounds dispute accordingly gilead prevailed first idenix interference decision board held idenix failed prove first conceive compounds dispute specifically idenix failed prove idenix inventors identified structure method making use disputed compounds board went conclude idenix failed work diligently toward making testing compounds dispute relevant time period idenix appealed boards decisions us district court district delaware december receiving request uspto declared interference second idenix interference pending us patent application patent patent includes claims directed methods treating hcv nucleoside compounds similar involved first idenix interference second idenix interference determine first invent claimed methods treating hcv january board issued decision favor gilead first phase second idenix interference board decided first file patent application disputed methods treating hcv designated gilead senior party second idenix interference invalidated patent claims idenix patent involved second idenix interference senior party presumed first invented disputed methods treating hcv idenix failed teach make use invention patent board invalidated idenix claims involved second idenix interference lack enablement board also placed idenix order show cause requiring idenix explain judgment entered second idenix interference based upon decision board first idenix interference decision second idenix interference consistent boards earlier rulings march january first idenix interference gilead declared senior party first invent certain fluoro methyl nucleoside compounds compounds relevant methods treating hcv issue second idenix interference believe idenix claims involved first second idenix interferences similar us foreign patents claiming compounds metabolites uses thereof invalid result filed impeachment action federal court canada invalidate idenix canadian patent patent canadian patent corresponds patent idenix patent application subject first idenix interference idenix asserted commercialization sovaldi canada infringe patent canadian patent corresponding patent involved first idenix interference invalid trial issues commenced january filed similar legal action norway oslo district court seeking invalidate idenix 's norwegian patent corresponding patent september idenix filed invalidation action norwegian proceedings norwegian patent patent corresponds patent march norwegian court found claims idenix norwegian patent invalid upheld validity claims challenged gilead patent april idenix appealed march decision norwegian court appeal idenixs obligation pay attorneys fees stayed pendency appeal appeal march decision scheduled commence february august april idenix filed two separate requests invalidation chinese patent office chinese patent cn zl corresponds ' patent august idenix withdrew invalidation requests chinese proceedings terminated challenged patent remaining valid enforceable january filed legal action federal court australia seeking invalidate idenixs australian patent corresponding patent april idenix asserted commercialization sovaldi australia infringe australian patent corresponding patent trial issues scheduled commence september sydney march european patent office epo granted idenix european patent patent corresponds patent day patent granted filed opposition epo seeking revoke patent also day idenix initiated infringement proceedings gilead united kingdom uk germany france alleging commercialization sovaldi countries would infringe respective national counterparts patent united kingdom trial held october determine issues infringement validity idenix uk patent december high court justice england wales uk court invalidated claims patent multiple grounds specifically uk court held patent lacked novelty earlier filed patent application teaching compounds patent lacked inventive step add anything knowledge existing time disclosure idenixs patent application insufficient teach make compounds show claimed compounds would activity viruses like hepatitis c virus january uk court held hearing court ordered idenix pay gileads costs interim payment due within days hearing uk court granted idenix permission appeal december judgment february german court dsseldorf held hearing determine issue infringement idenix german patent trial date french lawsuit idenix awarded patents corresponding patent japan china event patents issue expect challenge proceedings similar invoked countries december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringe patent interference exists patent us patent also december idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringe us patent nos june court massachusetts granted request transferred massachusetts litigation us district court district delaware believe idenixs patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir district court set trial dates october december resolution issues decision district court appealed either party us court appeals federal circuit cafc idenix acquired merck august acquisition change view lack merit claims made idenix merck greater resources idenix may therefore choose fund litigation higher levels idenix litigation merck co inc merck august merck contacted us requesting pay royalties sales sofosbuvir obtain license us patent nos coowns isis pharmaceuticals inc believe mercks patents invalid infringed commercialization sofosbuvir sole right commercialize sofosbuvir august filed lawsuit us district court northern district california seeking declaratory judgment merck patents invalid infringed mercks us patent nos cover compounds include may relate sofosbuvir patent prosecution merck amended patent application attempt cover compounds related sofosbuvir apparent goal ultimately extracting royalty payments sofosbuvirs commercialization eliminating competition excluding market court determines mercks patents valid infringed claims may required obtain license pay royalties merck commercialize sofosbuvir either party appeal decision district court cafc court set trial date march lawsuit litigation abbvie inc abbvie abbvie obtained us patent nos abbvie patents purport cover use combination ledipasvirsofosbuvir harvoni treatment hcv gilead aware abbvie pending patent applications united states countries published pending patent applications directed use combinations treatment hcv specifically combination ledipasvir sofosbuvir certain applications filed abbvie patents reason others believe abbvie patents invalid accordingly december filed lawsuit us district court district delaware seeking declaratory judgment abbvie patents invalid unenforceable well relief believe abbott laboratories inc abbvie conspired eliminate competition hcv market falsely representing uspto gilead invented methods treating hcv using combination ledipasvirsofosbuvir february march abbvie responded lawsuit filing two lawsuits also us district court district delaware alleging fixeddose combination ledipasvirsofosbuvir infringe patents lawsuits consolidated single action united states either party appeal decision district court cafc abbvie patents blocked delayed commercialization combination product united states europe expect foreign patents block delay commercialization around world court determines abbvie patents valid infringed claims may required obtain license pay royalties abbvie commercialize sofosbuvir combination products litigation generic manufacturers part approval process products fda granted us new chemical entity nce exclusivity period manufacturers ' applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug tenofovir disoproxil fumarate emtricitabine fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz received notices teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version truvada april teva reached agreement settle ongoing patent litigation concerning patents protect tenofovir disoproxil fumarate atripla truvada viread agreement teva allowed launch generic version viread december april teva entered agreement settle ongoing patent litigation concerning emtricitabine patents protect atripla truvada terms settlement confidential november received notice teva submitted ands canadian minister health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate notice teva alleges three patents associated truvada invalid unenforceable andor infringed teva 's manufacture use sale generic version truvada january filed lawsuit teva federal court canada seeking order prohibition approval ands december received notice teva submitted ands canadian minister health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz notice teva alleges three patents associated atripla two merck 's patents associated atripla invalid unenforceable andor infringed teva 's manufacture use sale generic fixeddose combination emtricitabine tenofovir disoproxil fumarate efavirenz february filed lawsuit teva federal court canada seeking order prohibition approval ands august received notice teva submitted ands canadian minister health requesting permission manufacture market generic version viread notice teva alleges two patents associated tenofovir disoproxil fumarate invalid unenforceable andor infringed teva 's manufacture use sale generic version viread truvada atripla september filed lawsuit teva federal court canada seeking order prohibition approval ands also august teva filed impeachment action federal court canada seeking invalidation two canadian patents associated viread currently defending impeachment action requests orders prohibition connection three tevas ands filings tevas generic versions viread truvada atripla consolidated december court issued requested order prohibiting canadian minister health issuing notice compliance tevas generic versions viread truvada atripla products expiry patent july teva appealed decision decision rule validity patents accordingly issue appeal whether minister health prohibited issuing notices compliance tevas products separately court determine validity patents pending impeachment action trial impeachment action scheduled september teva successful invalidating patents teva may able launch generic versions viread truvada atripla products canada prior expiry patents received notice lupin limited lupin submitted anda fda requesting permission manufacture market generic versions truvada viread may lupin amended andas certify longer seeking approval market generic versions truvada viread prior expiration four patents associated tenofovir disoproxil fumarate january including pediatric exclusivity september reached agreement lupin settle lawsuit related emtricitabine patents protect truvada atripla terms settlement confidential july received notice cipla ltd cipla submitted anda fda requesting permission manufacture market generic versions emtriva viread july cipla reached agreement settle lawsuits terms settlement confidential april received notice mylan inc mylan submitted anda fda requesting permission manufacture market generic version truvada notice mylan alleges two patents associated emtricitabine one patents associated fixeddose combination emtricitabine tenofovir disoproxil fumarate invalid unenforceable andor infringed mylan 's manufacture use sale generic version truvada june filed lawsuit mylan us district court northern district west virginia infringement patents june received notice mylan inc submitted petitions inter partes review ipr board alleging four patents associated tenofovir disoproxil fumarate invalid opposed mylans petitions december uspto patent trial appeal board ptab issued decisions denying mylans petitions ipr tenofovir disoproxil fumarateassociated patents grounds mylan established reasonable likelihood success would prevail challenge patents mylan requested rehearing basis believes ptab decision wrong june received notice apotex inc apotex submitted ands canadian minister health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate separate ands requesting permission manufacture market generic version viread notice apotex alleges three patents associated truvada two patents associated viread invalid unenforceable andor infringed apotex 's manufacture use sale generic version truvada viread august filed lawsuit apotex federal court canada seeking order prohibition approval ands ranolazine received notice lupin submitted anda fda requesting permission manufacture market generic version sustainedrelease ranolazine august parties reached agreement settle patent litigation prior issuance courts decision agreement lupin allowed launch generic version ranexa february tamiflu february received notice natco pharma ltd natco submitted anda fda requesting permission manufacture market generic version tamiflu notice natco alleges one patents associated oseltamivir phosphate invalid unenforceable andor infringed natco 's manufacture use sale generic version tamiflu march roche filed lawsuit natco us district court district new jersey infringement one patents associated tamiflu december court issued ruling favor gilead roche patent invalid reason stated natco 's notice letter natco appealed decision cafc issued decision april allowing natcos patent invalidity challenge proceed remanding district court new jersey full trial merits june filed petition rehearing en banc cafc subsequently denied filed petition certiorari supreme court united states concurrently proceeding district court letairis august natco filed complaint us district court district minnesota gilead express scripts holding co specialty pharmacy distributes letairis product distribute letairis pursuant fdamandated risk evaluation mitigation strategies rems program natco alleges gilead independently together express scripts denied natco access samples letairis natco claims needs order conduct bioequivalence testing file anda according natco conduct therefore violates antitrust laws natco seeking damages order restraining gilead limiting distribution letairis natco use rems program november zydus pharmaceuticals usa inc zydus cadila healthcare limited cadila filed complaint us district court district new jersey us relating letairis sales distribute letairis pursuant rems program zydus cadila allege denied access samples letairis claim need order conduct bioequivalence testing file anda according zydus cadila conduct therefore violates antitrust laws zydus cadila seeking damages order enjoining gilead provide zydus samples letairis february received notice watson laboratories inc watson submitted anda fda requesting permission manufacture market generic version letairis notice watson alleges one patents associated ambrisentan tablets invalid unenforceable andor infringed watson 's manufacture use sale generic version letairis currently evaluating watson 's notice file patent infringement lawsuit necessary protect exclusivity product lexiscan december astellas informed us received notice apotex submitted anda fda requesting permission manufacture market generic version lexiscan notice apotex alleges one patents associated regadenoson invalid unenforceable andor infringed apotexs manufacture use sale generic version lexiscan apotex challenged several patents associated regadenoson apotex product would eligible final approval expiry patents challenged astellas opportunity file patent infringement lawsuit apotex future decide necessary protect exclusivity product predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits claims patents may narrowed invalidated patent protection truvada viread lexiscan tamiflu united states atripla truvada viread canada could substantially shortened patents covering one products invalidated fda canadian minister health could approve requests manufacture generic version products united states canada respectively prior expiration date patents sale generic versions products earlier patent expiration would significant negative effect revenues results operations department justice investigation june received subpoena us attorney 's office northern district california requesting documents related manufacture related quality distribution practices complera atripla truvada viread emtriva hepsera letairis cooperated governments inquiry april united states department justice informed us following investigation declined intervene false claims act lawsuit filed two former employees april former employees served first amended complaint january federal district court issued order granting entirety without prejudice motion dismiss first amended complaint february former employees served second amended complaint move dismiss second amended complaint matters party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations item mine safety disclosures applicable part ii item market registrant 's common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild following table sets forth high low intraday sale prices per share common stock nasdaq global select market periods indicated prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record include shares held broker bank nominee paid cash dividends common stock since inception february announced initiation quarterly dividend per share begin second quarter subject declaration board directors quarterly dividend equivalent per share annual basis performance graph following graph compares total stockholder returns past five years two indices standard poor 's stock index labeled sp index nasdaq biotechnology index labeled nbi index total return index assumes reinvestment dividends paid companies included indices calculated december year composite member sp index nbi index intend use indices comparators stock performance purposes following graph going forward composite member sp index required applicable regulations use index comparator believe nbi index relevant comparator since composed peer companies linesofbusiness similar stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december issuer purchases equity securities third quarter completed billion stock repurchase program announced program repurchased billion program may board directors authorized new threeyear billion stock repurchase program program program expire september december repurchased billion common stock program february announced board directors authorized new billion fiveyear share repurchase program initiate completion program spent total billion repurchase retire approximately million shares common stock average purchase price per share see item note stockholders ' equity consolidated financial statements included annual report information regarding stock repurchase programs table summarizes stock repurchase activity three months ended december total number shares purchased maximum fair part publicly value shares total number average price announced may yet purchased shares purchased paid per share program program thousands dollars thousands millions october october november november december december total stock repurchases made program difference total number shares purchased total number shares purchased part publicly announced programs due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations item selected financial data gilead sciences inc selected consolidated financial data millions except per share data year ended december consolidated statement income data total revenues total costs expenses income operations provision income taxes net income attributable gilead net income per share attributable gilead common stockholders basic shares used per share calculationbasic net income per share attributable gilead common stockholders diluted shares used per share calculationdiluted december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible senior notes senior unsecured notes credit facility retained earnings total stockholders ' equity see item management 's discussion analysis description results operations completed acquisition pharmasset recognized consideration transferred billion primarily recorded intangible assets financed transaction approximately billion cash hand billion bank debt issued january billion senior unsecured notes issued december issued senior unsecured notes total aggregate principal amount billion also repaid million principal balance convertible senior notes billion cash related conversion spread notes million senior unsecured notes million revolving credit facility repaid billion principal balance convertible senior notes repaid million fiveyear revolving credit facility credit agreement fiveyear revolving credit agreement borrowed million fiveyear revolving credit agreement issued billion principal amount senior unsecured notes registered offerings issued billion principal amount convertible senior notes private placement item management 's discussion analysis financial condition results operations following management 's discussion analysis financial condition results operations mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report including disclosures item risk factors consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars management overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world gilead 's primary areas focus include human immunodeficiency virus hiv liver diseases chronic hepatitis c virus hcv infection chronic hepatitis b virus hbv infection oncology inflammation serious cardiovascular respiratory conditions operations countries worldwide headquarters foster city california continue add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategy portfolio marketed products includes sovaldi atripla truvada harvoni compleraeviplera stribild viread letairis ranexa ambisome zydelig cayston hepsera emtriva tybost vitekta tamiflu us international commercial sales operations marketing subsidiaries north south america europe asiapacific also sell distribute certain products corporate partners royaltypaying collaborative agreements business highlights continued advance product pipeline across therapeutic areas goal delivering bestinclass drugs advance current standard care andor address unmet medical needs highlights announcements include antiviral program received approval us food drug administration fda october european commission november harvoni ledipasvir mgsofosbuvir mg first oncedaily single tablet regimen treatment hcv genotype infection adults received approval european commission sovaldi combination antiviral agents ribavirin pegylated interferon alpha countries european union eu january submitted new drug application nda japans pharmaceutical medical devices agency approval sofosbuvir single tablet regimen ledipasvirsofosbuvir treatment chronic genotype hcv infection adults received approval fda tybost pharmacokinetic enhancer boosts blood levels certain hiv medicines vitekta integrase inhibitor treatment hiv infection adults without known mutations associated resistance elvitegravir submitted nda fda approval single tablet regimen containing elvitegravir cobicistat emtricitabine tenofovir alafenamide ecftaf treatment hiv infection adults announced expansion agreement janssen rd ireland limited janssen development commercialization new single tablet regimen containing taf emtricitabine janssen 's rilpivirine rftaf also amended agreement janssen collaborate single tablet regimen hiv infection containing taf emtricitabine cobicistat janssen 's darunavir entered agreement phenex pharmaceuticals ag phenex december acquired phenexs farnesoid x receptor fxr program comprised small molecule fxr agonists treatment liver diseases including nonalcoholic steatohepatitis nash announced nonexclusive licensing agreements indiabased generic pharmaceutical manufacturers expand access chronic hcv medicines developing countries announced new agreement medicines patent pool expand access taf hiv hbv contingent fda approval oncology program received approval fda july european commission september zydelig treatment three bcell blood cancers zydelig indicated combination rituximab patients relapsed chronic lymphocytic leukemia monotherapy patients relapsed follicular lymphoma small lymphocytic lymphoma entered exclusive license agreement ono pharmaceutical co ltd ono development commercialization ono 's oral bruton 's tyrosine kinase inhibitor treatment bcell malignancies diseases cardiovascular program announced positive results ambition study randomized doubleblind multicenter study firstline combination therapy letairis ambrisentan tadalafil patients pulmonary arterial hypertension conducted collaboration glaxosmithkline plc filed supplemental nda united states cover use ambrisentan combination tadalafil outlook continue focus key operating objectives include progression product pipeline continued uptake commercial products research development rd perspective continue invest conducting new ongoing clinical studies support existing products product candidates expect move forward number latestage clinical studies new product candidates plan file marketing applications product candidates various therapeutic areas commercial perspective continue focus supporting uptake single tablet regimens treatment hiv prepare launch new single tablet regimen containing taf united states continue promote use sovaldi harvoni zydelig united states europe plan buildout expand international commercial infrastructure asia particular japan international markets support anticipated launch sovaldi harvoni regions result launch sovaldi harvoni united states sovaldi parts europe business doubled expect level growth anticipate overall net product sales growth expect expanded access sovaldi harvoni united states launch harvoni additional european union countries international markets however growth subject number uncertainties uncertainties include continuation challenging macroeconomic environment europe inclusive potential adoption additional pricing measures reduce healthcare spending particularly hcv potential continued volatility foreign currency exchange rates number hcv patients treated increase discounts chargebacks rebates due ongoing private public payer negotiations larger anticipated shift payer mix highly discounted payer segments regulatory approval commercial launches sovaldi harvoni japan expect product pipeline investments expanding commercial infrastructure enable us execute operating objectives financial highlights total revenues increased billion total product sales increased billion compared billion billion respectively driven primarily sales sovaldi harvoni increased sales hiv single tablet regimen products stribild compleraeviplera sovaldi approved united states december european union january sovaldi available countries harvoni approved united states october european union november rd expenses increased billion compared due continued investment progression expansion product pipeline selling general administrative sga expenses increased billion compared due increased costs support business expansion related primarily liver diseases oncology increase branded prescription drug fee bpd fee net income attributable gilead billion per diluted share compared billion per diluted share due primarily launch sovaldi harvoni partially offset increases operating expenses december cash cash equivalents marketable securities totaled billion generated billion operating cash flows issued billion senior unsecured notes repaid billion debt results operations total revenues total revenues include product sales royalty contract revenues total revenues billion compared billion billion product sales represented total revenues respectively product sales total product sales billion compared billion billion driven primarily increase antiviral product sales antiviral product sales billion billion billion increase antiviral product sales driven primarily sales sovaldi harvoni driven primarily continued uptake hiv single tablet regimen products primarily stribild compleraeviplera product sales include letairis ranexa ambisome zydelig first oncology product launched billion increase compared billion increase product sales billion approximately product sales generated outside united states face exposure adverse movements foreign currency exchange rates primarily euro used foreign currency exchange contracts hedge percentage foreign currency exposure foreign currency exchange net hedges favorable impact million revenues compared unfavorable impact million revenues compared record product sales net estimated mandatory supplemental discounts government payers addition discounts private payers related costs deductions generally referred grosstonet deductions totaled billion billion billion percentage gross product sales grosstonet deductions decline grosstonet deductions percentage gross product sales compared primarily due change payer mix reflecting higher proportion private payers compared prior year given launch sovaldi december harvoni october increase grosstonet deductions percentage gross product sales compared resulted primarily changes payer mix dollar increase resulted payer mix higher level gross product sales product sales united states increased billion compared billion due primarily sales sovaldi harvoni increases sales stribild complera product sales united states increased compared billion driven sales growth single tablet regimen products specifically stribild complera well launch sovaldi fourth quarters noted inventory levels high end inventory management agreement range seen years past believe inventory could draw first quarter track normally demand rest product sales europe increased billion compared billion due primarily sales sovaldi increases sales stribild eviplera product sales europe increased billion compared billion driven primarily higher underlying demand antiviral products specifically eviplera partially offset decreases average net selling price hiv products foreign currency exchange net hedges favorable impact million european product sales compared unfavorable impact million european product sales compared following table summarizes period period changes product sales millions except percentages change change antiviral products sovaldi atripla truvada harvoni compleraeviplera stribild viread antiviral total antiviral products products letairis ranexa ambisome zydelig total product sales percentage meaningful antiviral products antiviral product sales increased compared compared following additional discussion results product hcv products sales sovaldi harvoni hcv products billion hcv product sales accounted total antiviral product sales year hcv product sales billion united states billion europe since launch sovaldi december harvoni october patients around world treated sofosbuvirbased regimen atripla atripla sales accounted total antiviral product sales respectively decreased compared due primarily declines volume doctors prescribed newer treatments compleraeviplera stribild efavirenz component atripla gross margin zero comprised billion billion billion atripla sales respectively generic version bristolmyers squibb company 's sustiva efavirenz component atripla made available canada europe made available united states observed pricing pressure related efavirenz component atripla sales yet observed meaningful splitting atripla single tablet regimen truvada truvada sales increased compared due primarily increase average net selling price sales volume growth united states decreases truvada sales due lower sales volume partially offset increase average net selling price truvada sales accounted total antiviral product sales respectively compleraeviplera sales compleraeviplera billion increase compared increases sales compleraeviplera driven primarily sales volume growth europe united states compleraeviplera sales increased due primarily sales volume growth united states stribild sales stribild billion increase compared due primarily increased sales volume united states europe increases sales stribild driven primarily sales volume growth united states products products include letairis ranexa ambisome zydelig first oncology product launched billion compared billion increase product sales due primarily increased sales volume royalty contract revenues following table summarizes period period changes royalty contract revenues millions except percentages change change royalty contract revenues royalty contract revenues includes royalty revenues f hoffmanla roche ltd roche sales tamiflu majority royalties recognized quarter following quarter corresponding product sales occur cost goods sold product gross margin following table summarizes period period changes product sales cost goods sold product gross margin millions except percentages change change total product sales cost goods sold product gross margin product gross margin increased compared primarily due changes product mix resulting launches sovaldi harvoni product gross margin consistent product gross margin research development expenses following table summarizes period period changes rd expenses millions except percentages change change research development rd expenses summarized consist primarily clinical studies performed contract research organizations materials supplies licenses fees milestone payments collaboration arrangements personnel costs including salaries benefits stockbased compensation overhead allocations consisting various support facilitiesrelated costs track total rd expenses product candidate therapeutic area development phase however manage rd expenses identifying rd activities anticipate performed given period prioritizing efforts based scientific data probability successful development market potential available human capital resources considerations continually review rd pipeline status development necessary reallocate resources among rd portfolio believe best support future growth business following table provides breakout rd expenses major cost type millions except percentages clinical studies outside services personnel infrastructure expenses facilities costs total rd expenses increased million compared due primarily increase clinical studies outside services increase clinical studies outside services includes onetime items million collaboration acquisition related expenses purchase fda priority review voucher million expenses related progression clinical study activity primarily oncology hiv areas personnel infrastructure expenses increased million support ongoing clinical study activity geographic expansion marketed product support rd expenses increased million compared due primarily million increase clinical studies million increase personnel infrastructure expenses support continued progression clinical studies particularly phase studies oncology liver diseases hiv increases partially offset million decrease stockbased compensation expense due acceleration vested stock options related acquisition pharmasset inc pharmasset january clinical studies outside services increased million compared due progression expansion phase studies particularly liver diseases oncology additionally personnel expenses increased million due higher headcount support product pipeline study progression expect rd expenses increase support expansion clinical studies various therapeutic areas including liver disease hiv oncology selling general administrative expenses following table summarizes period period changes sga expenses millions except percentages change change selling general administrative sga expenses relate sales marketing finance human resources legal administrative activities expenses primarily comprised facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses increased billion compared due primarily increase headcountrelated expenses million support ongoing growth expansion business including commercial expansion related launches sovaldi harvoni increase bpd fee third quarter internal revenues service irs issued final regulations indicated manufacturers obligation pay portion bpd fee given calendar year triggered qualifying sales previous year instead first qualifying sale current calendar year result final irs regulations required recognize fee million fee million consolidated statement income bpd fees approximately million million million respectively bpd fee tax deductible sga expenses increased million compared increase due primarily million increase headcountrelated expenses support ongoing growth business legal expenses bpd fee increase partially offset million decrease stock based compensation due acceleration vested stock options related acquisition pharmasset january expect sga expenses increase compared support continued buildout expansion commercial infrastructure europe asia support products interest expense interest expense increased million compared million increase primarily result issuance senior unsecured notes registered offerings march november offset repayment senior unsecured notes due december december notes conversion maturity convertible senior notes due may may notes partial conversion convertible senior notes due may may notes interest expense decreased million compared million decrease due primarily repayment convertible senior notes due may may notes conversion may notes partial conversion may notes repayment revolving credit facilities income expense net income expense net significant compared changes income expense net due primarily million loss greek bonds related greece 's restructuring sovereign debt first quarter provision income taxes provision income taxes billion billion billion respectively effective tax rate differed us federal statutory rate due primarily certain operating earnings nonus subsidiaries considered indefinitely reinvested tax credits partially offset state taxes portion nontax deductible bpd fee amortization expense intangible asset related sofosbuvir receive tax benefit provide us income taxes undistributed earnings foreign operations intended indefinitely reinvested foreign subsidiaries effective tax rate differed us federal statutory rate due primarily retroactive extension federal research tax credit january federal research tax credit certain operating earnings nonus subsidiaries considered indefinitely reinvested partially offset state taxes portion nontax deductible bpd fee amortization expense intangible asset related sofosbuvir contingent consideration expense related certain acquisitions receive tax benefit effective tax rate differed us federal statutory rate due primarily tax credits certain operating earnings nonus subsidiaries considered indefinitely reinvested partially offset state taxes stockbased compensation expense related pharmasset acquisition contingent consideration expense related certain acquisitions receive tax benefit acquisitions ym biosciences inc completed acquisition ym biosciences inc ym based canada total consideration transferred million february time ym became whollyowned subsidiary gilead ym drug development company primarily focused advancing momelotinib orally administered oncedaily candidate hematologic cancers fair values acquired assets assumed liabilities included primarily inprocess research development iprd million goodwill million deferred tax assets million full unrecognized tax benefit deferred tax liabilities million cash acquired million pro forma results operations acquisition ym presented acquisition material consolidated results operations see item note intangible assets goodwill consolidated financial statements included annual report description iprd acquired pharmasset inc january completed acquisition pharmasset publiclyheld clinicalstage pharmaceutical company committed discovering developing commercializing novel drugs treat viral infections pharmasset 's primary focus development oral therapeutics treatment hcv infection pharmasset 's lead compound sofosbuvir formerly referred gs nucleotide analog december approved fda name sovaldi oncedaily oral regimen treatment hcv patients genotypes infection including hepatocellular carcinoma meeting milan criteria awaiting liver transplantation hcvhiv coinfection october harvoni combines nsa inhibitor ledipasvir sofosbuvir received approval fda treatment chronic hcv genotype infection adults acquisition pharmasset allowed us advance effort develop alloral regimens treatment hcv acquired outstanding shares common stock pharmasset per share cash tender offer subsequent merger terms agreement plan merger entered november aggregate cash payment acquire outstanding shares common stock billion financed transaction approximately billion cash hand billion senior unsecured notes issued december billion bank debt issued january pharmasset acquisition accounted business combination results operations pharmasset included consolidated statements income since january date acquired approximately outstanding shares common stock pharmasset cash consideration transferred result obtained effective control pharmasset acquisition completed january time pharmasset became whollyowned subsidiary gilead integrated operations track earnings results product candidate therapeutic area maintain separate earnings results acquired pharmasset business following table summarizes components cash paid acquire pharmasset millions total consideration transferred stockbased compensation expense total cash paid billion cash payment consisted billion cash payment outstanding common stockholders well million cash payment option holders pharmasset stock option plans billion cash payment outstanding common stockholders million cash payment vested option holders pharmasset stock option plans accounted consideration transferred remaining million cash payment accounted stockbased compensation expense resulting accelerated vesting pharmasset employee options immediately prior acquisition following table summarizes acquisition date fair values assets acquired liabilities assumed consideration transferred millions identifiable intangible assets cash cash equivalents assets acquired liabilities assumed net total identifiable net assets goodwill total consideration transferred refer item note acquisitions consolidated financial statements included annual report detailed information liquidity capital resources believe existing capital resources supplemented cash flows generated operating activities adequate satisfy capital needs foreseeable future cash cash equivalents marketable securities working capital increased significantly compared issued total billion senior unsecured notes registered offerings march november following table summarizes cash cash equivalents marketable securities working capital cash flow activities end periods presented millions december cash cash equivalents marketable securities working capital year ended december cash provided used operating activities investing activities financing activities certain prior period amounts reclassified conform current presentation cash cash equivalents marketable securities cash cash equivalents marketable securities totaled billion december increase billion compared billion december generated billion cash flows operations received billion issuance senior unsecured notes registered offerings march november repaid billion debt net convertible note hedges repurchased billion common stock paid approximately billion settle warrants expiring warrants related may notes retired may cash cash equivalents marketable securities remained relatively flat billion december compared billion december generated billion operating cash flows paid billion warrants related may notes settled august repaid billion debt net proceeds convertible note hedges utilized million acquisition ym net cash acquired total cash cash equivalents marketable securities december approximately billion generated operations foreign jurisdictions intended use foreign operations rely unrepatriated earnings source funds domestic business expect sufficient cash flow borrowing capacity united states fund domestic operational strategic needs working capital working capital billion december increase billion working capital december driven primarily positive cash flows operations increase cash cash equivalents due issuance senior unsecured notes march november partially offset cash paid settle convertible senior notes warrants repayment bank debt repurchases common stock working capital million december decrease billion working capital december due increase current portion longterm debt accrued liabilities partially offset increases accounts receivable inventories cash cash equivalents cash provided operating activities cash provided operating activities billion consisting primarily net income billion adjusted noncash items billion depreciation amortization expenses million stockbased compensation expense million net cash outflow related changes operating assets liabilities cash provided operating activities billion consisting primarily net income billion adjusted noncash items million depreciation amortization expenses million stockbased compensation expenses partially offset million net cash outflow related changes operating assets liabilities cash provided operating activities billion consisting primarily net income billion adjusted noncash items million depreciation amortization expenses million stockbased compensation expenses million net cash inflow related changes operating assets liabilities cash used investing activities cash used investing activities billion consisting primarily billion net purchases marketable securities million capital expenditures related expansion business cash used investing activities million consisting primarily million used acquisition ym net cash acquired million capital expenditures primarily related construction progress associated new facilities headquarters support ongoing growth business partially offset million net proceeds sales marketable securities cash used investing activities billion consisting primarily billion used acquisition pharmasset net stockbased compensation expense cash acquired million net purchases marketable securities million capital expenditures related primarily purchase office building million million increase construction progress associated new facilities headquarters support ongoing growth business cash provided used financing activities cash used financing activities billion consisting primarily billion used repay debt net convertible notes hedges billion used repurchase common stock stock repurchase programs billion settle warrants related may notes payments primarily offset billion net proceeds issuances senior unsecured notes due april april notes senior unsecured notes due april april notes senior unsecured notes due april april notes together april notes april notes april notes registered offering total aggregate principal amount billion issuances senior unsecured notes due february february notes senior unsecured notes due february february notes senior unsecured notes due february february notes together february notes february notes february notes registered offering aggregate principal amount billion cash used financing activities billion consisting primarily billion used repay debt financing includes maturity may notes conversions may notes may notes billion settle warrants related may notes settled august million used repurchase common stock stock repurchase program cash outflow partially offset proceeds billion related convertible note hedges cash provided financing activities million driven primarily net proceeds billion issuance bank debt conjunction pharmasset acquisition proceeds million issuances common stock employee stock plans million proceeds received related convertible note hedges cash proceeds partially offset billion used repay debt financing year million used repurchase common stock stock repurchase programs debt credit facility debt financing march issued senior unsecured notes registered offering total aggregate principal amount billion issued april notes million pay interest fixed annual rate april notes billion pay interest fixed annual rate april notes billion pay interest fixed annual rate november issued senior unsecured notes registered offering total aggregate principal amount billion issued february notes million pay interest fixed annual rate february notes billion pay interest fixed annual rate february notes billion pay interest fixed annual rate bank debt january conjunction acquisition pharmasset entered fiveyear billion revolving credit facility credit agreement five year revolving credit agreement borrowed million fiveyear revolving credit agreement upon close acquisition five year revolving credit agreement contains customary representations warranties affirmative negative financial maintenance covenants events default loan bears interest either eurodollar rate plus applicable margin ii base rate plus applicable margin defined credit agreement may reduce commitments may prepay loan whole part time without premium penalty required comply certain covenants credit agreement note indentures december violation covenants repaid million fiveyear revolving credit agreement repaid remaining balance million outstanding fiveyear revolving credit agreement fiveyear revolving credit agreement terminate amounts owed agreement shall due payable january convertible senior notes may notes matured portion may notes together may notes converted repaid million principal balance relating may notes also paid billion cash related conversion spread may notes represents conversion value excess principal amount received billion cash convertible note hedges related may notes year ended december exercised option settle cash warrants result paid billion settle warrants market value common stock time exercise warrants exceeds strike price million shares common stock underlying warrants strike price per share expired tradingday period commencing august ending september warrants could settled option cash shares common stock related contracts met applicable criteria equity classification settlement recorded reduction additional paidin capital consolidated balance sheets december may notes classified current given conversion criteria met result related unamortized discount million classified equity component currently redeemable convertible notes consolidated balance sheets million shares common stock underlying warrants expiring warrants warrants strike price per share exercisable expiration date market value common stock time exercise warrants exceeds strike price required net settle cash shares common stock option value warrants excess warrant strike price stock repurchase programs stock repurchase program authorized january program repurchased total billion million shares common stock may board directors authorized new billion stock repurchase program program open market private block transactions pursuant rule b plans privately negotiated transactions means new program expires three years completion program began repurchases program october repurchased total billion million shares intend use additional authorization repurchase shares opportunistically offset dilution created shares issued employee stock plans february announced board directors authorized new billion fiveyear share repurchase program initiate completion program longterm obligations summary borrowings various financing arrangements included item note debt credit facility consolidated financial statements included annual report believe existing capital resources supplemented cash flows generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products costs associated settlement conversion convertible senior notes related warrants establishment additional collaborative relationships companies costs associated defense settlement adverse results litigation government investigations may future require additional funding could form proceeds equity debt financings funding required guarantee available us favorable terms critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition allowance doubtful accounts valuation intangible assets contingent consideration liabilities resulting business combinations tax provision base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition product sales recognize revenues product sales persuasive evidence arrangement exists delivery occurred price fixed determinable collectability reasonably assured record product sales net estimated mandatory supplemental discounts government payers addition discounts private payers related charges generally referred grosstonet deductions recorded period related sales occur government rebates chargebacks represent majority grosstonet deductions require complex significant judgment management estimates assessed period updated reflect current information government rebates chargebacks government rebates chargebacks include amounts paid payers healthcare providers united states including medicaid rebates adaps veterans administration public health service discounts rebates well foreign government rebates rebates chargebacks based contractual arrangements statutory requirements may vary product payer individual payer plans qualified programs purchase products wholesalers distributors lower contractual price wholesalers distributors charge back us difference acquisition cost lower contractual price consolidated allowances government chargebacks payable direct customers classified reductions accounts receivable totaled million december million december consolidated allowance government rebates paid parties direct customers recorded accrued government rebates consolidated balance sheets totaled billion december billion december allowances government rebates chargebacks estimated based products sold historical utilization rates pertinent third party industry information estimated patient population known market events trends channel inventory andor market data also take consideration new information regarding changes programs ' regulations guidelines would impact amount actual rebates andor expectations regarding future utilization rates programs believe methodology use estimate government rebates chargebacks reasonable appropriate given current facts circumstances however actual results may differ significantly estimates last three years actual government rebates chargebacks claimed prior periods varied less estimates following table summarizes consolidated activity government rebates chargebacks accounts millions balance balance beginning decreaseincrease end accrued government rebates chargebacks year product sales payments year year ended december activity related sales activity related sales prior total year ended december activity related sales activity related sales prior total allowance doubtful accounts maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required believe allowance doubtful accounts adequate however significant deterioration factors could materially change expectations may result increase allowance doubtful accounts december allowance doubtful accounts million million respectively valuation intangible assets conjunction business combinations recorded intangible assets primarily related iprd projects total intangible assets billion december billion december identifiable intangible assets measured respective fair values acquisition date models used valuing intangible assets require use significant estimates assumptions including limited estimates revenues operating profits related products product candidates probability success unapproved product candidates considering stages development time resources needed complete development approval product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets believe fair values used record intangible assets acquired connection business combination based upon reasonable estimates assumptions given facts circumstances related valuation dates intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts development complete generally occurs regulatory approval market product obtained associated assets would deemed finitelived would amortized based respective estimated useful lives point time period assets considered indefinite lived amortized tested impairment annual basis well annual tests become aware events changes would indicate likely fair value iprd projects respective carrying amounts fair value indefinite lived intangible assets dependent assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates significant judgment employed determining assumptions changes assumptions could significant impact results operations given period intangible assets finite useful lives amortized estimated useful lives primarily straightline basis intangible assets finite useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable valuation contingent consideration liabilities resulting business combinations conjunction business combinations consolidation variable interest entity primary beneficiary recorded contingent consideration liabilities payable upon achievement specified development regulatory approval salesbased milestone events financial results contingent consideration liabilities measured respective fair values acquisition initial consolidation date models used valuing contingent consideration liabilities require use significant estimates assumptions including limited estimates revenues operating profits related products product candidates probability success unapproved product candidates considering stages development time resources needed complete development approval product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets revalue contingent consideration obligations reporting period record changes fair value rd expense within consolidated statement income changes fair value contingent consideration liabilities result updates one multiple assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates significant judgment employed determining assumptions acquisition date subsequent reporting period updates assumptions could significant impact results operations given period actual results may differ estimates total contingent consideration liabilities million december million december tax provision estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made subject income taxes united states various foreign jurisdictions including ireland due economic political conditions various countries actively considering changes existing tax laws predict form timing potential legislative changes could material adverse impact results operations addition significant judgment required determining worldwide provision income taxes record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprise 's financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return believe uncertain tax positions currently pending material adverse effect consolidated financial statements although adverse resolution one uncertain tax positions period could material impact results operations period december total federal state foreign unrecognized tax benefits million million respectively total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs tax authorities regarding uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities file federal state foreign income tax returns many jurisdictions united states abroad federal income tax purposes statute limitations open onwards certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years california income tax purposes statute limitations open onwards income tax returns audited federal state foreign tax authorities currently examination irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions branded prescription drug fee along pharmaceutical manufacturers branded drug products required pay portion bpd fee calculated based select government sales calendar year percentage total industry government sales fee determined estimating total sales government agencies along assumption total pharmaceutical industry sales government agencies estimates based past history along expectations future branded drug sales activity us along pharmaceutical companies judgment employed determining assumptions updates assumptions could impact results operations adjustments estimates past material irs issued final regulations related bpd fee indicate entity 's obligation pay portion bpd fee given calendar year triggered qualifying sales previous year instead first qualifying sale current calendar year result final irs regulations required recognize fee million fee million consolidated statement income bpd fees approximately million million million respectively irs expected communicate final bpd fee amounts due sales third quarter sales third quarter bpd fee accrual totaled million december million december balance sheet arrangements balance sheet arrangements defined item aii regulation sk contractual obligations contractual obligations consist debt obligations operating leases capital commitments purchase obligations active pharmaceutical ingredients inventoryrelated items clinical trials contracts following table summarizes significant enforceable legally binding obligations future commitments obligations related contracts likely continue regardless fact certain obligations may cancelable december millions payments due period less one contractual obligations total year years years years debt operating lease obligations capital commitments purchase obligations clinical trials total debt obligations include convertible senior notes senior unsecured notes interest payments incurred calculated based terms related notes information see item note debt credit facility consolidated financial statements included annual report form k december firm capital project commitments approximately million primarily relating construction new buildings december firm purchase commitments related active pharmaceutical ingredients certain inventoryrelated items amounts include minimum purchase requirements addition committed make potential future milestone payments third parties part licensing collaboration development arrangements payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded consolidated balance sheets included table december several clinical studies various clinical trial phases significant clinical trial expenditures contract research organizations cros although material contracts cros cancelable historically canceled contracts amounts reflect commitments based existing contracts reflect future modifications terminations existing contracts anticipated potential new contracts total gross unrecognized tax benefit liabilities including interest penalties million december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs tax authorities regarding uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities unrecognized tax benefits included current longterm income taxes payable longterm deferred tax assets consolidated balance sheets included table recent accounting pronouncements information required item included item note organization summary significant accounting policies consolidated financial statements included annual report item quantitative qualitative disclosures market risk exposed market risks may result changes foreign currency exchange rates interest rates credit risks reduce certain risks enter various types foreign currency interest rate derivative hedging transactions follow investment guidelines monitor outstanding receivables part risk management program foreign currency exchange risk operations include manufacturing sales activities united states canada ireland well sales activities countries outside united states including europe asia pacific result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business approximately product sales denominated foreign currencies partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales may enter foreign currency exchange forward option contracts also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged december open foreign currency forward contracts notional amounts billion billion respectively hypothetical adverse movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million date realized would negatively affect earnings remaining life contracts hypothetical movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million date realized would negatively affect earnings remaining life contracts analysis consider impact hypothetical changes foreign currency exchange rates would anticipated transactions foreign currency sensitive instruments designed offset interest rate risk portfolio availableforsale marketable securities fixed variable rate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestgenerating assets fixed interestbearing liabilities december millions except percentages expected maturity total fair value december thereafter total assets available forsale debt securities average interest rate liabilities debt average interest rate december issued senior unsecured notes due december registered offering notes pay interest fixed annual rates ranging march issued senior unsecured notes due april registered offering notes pay interest fixed annual rate march november issued april notes february notes respectively interest rates ranging july issued may notes private placement pursuant rule securities act amended may notes issued par bear interest rate may converted shares common stock subject certain circumstances connection acquisition pharmasset entered credit agreements subject variable interest rates portion interest expense related variable interest totaled million credit risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe december accounts receivable southern europe specifically greece italy portugal spain totaled approximately million million greater days past due million greater days past due december accounts receivable southern europe specifically greece italy portugal spain totaled approximately million million greater days past due million greater days past due date experienced significant losses respect collection accounts receivable believe allowance doubtful accounts adequate december item financial statements supplementary data gilead sciences inc consolidated financial statements years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements comprehensive income consolidated statements stockholders ' equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements income comprehensive income stockholders ' equity cash flows three years period ended december audits also included financial statement schedule listed index item financial statements schedule responsibility company 's management responsibility express opinion financial statements schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein also audited accordance standards public company accounting oversight board united states gilead sciences inc 's internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon ernst young llp redwood city california february gilead sciences inc consolidated balance sheets millions except per share amounts december assets current assets cash cash equivalents shortterm marketable securities accounts receivable net allowances december december inventories deferred tax assets prepaid taxes prepaid expenses current assets total current assets property plant equipment net longterm portion prepaid royalties longterm deferred tax assets longterm marketable securities intangible assets net goodwill longterm assets total assets liabilities stockholders equity current liabilities accounts payable accrued government rebates accrued compensation employee benefits income taxes payable accrued liabilities deferred revenues current portion longterm debt obligations net total current liabilities longterm debt net longterm income taxes payable longterm deferred tax liabilities longterm obligations commitments contingencies note equity component currently redeemable convertible notes stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized december december shares issued outstanding december december additional paidin capital accumulated comprehensive income loss retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity see accompanying notes gilead sciences inc consolidated statements income millions except per share amounts year ended december revenues product sales royalty contract revenues total revenues costs expenses cost goods sold research development expenses selling general administrative expenses total costs expenses income operations interest expense income expense net income provision income taxes provision income taxes net income net loss attributable noncontrolling interest net income attributable gilead net income per share attributable gilead common stockholdersbasic shares used per share calculationbasic net income per share attributable gilead common stockholdersdiluted shares used per share calculationdiluted see accompanying notes gilead sciences inc consolidated statements comprehensive income millions year ended december net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale securities net unrealized gain net tax impact reclassifications net income net tax impact net change cash flow hedges net unrealized gain loss net tax impact reclassification net income net tax impact net change comprehensive income loss comprehensive income comprehensive loss attributable noncontrolling interest comprehensive income attributable gilead see accompanying notes gilead sciences inc consolidated statements stockholders ' equity millions gilead stockholders ' equity common stock accumulated additional total paidin comprehensive retained noncontrolling stockholders ' shares amount capital income loss earnings interest equity balance december contributions noncontrolling interest net income loss comprehensive income net tax issuances employee stock purchase plan issuances equity incentive plans tax benefits employee stock plans stockbased compensation repurchases common stock convertible notes settlement convertible notes hedge settlement reclassification equity component currently redeemable convertible notes balance december contributions noncontrolling interest net income loss comprehensive income net tax issuances employee stock purchase plan issuances equity incentive plans tax benefits employee stock plans stockbased compensation repurchases common stock warrants settlement convertible notes settlement convertible notes hedge settlement reclassification equity component currently redeemable convertible notes balance december change noncontrolling interest net income loss comprehensive income net tax issuances employee stock purchase plan issuances equity incentive plans tax benefits employee stock plans stockbased compensation repurchases common stock warrants settlement convertible notes settlement convertible notes hedge settlement purchases convertible note hedges reclassification equity component currently redeemable convertible notes balance december see accompanying notes gilead sciences inc consolidated statements cash flows millions year ended december operating activities net income adjustments reconcile net income net cash provided operating activities depreciation expense amortization expense stockbased compensation expense excess tax benefits stockbased compensation tax benefits exercise vesting stockbased awards deferred income taxes change fair value contingent consideration changes operating assets liabilities accounts receivable net inventories prepaid expenses assets accounts payable income taxes payable accrued liabilities deferred revenues net cash provided operating activities investing activities purchases marketable securities proceeds sales marketable securities proceeds maturities marketable securities investments acquisitions net cash acquired capital expenditures net cash used investing activities financing activities proceeds debt financing net issuance costs proceeds convertible note hedges purchases convertible note hedges proceeds issuances common stock repurchases common stock repayments debt longterm obligations payments settle warrants excess tax benefits stockbased compensation payment contingent consideration contributions noncontrolling interest net cash provided used financing activities effect exchange rate changes cash cash equivalents net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid net amounts capitalized income taxes paid see accompanying notes gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world gilead 's primary areas focus include human immunodeficiency virus hiv liver diseases chronic hepatitis c virus hcv infection chronic hepatitis b virus hbv infection oncology inflammation serious cardiovascular respiratory conditions operations countries worldwide headquarters foster city california continue add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategy product portfolio comprised sovaldi atripla truvada harvoni compleraeviplera stribild viread letairis ranexa ambisome zydelig cayston hepsera emtriva tybost vitekta global commercial sales operations marketing subsidiaries north south america europe asiapacific addition also sell distribute certain products corporate partners royaltypaying collaborative agreements basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries certain variable interest entities primary beneficiary consolidated entities exposed less economics record net income loss attributable noncontrolling interests consolidated statements income equal percentage economic ownership interest retained entities respective noncontrolling parties intercompany transactions eliminated consolidated financial statements include results companies acquired us date acquisition applicable reporting periods january completed twoforone stock split form stock dividend stockholders record january declared december accordingly share per share amounts periods presented consolidated financial statements notes adjusted retroactively reflect stock split significant accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis management evaluates significant accounting policies estimates base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates estimates assessed period updated reflect current information actual experience revenue recognition product sales recognize revenue product sales persuasive evidence arrangement exists delivery occurred price fixed determinable collectability reasonably assured upon recognition revenue product sales provisions made government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products appropriate items deducted gross product sales rebates chargebacks estimate reductions revenues amounts paid payers healthcare providers united states including medicaid rebates adaps veterans administration public health service discounts rebates well foreign government rebates rebates chargebacks based contractual arrangements statutory requirements may vary product payer individual payer plans estimates based products sold historical utilization rates available pertinent third party industry information estimated patient population known market events trends us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements also take consideration available new information regarding changes programs ' regulations guidelines would impact amount actual rebates andor expectations regarding future utilization rates programs government chargebacks payable direct customers classified reductions accounts receivable consolidated balance sheets government rebates invoiced directly us recorded accrued government rebates consolidated balance sheets cash discounts estimate cash discounts based contractual terms historical utilization rates available expectations regarding future utilization rates distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractually determined covenants maintenance agreed upon inventory levels distributor fees based contractually determined fixed percentage sales product returns provide customers general right product return typically permit returns product damaged defective received customer case product sold united states certain countries outside united states product expired accept returns product expire within six months expired one year expiration dates estimates expected returns expired products based primarily ongoing analysis historical return patterns historical industry information reporting return rates similar products contractual agreements intended limit amount inventory maintained wholesalers royalty contract revenues royalty revenue sales products generally recognized received generally quarter following quarter corresponding sales occur month following month corresponding sales occur revenue nonrefundable upfront license fees milestone payments development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms obligations arrangements revenue recognized obligation fulfilled ratably development manufacturing period revenue associated substantive atrisk milestones recognized based upon achievement milestones set forth respective agreements advance payments received excess amounts earned classified deferred revenue consolidated balance sheets research development expenses research development rd expenses consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations cros materials supplies licenses fees milestone payments collaboration arrangements overhead allocations consisting various support facilityrelated costs charge rd costs including clinical study costs expense incurred clinical study costs significant component rd expenses clinical studies performed thirdparty cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros material cro contracts terminable us upon written notice generally liable actual services completed cro certain noncancelable expenses incurred point termination amounts paid advance related uncompleted services refunded us contract terminated advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million stockbased compensation utilize share based compensation form various types equitybased awards including restricted stock units rsus performancebased restricted stock units psus stock options compensation expense recognized consolidated statements income based estimated fair value grant date estimated fair values rsus based closing price common stock psus estimated fair values based either monte carlo valuation methodology stock price date grant stock option awards estimated fair values based blackscholes option valuation model cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents eligible instruments investment policy included cash equivalents include commercial paper money market funds overnight repurchase agreements repos major banks authorized dealers bank obligations marketable nonmarketable securities determine appropriate classification marketable securities consist primarily debt securities time purchase reevaluate designation balance sheet date marketable securities considered availableforsale carried estimated fair values reported cash equivalents shortterm marketable securities longterm marketable securities unrealized gains losses availableforsale securities excluded net income reported accumulated comprehensive income loss separate component stockholders ' equity income expense net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities otherthantemporary declines fair value securities cost securities sold based specific identification method regularly review investments otherthan temporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position severity duration unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carrying value security hold record loss amount decline result entering collaborations time time may hold investments nonpublic companies record nonmarketable securities cost longterm assets less amounts otherthantemporary impairment regularly review securities indicators impairment investments nonmarketable securities material periods presented concentrations risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe december accounts receivable southern europe specifically greece italy portugal spain totaled approximately million million greater days past due million greater days past due date experienced significant losses respect collection accounts receivable believe allowance doubtful accounts adequate december certain raw materials components utilize operations obtained single suppliers certain raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application nda filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship commercial products supply product candidates clinical trials accounts receivable trade accounts receivable recorded net allowances wholesaler chargebacks related government programs cash discounts prompt payment doubtful accounts estimates wholesaler chargebacks government programs cash discounts based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices historically amounts uncollectible accounts receivable written insignificant consistent management 's expectations inventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventories order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized future commercialization considered probable future economic benefit expected realized based management 's judgment capitalize prelaunch inventory costs prior regulatory approval number factors taken consideration including current status regulatory approval process potential impediments approval process safety efficacy anticipated research development initiatives could impact indication compound used viability commercialization marketplace trends december amount prelaunch inventory consolidated balance sheets significant property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straight line method repairs maintenance costs expensed incurred estimated useful lives years follows description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term office computer equipment includes capitalized software unamortized capitalized software costs consolidated balance sheets million december million december leasehold improvements amortized shorter lease term asset 's useful life capitalized interest construction inprogress included property plant equipment interest capitalized significant goodwill intangible assets goodwill represents excess consideration transferred estimated fair value assets acquired liabilities assumed business combination intangible assets indefinite useful lives related purchased inprocess research development iprd projects measured respective fair values acquisition date amortize goodwill intangible assets indefinite useful lives intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts development complete generally occurs regulatory approval market product obtained associated assets deemed finitelived amortized based respective estimated useful lives point time test goodwill indefinitelived intangible assets impairment annual basis annual tests become aware events changes would indicate fair values assets carrying amounts intangible assets finite useful lives amortized estimated useful lives primarily straightline basis reviewed impairment facts circumstances suggest carrying value assets may recoverable impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment fda another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated income producing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset asset group eventual disposition carrying amount asset asset group excess carrying value asset asset group estimated fair value recognized impairment loss valuation contingent consideration resulting business combination connection certain business combinations may required pay future consideration contingent upon achievement specified development regulatory approval salesbased milestone events record contingent consideration resulting business combination fair value acquisition date connection consolidation variable interest entity primary beneficiary record contingent consideration related future earnout payments based upon percentage gross margin entity reporting period thereafter revalue obligations record changes fair value within consolidated statement income record changes fair value related future milestone payments rd expense time related product candidate receives marketing approval changes fair value contingent consideration liabilities result updates assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates significant judgment employed determining assumptions acquisition consolidation date subsequent period updates assumptions could significant impact results operations given period actual results may differ estimates foreign currency translation transaction gains losses hedging contracts nonus entity operations recorded functional currency entity results operations nonus dollar functional currency entities translated us dollars using average currency rates assets liabilities translated using currency rates period end foreign currency translation adjustments recorded component comprehensive income loss within stockholders ' equity foreign currency transaction gains losses recorded income expense net consolidated statements income net foreign currency transaction gains totaled million losses totaled million million hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge net investment foreign subsidiaries fair value financial instruments apply fair value accounting financial assets liabilities nonfinancial assets liabilities recognized disclosed fair value financial statements recurring basis define fair value price would received selling asset paid transfer liability orderly transaction market participants measurement date determining fair value measurements assets liabilities required recorded fair value consider principal advantageous market would transact marketbased risk measurements assumptions market participants would use pricing asset liability risks inherent valuation techniques transfer restrictions credit risks derivative financial instruments recognize derivative instruments either assets liabilities fair value consolidated balance sheets changes fair value derivatives recorded period current earnings accumulated comprehensive income loss depending whether derivative designated part hedge transaction type hedge transaction classify cash flows instruments category cash flows hedged items hold issue derivative instruments trading speculative purposes assess inception ongoing basis whether derivatives used hedging transactions highly effective offsetting changes cash flows fair values hedged items also assess hedge ineffectiveness quarterly basis record gain loss related ineffective portion current earnings extent significant determine forecasted transaction longer probable occurring discontinue hedge accounting affected portion hedge instrument related unrealized gain loss contract recognized current earnings income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations existing tax laws regulations record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprise 's financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return believe uncertain tax positions currently pending material adverse effect consolidated financial statements although adverse resolution one uncertain tax positions period could material impact results operations period branded prescription drug fee along pharmaceutical manufacturers branded drug products required pay portion bpd fee calculated based select government sales calendar year percentage total industry government sales internal revenue service irs issued final regulations related bpd fee indicate entity 's obligation pay portion bpd fee given calendar year triggered qualifying sales previous year instead first qualifying sale current calendar year result final irs regulations required recognize fee million fee million consolidated statement income irs expected communicate final bpd fee amounts due sales third quarter sales third quarter bpd fee accrual totaled million december million december consolidated balance sheets recent accounting pronouncements may financial accounting standards board jointly international accounting standards board issued comprehensive new standard revenue recognition contracts customers standard 's core principle reporting entity recognize revenue transfers promised goods services customers amount reflects consideration entity expects entitled exchange goods services applying new guidance contracts within scope entity identify contracts customer identify performance obligations contract determine transaction price allocate transaction price performance obligations contract recognize revenue entity satisfies performance obligation additionally new guidance require significantly expanded revenue recognition disclosures guidance become effective us beginning first quarter early application permitted entities option using either full retrospective modified retrospective approach adopt new guidance currently evaluating impact adoption standard consolidated financial statements fair value measurements determine fair value financial nonfinancial assets liabilities using fair value hierarchy establishes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability marketable securities review trading activity pricing measurement date sufficient quoted pricing identical securities available use market pricing observable market inputs similar securities obtained various thirdparty data providers inputs either represent quoted prices similar assets active markets derived observable market data level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques significant management judgment estimation financial instruments consist principally cash cash equivalents marketable securities accounts receivable foreign currency exchange contracts accounts payable shortterm longterm debt cash cash equivalents marketable securities foreign currency exchange contracts hedge accounts receivable forecasted sales reported respective fair values consolidated balance sheets shortterm longterm debt reported amortized cost consolidated balance sheets remaining financial instruments reported consolidated balance sheets amounts approximate current fair values following table summarizes assets liabilities recorded fair value respective fair value classification level input within fair value hierarchy millions december december level level level total level level level total assets money market funds corporate debt securities us treasury securities residential mortgage assetbacked securities us government agencies securities municipal debt securities foreign currency derivative contracts deferred compensation plan liabilities contingent consideration deferred compensation plan foreign currency derivative contracts maintain deferred compensation plan directors key employees may defer compensation income tax purposes amounts deferred participants deposited rabbit trust amount periodically adjusted reflect earnings losses based participant 's investment elections among select group investment funds consists money market funds mutual funds level inputs estimate fair values government related debt corporate debt residential mortgage assetbacked securities taking consideration valuations obtained thirdparty pricing services pricing services utilize industry standard valuation models including income marketbased approaches significant inputs observable either directly indirectly estimate fair value inputs include reported trades brokerdealer quotes similar securities issuer credit spreads benchmark securities prepaymentdefault projections based historical data observable inputs substantially foreign currency derivatives contracts maturities primarily month time horizon counterparties minimum credit rating equivalent standard poor 's moody 's investors service inc fitch inc estimate fair values contracts taking consideration valuations obtained thirdparty valuation service utilizes incomebased industry standard valuation model significant inputs observable either directly indirectly inputs include foreign currency rates london interbank offered rates libor swap rates inputs applicable commonly quoted intervals fair values convertible senior notes senior unsecured notes determined using level inputs based quoted market values following table summarizes carrying values fair values convertible senior notes senior unsecured notes millions december december type borrowing description carrying value fair value carrying value fair value convertible senior may notes convertible senior may notes senior unsecured april notes senior unsecured december notes senior unsecured december notes senior unsecured december notes senior unsecured december notes senior unsecured april notes senior unsecured april notes senior unsecured april notes senior unsecured february notes senior unsecured february notes senior unsecured february notes level inputs december assets liabilities measured using level inputs contingent consideration liabilities policy recognize transfers level classification actual date event change circumstances caused transfer contingent consideration liabilities connection certain acquisitions may required pay future consideration contingent upon achievement specified development regulatory approval salesbased milestone events financial results estimate fair value contingent consideration liabilities acquisition date initial consolidation date reporting period thereafter using probabilityweighted income approach reflects probability timing future payments fair value measurement based significant level inputs anticipated timelines probability achieving development regulatory approval salesbased milestone events projected revenues resulting probabilityweighted cash flows discounted using creditrisk adjusted interest rates reporting period thereafter revalue obligations performing review assumptions listed record increases decreases fair value contingent consideration obligations within consolidated statements income record fair value related future milestone payments rd expense time related product candidate receives marketing approval change fair value future earnout payments recorded selling general administrative sga expense absence significant changes key assumptions quarterly determination fair values contingent consideration obligations would primarily reflect passage time significant judgment employed determining level inputs fair value measurements acquisition date initial consolidation date subsequent period updates assumptions could significant impact results operations given period actual results may differ estimates example significant increases probability achieving milestone projected revenues would result significantly higher fair value measurement significant decreases estimated probability achieving milestone projected revenues would result significantly lower fair value measurement significant increases discount rate anticipated timelines would result significantly lower fair value measurement significant decreases discount rate anticipated timelines would result significantly higher fair value measurement potential contingent consideration payments required upon achievement development regulatory approvalbased milestones related acquisitions cgi pharmaceuticals inc calistoga pharmaceuticals inc calistoga ranged payment none milestones achieved estimated maximum million undiscounted july upon receiving fda approval zydelig certain regulatory approvalbased milestones related calistoga acquisition met result made contingent consideration payments totaling million third quarter december december accrued million million respectively related acquisitions remainder contingent consideration liabilities december primarily relate potential future payments resulting acquisition arresto biosciences inc royalty obligations future sales specified salesbased milestones achieved following table provides rollforward contingent consideration liabilities recorded part accrued liabilities longterm obligations consolidated balance sheets millions year ended december balance beginning period milestone payments calistoga net changes valuation addition consolidation variable interest entity balance end period availableforsale securities estimated fair values availableforsale securities generally based prices obtained commercial pricing services following table summary availableforsale securities recorded cash cash equivalents marketable securities consolidated balance sheets millions december december gross gross gross gross amortized unrealized unrealized estimated amortized unrealized unrealized estimated cost gains losses fair value cost gains losses fair value money market funds corporate debt securities us treasury securities residential mortgage asset backed securities us government agencies securities municipal debt securities total following table summarizes classification availableforsale securities consolidated balance sheets millions december december cash cash equivalents shortterm marketable securities longterm marketable securities total cash cash equivalents table exclude cash billion december million december following table summarizes portfolio availableforsale securities contractual maturity millions december amortized cost fair value less one year greater one year less five years greater five years less ten years greater ten years total following table summarizes gross realized gains losses related sales marketable securities millions year ended december gross realized gains sales gross realized losses sales following table summarizes availableforsale debt securities continuous unrealized loss position deemed otherthan temporarily impaired millions less months months greater total gross gross gross unrealized estimated unrealized estimated unrealized estimated losses fair value losses fair value losses fair value december debt securities corporate debt securities residential mortgage assetbacked securities us treasury securities us government agencies securities municipal debt securities total december debt securities corporate debt securities residential mortgage assetbacked securities us treasury securities us government agencies securities municipal debt securities total held total positions december positions december unrealized loss position unrealized losses immaterial individually aggregate based review securities believe otherthantemporary impairments securities december intend sell securities believe likely required sell securities recovery amortized cost basis derivative financial instruments operate foreign countries exposes us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies significant euro order manage risk may hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge exposure foreign currency exchange rate fluctuations certain monetary assets liabilities foreign subsidiaries denominated nonfunctional currency derivative instruments use hedge exposure designated hedges result changes fair value recorded income expense net consolidated statements income hedge exposure foreign currency exchange rate fluctuations forecasted product sales denominated nonfunctional currency derivative instruments use hedge exposure designated cash flow hedges maturity dates months less upon executing hedging contract quarterly thereafter assess prospective hedge effectiveness using regression analysis calculates change cash flow result hedge instrument monthly basis assess retrospective hedge effectiveness using dollar offset approach exclude time value effectiveness testing recognize changes time value hedge income expense net effective component hedge recorded unrealized gain loss hedging instrument accumulated comprehensive income oci within stockholders ' equity hedged forecasted transaction occurs hedge dedesignated unrealized gains losses reclassified product sales majority gains losses related hedged forecasted transactions reported accumulated oci december reclassified product sales within months cash flow effects derivative contracts three years ended december included within net cash provided operating activities consolidated statements cash flows notional amounts foreign currency exchange contracts outstanding billion december billion december derivative contracts allow us right offset assets liabilities presented amounts gross basis international swap dealers association inc master agreements respective counterparties foreign currency exchange contracts subject applicable requirements allowed net settle transactions currency single net amount payable one party following table summarizes classification fair values derivative instruments consolidated balance sheets millions december asset derivatives liability derivatives fair classification fair value classification value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives december asset derivatives liability derivatives fair classification fair value classification value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives december december material derivatives designated hedges following table summarizes effect foreign currency exchange contracts consolidated financial statements millions year ended december derivatives designated hedges gains losses recognized accumulated oci effective portion gains losses reclassified accumulated oci product sales effective portion gains losses recognized income expense net ineffective portion amounts excluded effectiveness testing derivatives designated hedges gains losses recognized income expense net time time may discontinue cash flow hedges result record related amounts income expense net consolidated statements income material amounts recorded income expense net years ended december result discontinuance cash flow hedges december held one type financial instrument derivative contracts related foreign currency exchange contracts following table summarizes potential effect offsetting derivatives type financial instrument consolidated balance sheets millions december offsetting derivative assetsliabilities gross amounts offset consolidated balance sheet amounts assetsliabilities gross amounts offset presented gross amounts consolidated balance consolidated derivative financial cash collateral net amount description recognized assetsliabilities sheet balance sheet instruments receivedpledged legal offset derivative assets derivative liabilities december offsetting derivative assetsliabilities gross amounts offset consolidated balance sheet gross amounts offset amounts assetsliabilities gross amounts consolidated balance presented consolidated derivative financial cash collateral net amount description recognized assetsliabilities sheet balance sheet instruments receivedpledged legal offset derivative assets derivative liabilities acquisitions ym biosciences inc february completed acquisition ym biosciences inc ym based canada total consideration transferred million time ym became whollyowned subsidiary gilead ym drug development company primarily focused advancing momelotinib orally administered daily candidate hematologic cancers ym acquisition accounted business combination fair values acquired assets assumed liabilities primarily included iprd million goodwill million deferred tax assets million full unrecognized tax benefit deferred tax liabilities million cash acquired million pro forma results operations acquisition ym presented acquisition material consolidated results operations see note intangible assets goodwill description iprd acquired pharmasset inc january completed acquisition pharmasset inc pharmasset publiclyheld clinicalstage pharmaceutical company committed discovering developing commercializing novel drugs treat viral infections pharmasset 's primary focus development oral therapeutics treatment hcv infection pharmasset 's lead compound sofosbuvir nucleotide analog december approved fda name sovaldi oncedaily oral regimen treatment hcv patients genotypes infection including hepatocellular carcinoma meeting milan criteria awaiting liver transplantation hcvhiv coinfection october harvoni combines nsa inhibitor ledipasvir sofosbuvir received approval fda treatment chronic hcv genotype infection adults acquisition pharmasset allowed us advance effort develop alloral regimens treatment hcv acquired outstanding shares common stock pharmasset per share cash tender offer subsequent merger terms agreement plan merger entered november aggregate cash payment acquire outstanding shares common stock billion financed transaction approximately billion cash hand billion senior unsecured notes issued december billion bank debt issued january pharmasset acquisition accounted business combination results operations pharmasset included consolidated statements income since january date acquired approximately outstanding shares common stock pharmasset following table summarizes components cash paid acquire pharmasset millions total consideration transferred stockbased compensation expense total cash paid billion cash payment consisted billion cash payment outstanding common stockholders million cash payment option holders pharmasset stock option plans billion cash payment outstanding common stockholders million cash payment vested option holders pharmasset stock option plans accounted consideration transferred remaining million cash payment accounted stockbased compensation expense resulting accelerated vesting pharmasset employee options immediately prior acquisition following table summarizes acquisition date fair values assets acquired liabilities assumed consideration transferred millions identifiable intangible assets cash cash equivalents assets acquired liabilities assumed net total identifiable net assets goodwill total consideration transferred identifiable intangible assets acquired intangible assets primarily comprised sofosbuvir iprd compound estimated fair value billion date acquisition fair value asset determined using probabilityweighted income approach discounts expected future cash flows present value estimated net cash flows discounted using discount rate based estimated weightedaverage cost capital companies profiles similar pharmasset rate comparable estimated internal rate return acquisition represents rate market participants would used value intangible asset projected cash flow sofosbuvir based key assumptions estimates revenues operating profits related project considering stage development acquisition date time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing product candidate obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived assets completion abandonment associated rd efforts december billion purchased iprd project sofosbuvir completed reclassified finitelived intangible asset amortizing asset estimated useful life utilizing straightline method goodwill million goodwill represents excess consideration transferred fair values assets acquired liabilities assumed attributable synergies expected combining rd operations pharmasset 's operations none goodwill expected deductible income tax purposes stockbased compensation expense stockbased compensation expense recognized accelerated vesting employee options immediately prior acquisition reported consolidated statements income follows millions year ended december research development expense selling general administrative expense total stockbased compensation expense costs costs incurred connection acquisition include millions year ended december transaction costs eg investment advisory legal accounting fees bridge financing costs restructuring costs total costs following table summarizes costs line item consolidated statements income costs recognized millions year ended december research development expense selling general administrative expense interest expense total costs pro forma information following unaudited pro forma information presents combined results operations gilead pharmasset acquisition pharmasset completed january adjustments give effect pro forma events directly attributable acquisition unaudited pro forma results reflect operating efficiencies potential cost savings may result consolidation operations gilead pharmasset accordingly unaudited pro forma results presented informational purposes necessarily indicative actual results operations combined company would acquisition occurred beginning period presented indicative future results operations millions year ended december total revenues net income attributable gilead unaudited pro forma consolidated results include nonrecurring pro forma adjustments assume acquisition occurred january stock based compensation expenses million incurred included net income attributable gilead year ended december costs million incurred year ended december included net income attributable gilead year ended december inventories inventories summarized follows millions december raw materials work process finished goods total recognized inventories longterm assets total amounts reported longterm assets comprised almost entirely raw materials december december prior period amounts reclassified conform current presentation joint ventures formed gilead sciences llc bristolmyers squibb bms see note collaborative arrangements included consolidated financial statements held efavirenz active pharmaceutical ingredient inventory efavirenz inventory purchased bms bms 's estimated net selling price efavirenz totaled million december billion december property plant equipment property plant equipment summarized follows millions december property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment construction progress subtotal less accumulated depreciation amortization including relating capitalized leased equipment subtotal land total intangible assets goodwill intangible assets following table summarizes carrying amount intangible assets millions december finitelived intangible assets indefinitelived intangible assets total intangible assets finitelived intangible assets following table summarizes finitelived intangible assets millions december december gross carrying accumulated gross carrying accumulated amount amortization amount amortization intangible asset sofosbuvir intangible asset ranexa total upon fda approval commercial launch sovaldi december reclassified iprd related sofosbuvir finitelived intangible assets amortization expense related finitelived intangible assets included primarily cost goods sold consolidated statements income totaled million million million december estimated future amortization expense associated finitelived intangible assets five succeeding fiscal years follows millions fiscal year amount total indefinitelived intangible assets completed acquisition ym total million fair value acquired assets assumed liabilities ym attributed million iprd related momelotinib consolidated balance sheets following table summarizes indefinitelived intangible assets millions december indefinitelived intangible asset momelotinib formerly cyt indefinitelived intangible assets foreign currency translation adjustment total goodwill following table summarizes changes carrying amount goodwill millions balance december foreign currency translation adjustment balance december collaborative arrangements enter collaboration arrangements third parties development commercialization certain products parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities collaboration arrangements assessed inception reporting date determine whether primary beneficiary entity determined vie therefore would required consolidate third party vies may required consolidate entity contractual terms arrangement essentially provide us control entity even majority voting interest assess whether primary beneficiary vie based power direct activities vie significantly impact vie 's economic performance obligation absorb losses right receive benefits vie could potentially significant vie consolidated entities consolidated financial statements december material vie joint venture bms described bristolmyers squibb company north america entered collaboration arrangement bms develop commercialize single tablet regimen containing truvada bms 's sustiva efavirenz united states combination approved use united states sold brand name atripla bms structured collaboration joint venture operates limited liability company named bristolmyers squibb gilead sciences llc consolidate bms granted royaltyfree sublicenses joint venture use respective company owned technologies return granted license joint venture use intellectual property results collaboration bms amended joint venture 's collaboration agreement allow joint venture sell atripla canada economic interests joint venture held us bms including share revenues outofpocket expenses based portion net selling price atripla attributable efavirenz truvada since net selling price truvada may change time relative net selling price efavirenz bms 's respective economic interests joint venture may vary annually bms shared marketing sales efforts starting second quarter except limited number activities jointly managed parties longer coordinate detailing promotional activities united states parties reduced joint promotional efforts since launched complera august stribild august parties continue collaborate activities manufacturing regulatory compliance pharmacovigilance daily operations joint venture governed four primary joint committees formed bms gilead responsible accounting financial reporting tax reporting manufacturing product distribution joint venture parties provide respective bulk active pharmaceutical ingredients joint venture approximate market values agreement continue terminated mutual agreement parties addition either party may terminate party 's participation collaboration within days launch least one generic version party 's single agent products double agent products terminating party right continue sell atripla become continuing party obligated pay terminated party certain royalties threeyear period following effective date termination december joint venture held efavirenz active pharmaceutical ingredient purchased bms bms 's estimated net selling price efavirenz us market amounts included inventories consolidated balance sheets december total assets held joint venture billion consisted primarily cash cash equivalents million accounts receivable million inventories billion total liabilities billion consisted primarily accounts payable million accrued expenses million december total assets held joint venture billion consisted primarily cash cash equivalents million accounts receivable million inventories billion total liabilities billion consisted primarily accounts payable million accrued expenses million asset liability amounts reflect impact intercompany eliminations included consolidated balance sheets although consolidate joint venture legal structure joint venture limits recourse creditors general credit assets similarly assets held joint venture used settle obligations joint venture europe gilead sciences ireland unlimited company whollyowned subsidiary formerly known gilead sciences limited bms entered collaboration agreement bms sets forth terms conditions bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bms 's estimated net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehousing local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling sales returns territories bms promote atripla general parties share revenues outofpocket expenses proportion net selling prices components atripla truvada efavirenz starting except limited number activities jointly managed parties longer coordinate detailing promotional activities region responsible accounting financial reporting tax reporting collaboration december efavirenz purchased bms bms 's estimated net selling price efavirenz european territory included inventories consolidated balance sheets parties also formed limited liability company hold marketing authorization atripla europe primary responsibility regulatory activities major market countries parties agreed independently continue use commercially reasonable efforts promote atripla agreement terminate upon expiration lasttoexpire patent affords market exclusivity atripla one components european territory addition since december either party may terminate agreement reason termination effective two calendar quarters notice termination nonterminating party right continue sell atripla become continuing party obligated pay terminating party certain royalties threeyear period following effective date termination event continuing party decides sell atripla effective date termination date atripla withdrawn country date third party assumes distribution atripla whichever earlier december neither party elected terminate agreement japan tobacco inc japan tobacco inc japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retained rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize elvitegravir treatment hiv infection bear costs expenses associated commercialization efforts received approval stribild elvitegravircontaining product fda august european commission may capitalized million related milestone incurred connection fda approval stribild million related milestone incurred connection european commission approval milestones amortized useful patent life elvitegravir approximately years expiring agreement obligation pay royalties japan tobacco terminate productbyproduct basis patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement reason case license granted japan tobacco us would terminate either party may terminate agreement response material breach party janssen entered license collaboration agreement janssen sciences ireland uc janssen formerly tibotec pharmaceuticals develop commercialize fixeddose combination truvada janssen 's nonnucleoside reverse transcriptase inhibitor rilpivirine combination approved united states european union sold brand name complera united states eviplera european union original agreement janssen granted us exclusive license compleraeviplera worldwide excluding certain middle income developing world countries japan amended agreement include distribution compleraeviplera rest world amended agreement expand collaboration include another product containing janssens rilpivirine emtricitabine tenofovir alafenamide rftaf amended agreement janssen granted us exclusive license compleraeviplera rftaf worldwide retained rights distribute combination products countries including mexico russia japan neither party restricted combining drugs drug products except similar components compleraeviplera rftaf responsible manufacturing compleraeviplera rftaf lead role registration distribution commercialization products except countries janssen distributes janssen exercised right codetail combination product countries gilead selling party initial agreement price compleraeviplera expected sum price truvada price rilpivirine purchased separately cost rilpivirine purchased us janssen compleraeviplera approximately market price rilpivirine less specified percentage major markets amendment effective enables selling party set price combined products parties share revenues based ratio net selling prices partys components subject certain restrictions adjustments gilead continue retain specified percentage janssens share revenues major markets either party may terminate collaboration agreement respect product country product withdrawn market country respect product countries party materially breaches agreement respect product agreement parties obligation share revenues expire productbyproduct countrybycountry basis janssen patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement without cause respect countries sell products case janssen right become selling party country product launched market fewer years debt credit facility financing arrangements following table summarizes carrying amount borrowings various financing arrangements millions interest december type borrowing description issue date due date rate convertible senior may notes july may convertible senior may notes july may senior unsecured april notes march april senior unsecured december notes december december senior unsecured december notes december december senior unsecured december notes december december senior unsecured december notes december december senior unsecured april notes march april senior unsecured april notes march april senior unsecured april notes march april senior unsecured february notes november february senior unsecured february notes november february senior unsecured february notes november february credit facility fiveyear revolver january january variable total debt net less current portion total longterm debt net may may convertible senior notes july issued billion convertible senior notes due may may notes billion convertible senior notes due may may notes collectively may notes may notes private placement pursuant rule securities act amended may notes may notes issued par may notes bore annual interest rates may notes bear annual interest rate debt issuance costs million recorded longterm assets amortized interest expense contractual terms may notes aggregate principal amount may notes sold reflects full exercise initial purchasers option purchase additional notes cover overallotments initial conversion rate may notes shares per principal amount represented initial conversion price approximately per share initial conversion rate may notes shares per principal amount represents initial conversion price approximately per share conversion rates subject customary antidilution adjustments may notes may converted prior april following circumstances calendar quarter commencing september closing price common stock least trading days whether consecutive period consecutive trading days ending last trading day preceding calendar quarter greater applicable conversion price applicable trading day five business day period measurement period ten consecutive trading days trading day period trading price per principal amount notes less product last reported sale price common stock applicable conversion rate trading day upon occurrence specified corporate transactions distribution certain stock rights cash amounts assets shareholders occurrence change control april case may notes holders may convert notes time regardless foregoing circumstances generally upon conversion holder would receive amount cash equal lesser principal amount note ii conversion value note measured indenture governing relevant notes conversion value exceeds principal amount may also deliver option cash common stock combination cash common stock conversion value excess principal amount year ended december may notes matured portion may notes converted year ended december repaid million principal balance related may notes also paid billion cash related conversion spread may notes represents conversion value excess principal amount received billion cash convertible note hedges related may notes december may notes classified current given conversion criteria met december given maturity date may notes classified current result related unamortized discounts million million december respectively classified equity component currently redeemable convertible notes consolidated balance sheets may notes converted connection change control may required provide make whole premium form increase conversion rate subject stated maximum amount addition event change control holders may require us purchase portion notes purchase price equal principal amount plus accrued unpaid interest december ifconverted value may notes would exceed principal amounts may notes billion concurrent issuance may notes purchased convertible note hedges private transactions cost million tax deductible life notes also sold warrants private transactions acquire million shares common stock received net proceeds million sale warrants convertible note hedges warrants intended reduce potential economic dilution upon future conversions may notes effectively increasing conversion price per share may notes per share may notes net cost million convertible note hedge warrant transactions recorded stockholders ' equity consolidated balance sheets addition contracts classified stockholders equity indexed common stock accounted derivatives convertible note hedges covered subject customary antidilution adjustments million shares common stock strike prices initially correspond initial conversion prices may notes subject adjustments similar applicable conversion price related notes market value per share common stock time conversion may notes strike price applicable convertible note hedges entitled receive counterparties transactions shares common stock extent made corresponding election respect related convertible notes cash combination cash shares common stock option excess market value common stock strike price convertible note hedges convertible note hedges terminate upon maturity may notes none may notes remain outstanding due conversion otherwise million shares common stock underlying warrants subject customary antidilution adjustments warrants strike price per share warrants expired per share warrants expiring warrants expired warrants expire terms whereby exercisable respective expiration dates market value common stock time exercise applicable warrants exceeds respective strike prices required net settle cash shares common stock option respective counterparties value warrants excess warrant strike prices year ended december exercised option settle cash warrants expiring warrants related may notes result paid billion settle warrants market value common stock time exercise warrants exceeded strike price million shares common stock underlying warrants strike price per share expired tradingday period commencing august ending september warrants could settled option cash shares common stock related contracts met applicable criteria equity classification settlement recorded reduction additional paidin capital consolidated balance sheets current accounting guidance bifurcated conversion option may notes debt instrument classified conversion option equity accreting resulting debt discount interest expense contractual terms may notes following table summarizes information equity liability components may notes millions carrying value net carrying amount unamortized discount equity component liability component liability component december december december may notes may notes total may notes recognized million million million interest expense related contractual coupon rates amortization debt discount issuance costs may notes effective interest rates liability components may notes may notes respectively used net proceeds general corporate purposes include repayment existing indebtedness repurchase shares common stock april senior unsecured notes march issued senior unsecured notes due april april notes registered offering aggregate principal amount billion april notes pay interest fixed annual rate debt issuance costs incurred connection issuance debt totaled approximately million amortized interest expense contractual term april notes recognized million interest expense related contractual coupon rates amortization debt discount issuance costs april notes april notes may redeemed option time time time redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus basis points plus case accrued unpaid interest notes redeemed date redemption time january may redeem april notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption addition event occurrence change control downgrade rating april notes investment grade standard poor 's ratings services moody 's investors service inc holders may require us purchase portion notes price equal principal amount plus accrued unpaid interest used net proceeds general corporate purposes include repayment existing indebtedness repurchase shares common stock december senior unsecured notes december issued senior unsecured notes due december december december december december notes december notes december notes december notes respectively collectively december notes registered offering million million billion billion respectively aggregate principal amount billion december notes paid interest fixed annual rate matured december remaining notes mature december respectively pay interest fixed annual rates respectively debt issuance costs incurred connection issuance debt totaled approximately million amortized interest expense contractual term respective notes recognized million million million interest expense related contractual coupon rates amortization debt discount issuance costs december notes outstanding december notes may redeemed option time time time redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus basis points case december notes basis points case december notes december notes plus case accrued unpaid interest notes redeemed date redemption time date three months prior maturity date december notes may redeem december notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption time date six months prior maturity date december notes may redeem december notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption event occurrence change control downgrade rating series outstanding december notes investment grade standard poor 's ratings services moody 's investors service inc remaining holders series may require us purchase portion notes series price equal aggregate principal amount notes repurchased plus accrued unpaid interest date repurchase used net proceeds december notes fund acquisition pharmasset completed january see note april senior unsecured notes march issued senior unsecured notes due april april april april notes april notes april notes respectively collectively april notes registered offering total aggregate principal amount billion issued april notes million pay interest fixed annual rate april notes billion pay interest fixed annual rate april notes billion pay interest fixed annual rate debt issuance costs incurred connection issuance debt totaled approximately million amortized interest expense contractual term respective notes recognized million interest expense related contractual coupon rates amortization debt discount issuance costs april notes april notes may redeemed option time time time redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus basis points case april notes basis points case april notes basis points case april notes plus case accrued unpaid interest notes redeemed date redemption time date three months prior maturity date april notes may redeem april notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption time date six months prior maturity date april notes may redeem april notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption event occurrence change control downgrade rating april notes investment grade standard poor 's ratings services moody 's investors service inc holders may require us purchase portion notes price equal aggregate principal amount notes repurchased plus accrued unpaid interest date repurchase used net proceeds general corporate purposes include repayment existing indebtedness repurchases common stock february senior unsecured notes november issued senior unsecured notes due february february february february notes february notes february notes respectively collectively february notes registered offering million billion billion respectively aggregate principal amount billion february notes february notes february notes pay interest fixed annual rates respectively debt issuance costs incurred connection issuance debt totaled approximately million amortized interest expense contractual term respective notes recognized million interest expense related contractual coupon rates amortization debt discount issuance costs february notes february notes may redeemed option time time time redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus basis points case february notes basis points february notes basis points february notes case accrued unpaid interest also redeemed date redemption time date three months prior maturity date february notes may redeem february notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption time date six months prior maturity date february notes may redeem february notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption event occurrence change control downgrade rating february notes investment grade standard poor 's ratings services moody 's investors service inc holders may require us purchase portion february notes price equal aggregate principal amount notes repurchased plus accrued unpaid interest date repurchase use net proceeds general corporate purposes include repayment existing indebtedness repurchases common stock credit facilities january conjunction acquisition pharmasset entered fiveyear billion revolving credit facility credit agreement five year revolving credit agreement million shortterm revolving credit facility credit agreement shortterm revolving credit agreement billion term loan facility term loan credit agreement borrowed million fiveyear revolving credit agreement million shortterm revolving credit agreement billion term loan credit agreement upon close acquisition fully repaid outstanding debt term loan credit agreement shortterm revolving credit agreement time agreements terminated repaid million fiveyear revolving credit agreement repaid remaining balance million outstanding fiveyear revolving credit agreement fiveyear revolving credit agreement contains customary representations warranties affirmative negative financial maintenance covenants events default loan bears interest either eurodollar rate plus applicable margin ii base rate plus applicable margin defined credit agreement may reduce commitments may prepay loan whole part time without premium penalty required comply certain covenants credit agreement notes indentures december violation covenants fiveyear revolving credit agreement inclusive million swing line loan subfacility million letter credit subfacility fiveyear revolving credit agreement terminate amounts owed agreement shall due payable january contractual maturities financing obligations based contractual due dates aggregate maturities financing obligations due subsequent december follows millions maturity date amount total commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities lease facilities foster city fremont la verne palo alto rancho cucamonga san dimas california branford connecticut seattle washington dublin cork areas ireland london area united kingdom dubai united arab emirates also operating leases sales marketing administrative facilities europe canada south america asiapacific leases expire various dates many leases containing options renew certain facility leases also contain rent escalation clauses significant rent escalation clause lease related facility seattle washington expires year term lease provides us three consecutive rights extend term lease contains annual three percent rent escalation clause lease also requires us pay additional amounts operating expenses maintenance also leases four corporate aircraft varying terms renewal options upon expiration initial lease terms lease expense operating leases approximately million million million aggregate noncancelable future minimum rental payments operating leases follows millions thereafter total legal proceedings party various legal actions significant described possible determine outcome matters reasonably estimate maximum potential exposure range possible loss litigation related sofosbuvir january acquired pharmasset acquisition acquired sofosbuvir nucleotide analog acts inhibit replication hcv december received fda approval sofosbuvir known commercially sovaldi october also received approval fixeddose combination ledipasvir sofosbuvir known commercially harvoni patents patent applications claim sofosbuvir sovaldi chemical entity metabolites fixeddose combination ledipasvir sofosbuvir harvoni third parties may may obtain rights patents allegedly could used prevent attempt prevent us commercializing sovaldi harvoni example aware patents patent applications owned parties may alleged parties cover use sovaldi harvoni predict ultimate outcome intellectual property claims related sovaldi harvoni spent continue spend significant resources defending claims parties successfully obtain valid enforceable patents successfully prove infringement patents sovaldi andor harvoni could prevented selling sofosbuvir unless able obtain license patents license may available commerciallyreasonable terms predict ultimate outcome intellectual property claims related sofosbuvir may spend significant resources enforcing defending patents range loss estimated time current legal proceedings significance regarding sofosbuvir include arbitration f hoffmanla roche ltd hoffmanla roche inc collectively roche gilead successor pharmasset party collaboration agreement roche agreement granted roche rights develop psi cytidine analog prodrugs treatment hcv infection collaborative research efforts agreement ended march roche served arbitration us pharmasset predecessor gilead pharmasset llc arbitration demand roche asserted exclusive license sofosbuvir pursuant collaboration agreement sofosbuvir prodrug uridine analog allegedly prodrug psi cytidine analog roche claimed exclusive rights sofosbuvir also exclusive license patent covering sofosbuvir infringed patent selling offering sale products containing sofosbuvir gilead gilead pharmasset llc filed response roche 's arbitration demand april arbitration hearing held june august arbitration panel determined roche failed establish claims ruled favor result roche entitled damages relief interference proceedings litigation idenix pharmaceuticals inc february received notice us patent trademark office uspto declared interference first idenix interference us patent patent idenix 's pending us patent application interference administrative proceeding uspto designed determine first invent subject matter claimed parties patent covers metabolites sofosbuvir idenix attempting patent class compounds including metabolites purpose first idenix interference determine first invent compounds therefore entitled patent claiming compounds march uspto patent trial appeal board board determined idenix entitled benefit early application filing dates none patent applications including application granted idenixs us patent patent taught make compounds dispute board also determined entitled filing date earliest application first file patent application compounds dispute therefore senior party first idenix interference january board determined pharmasset idenix first invent compounds dispute accordingly gilead prevailed first idenix interference decision board held idenix failed prove first conceive compounds dispute specifically idenix failed prove idenix inventors identified structure method making use disputed compounds board went conclude idenix failed work diligently toward making testing compounds dispute relevant time period idenix appealed boards decisions us district court district delaware december receiving request uspto declared interference second idenix interference pending us patent application patent patent includes claims directed methods treating hcv nucleoside compounds similar involved first idenix interference second idenix interference determine first invent claimed methods treating hcv january board issued decision favor gilead first phase second idenix interference board decided first file patent application disputed methods treating hcv designated gilead senior party second idenix interference invalidated patent claims idenix patent involved second idenix interference senior party presumed first invented disputed methods treating hcv idenix failed teach make use invention patent board invalidated idenix claims involved second idenix interference lack enablement board also placed idenix order show cause requiring idenix explain judgment entered second idenix interference based upon decision board first idenix interference decision second idenix interference consistent boards earlier rulings march january first idenix interference gilead declared senior party first invent certain fluoro methyl nucleoside compounds compounds relevant methods treating hcv issue second idenix interference believe idenix claims involved first second idenix interferences similar us foreign patents claiming compounds metabolites uses thereof invalid result filed impeachment action federal court canada invalidate idenix canadian patent patent canadian patent corresponds patent idenix patent application subject first idenix interference idenix asserted commercialization sovaldi canada infringe patent canadian patent corresponding patent involved first idenix interference invalid trial issues commenced january filed similar legal action norway oslo district court seeking invalidate idenix 's norwegian patent corresponding patent september idenix filed invalidation action norwegian proceedings norwegian patent patent corresponds patent march norwegian court found claims idenix norwegian patent invalid upheld validity claims challenged gilead patent april idenix appealed march decision norwegian court appeal idenixs obligation pay attorneys fees stayed pendency appeal appeal march decision scheduled commence february january filed legal action federal court australia seeking invalidate idenixs australian patent corresponding patent april idenix asserted commercialization sovaldi australia infringe australian patent corresponding patent trial issues scheduled commence september sydney march european patent office epo granted idenix european patent patent corresponds patent day patent granted filed opposition epo seeking revoke patent also day idenix initiated infringement proceedings gilead united kingdom uk germany france alleging commercialization sovaldi countries would infringe respective national counterparts patent united kingdom trial held october determine issues infringement validity idenix uk patent december high court justice england wales uk court invalidated claims patent multiple grounds specifically uk court held patent lacked novelty earlier filed patent application teaching compounds patent lacked inventive step add anything knowledge existing time disclosure idenixs patent application insufficient teach make compounds show claimed compounds would activity viruses like hepatitis c virus uk court granted idenix permission appeal december judgment february german court dsseldorf held hearing determine issue infringement idenix german patent trial date french lawsuit idenix awarded patents corresponding patent japan china event patents issue expect challenge proceedings similar invoked countries december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringe patent interference exists patent us patent also december idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringe us patent nos june court massachusetts granted request transferred massachusetts litigation us district court district delaware believe idenixs patents invalid would infringed commercialization sofosbuvir sole right commercialize sofosbuvir district court set trial dates october december resolution issues decision district court appealed either party us court appeals federal circuit cafc idenix acquired merck august acquisition change view lack merit claims made idenix merck greater resources idenix may therefore choose fund litigation higher levels idenix litigation merck co inc august merck contacted us requesting pay royalties sales sofosbuvir obtain license us patent nos coowns isis pharmaceuticals inc believe mercks patents invalid infringed commercialization sofosbuvir sole right commercialize sofosbuvir august filed lawsuit us district court northern district california seeking declaratory judgment merck patents invalid infringed mercks us patent nos cover compounds include may relate sofosbuvir patent prosecution merck amended patent application attempt cover compounds related sofosbuvir apparent goal ultimately extracting royalty payments sofosbuvirs commercialization eliminating competition excluding market court determines mercks patents valid infringed claims may required obtain license pay royalties merck commercialize sofosbuvir either party appeal decision district court cafc court set trial date march lawsuit litigation abbvie inc abbvie abbvie obtained us patent nos abbvie patents purport cover use combination ledipasvirsofosbuvir harvoni treatment hcv gilead aware abbvie pending patent applications united states countries published pending patent applications directed use combinations treatment hcv specifically combination ledipasvir sofosbuvir certain applications filed abbvie patents reason others believe abbvie patents invalid accordingly december filed lawsuit us district court district delaware seeking declaratory judgment abbvie patents invalid unenforceable well relief believe abbott laboratories inc abbvie conspired eliminate competition hcv market falsely representing uspto gilead invented methods treating hcv using combination ledipasvirsofosbuvir february march abbvie responded lawsuit filing two lawsuits also us district court district delaware alleging fixeddose combination ledipasvirsofosbuvir infringe patents lawsuits consolidated single action united states either party appeal decision district court cafc abbvie patents blocked delayed commercialization combination product united states europe expect foreign patents block delay commercialization around world court determines abbvie patents valid infringed claims may required obtain license pay royalties abbvie commercialize sofosbuvir combination products litigation generic manufacturers part approval process products fda granted us new chemical entity nce exclusivity period manufacturers ' applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug sale generic versions products earlier patent expiration would significant negative effect revenues results operations current legal proceedings significance generic manufacturers include mylan inc mylan april received notice mylan submitted anda fda requesting permission manufacture market generic version truvada notice mylan alleges two patents associated emtricitabine one patents associated fixeddose combination emtricitabine tenofovir disoproxil fumarate invalid unenforceable andor infringed mylan 's manufacture use sale generic version truvada june filed lawsuit mylan us district court northern district west virginia infringement patents june received notice mylan inc submitted petitions inter partes review ipr board alleging four patents associated tenofovir disoproxil fumarate invalid opposed mylans petitions december uspto patent trial appeal board ptab issued decisions denying mylans petitions ipr tenofovir disoproxil fumarateassociated patents grounds mylan established reasonable likelihood success would prevail challenge patents mylan requested rehearing basis believes ptab decision wrong apotex corp apotex june received notice apotex submitted ands canadian minister health requesting permission manufacture market generic fixeddose combination emtricitabine tenofovir disoproxil fumarate separate ands requesting permission manufacture market generic version viread notice apotex alleges three patents associated truvada two patents associated viread invalid unenforceable andor infringed apotex 's manufacture use sale generic version truvada viread august filed lawsuit apotex federal court canada seeking order prohibition approval ands teva pharmaceuticals teva received notice teva submitted andss canadian minister health requesting permission manufacture market generic fixeddose combination atripla truvada viread teva filed impeachment action federal court canada seeking invalidation certain patents associated atripla truvada viread december court issued requested order prohibiting canadian minister health issuing notice compliance tevas generic versions viread truvada atripla products expiry patent july teva appealed decision decision rule validity patents accordingly issue appeal whether minister health prohibited issuing notices compliance tevas products separately court determine validity patents pending impeachment action trial impeachment action scheduled september teva successful invalidating patents teva may able launch generic versions viread truvada atripla products canada prior expiry patents department justice investigation june received subpoena us attorney 's office northern district california requesting documents related manufacture related quality distribution practices complera atripla truvada viread emtriva hepsera letairis cooperated governments inquiry april united states department justice informed us following investigation declined intervene false claims act lawsuit filed two former employees april former employees served first amended complaint january federal district court issued order granting entirety without prejudice motion dismiss first amended complaint february former employees served second amended complaint move dismiss second amended complaint matters party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations commitments normal course business enter various firm purchase commitments primarily related active pharmaceutical ingredients certain inventory related items december commitments next five years approximately billion million million million million amounts related active pharmaceutical ingredients represent minimum purchase requirements actual payments purchases related active pharmaceutical ingredients billion billion billion stockholders ' equity stock repurchase programs january board authorized threeyear billion stock repurchase program program program spent total million repurchase retire million shares common stock average purchase price per share million repurchase retire million shares common stock average purchase price per share billion repurchase retire million shares common stock average purchase price per share third quarter completed program may board directors authorized new stock repurchase program program billion common stock program spent total billion repurchase retire million shares common stock average purchase price per share december remaining authorized amount stock repurchases may made program billion spent billion repurchase million shares common stock total average price use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated additional paidin capital apic based estimated average sales price per issued share excess amounts charged retained earnings addition repurchases stock repurchase program repurchased shares common stock withheld us employee restricted stock awards satisfy applicable tax withholding obligations following table summarizes reduction common stock apic charge retained earnings result stock repurchases millions year ended december reduction common stock apic charge retained earnings preferred stock million shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series preferred stock outstanding december rights plan september terminated rights plan provided distribution preferred stock purchase right dividend share common stock accumulated comprehensive income following table summarizes changes accumulated oci component net tax millions unrealized gains losses unrealized gains foreign currency availableforsale losses cash items securities flow hedges total balance december comprehensive income loss reclassifications amounts reclassified accumulated comprehensive income net current period comprehensive income loss balance december comprehensive income loss reclassifications amounts reclassified accumulated comprehensive income net current period comprehensive income loss balance december amounts reclassified gains losses cash flow hedges recorded part product sales consolidated statements income amounts reclassified unrealized gains losses availableforsale securities recorded part income expense net consolidated statements income employee benefits equity incentive plan may stockholders approved adopted gilead sciences inc equity incentive plan plan plan broad based incentive plan provides grant equitybased awards including stock options restricted stock units restricted stock awards performance awards employees directors consultants plan authorized issue maximum million shares fullvalue awards restricted stock restricted stock units performance shares performance units extent settled common stock phantom shares term plan plan authorizes issuance total million shares common stock december total million shares remain available future grant plan stock options plan provides option grants designated either nonqualified incentive stock options prior january granted nonqualified incentive stock options stock options granted january nonqualified stock options plan employee stock options granted prior generally vest five years stock options granted starting generally vest four years options exercisable period exceed contractual term ten years date stock options issued granted prices less fair market value common stock grant date stock option exercises settled common stock plan 's previously authorized available pool shares following table summarizes activity related information stock option plans option grants presented table exercise prices less fair value underlying common stock grant date weighted weightedaverage average remaining shares exercise price contractual term aggregate intrinsic thousands dollars years value millions outstanding december granted forfeited expired exercised outstanding december exercisable december expected vest net estimated forfeitures december aggregate intrinsic value represents value company 's closing stock price last trading day period excess weightedaverage exercise price multiplied number options outstanding exercisable total intrinsic value options exercised billion million million weightedaverage grant date fair values stock options granted per share per share per share december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years performancebased restricted stock units plan grant psus vest upon achievement specified market performance goals could include achieving total shareholder return compared predetermined peer group achieving revenue targets actual number common shares ultimately issued calculated multiplying number psus payout percentage ranging awards generally vest committee subcommittee board determined specified market performance goals achieved fair value psu estimated date grant performance objectives defined grants depending terms award fair value date grant determined based either monte carlo valuation methodology stock price date grant addition also granted psus certain employees plan vesting awards subject achievement specified individual performance goals typically within one year period fair value award equal closing price common stock grant date following table summarizes activity related information psus weighted average grantdate fair value per shares share thousands dollars outstanding december granted vested forfeited outstanding december weightedaverage grantdate fair value per share excludes shares related grants currently grantdate fair value performance objectives yet defined weightedaverage grant date fair values psus granted per share per share per share total fair value psus vested million million million recognized stockbased compensation expenses million million million related psus december million unrecognized compensation costs related psus expected recognized estimated weighted average period years restricted stock units grant timebased rsus certain employees part annual employee equity compensation review program well new hire employees nonemployee members board rsus share awards entitle holder receive freely tradable shares common stock upon vesting awards granted prior employees rsus vest ratably annual basis five years date grant starting january rsus vest four years date grant fair value rsu equal closing price common stock grant date following table summarizes rsu activities related information weighted average grantdate fair value per shares share thousands dollars outstanding december granted assumed vested forfeited outstanding december weightedaverage grant date fair values rsus granted per share per share per share total fair value rsus vested million million million december million unrecognized compensation cost related unvested rsus expected recognized weightedaverage period years employee stock purchase plan employee stock purchase plan amended international employee stock purchase plan together espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date espp offers twoyear lookback feature well automatic reset feature provides offering period reset new lowerpriced offering offering price new offering period less current offering period espp purchases settled common stock espp 's previously authorized available pool shares million shares issued espp million total million shares common stock reserved issuance espp million shares available issuance espp december december million unrecognized compensation cost related espp expected recognized estimated weightedaverage period years stockbased compensation following table summarizes stockbased compensation expenses included consolidated statements income millions year ended december cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense net tax capitalized stockbased compensation costs inventory totaling million million million capitalized stockbased compensation costs remaining inventory million december million december million december total stockbased compensation year ended december included million million rd sga expenses respectively related acceleration unvested stock options connection acquisition pharmasset closed first quarter stockbased compensation recognized expense requisite service periods consolidated statements income using graded vesting expense attribution approach unvested stock options granted prior january using straightline expense attribution approach stock options granted adoption new guidance sharebased payments employees directors january stockbased compensation expenses related stock options recognized adoption new guidance based awards ultimately expected vest gross expense reduced estimated forfeitures guidance requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates estimated forfeitures based historical experience prior adoption guidance pro forma information required disclosed included forfeitures occurred result guidance adopted january recognize tax benefit stockbased compensation apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements income rather apic valuation assumptions fair values options granted plan purchases espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life used following assumptions calculate estimated fair value awards year ended december expected volatility stock options espp expected term years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted calculated using single option approach use blend historical volatility along implied volatility traded options common stock determine expected volatility expected term stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected term based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts deferred compensation maintain retirement saving plan eligible us employees may defer compensation income tax purposes section k internal revenue code gilead plan certain foreign subsidiaries maintain defined benefit plans required local regulatory requirements total matching contribution expense gilead plan defined benefit plans million million million net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding period diluted net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding dilutive securities outstanding period potential dilutive shares common stock resulting assumed exercise outstanding stock options psus assumed exercise warrants relating convertible senior notes including may notes may notes may notes determined treasury stock method principal amount may notes may notes may notes settled cash conversion spread relating respective notes included calculation diluted net income per share attributable gilead common stockholders common stock resulting assumed settlement conversion spread may notes may notes dilutive effect average market price common stock period exceeds conversion price may notes may notes warrants relating may notes may notes dilutive effect average market price common stock period exceeds warrants ' exercise price may notes may notes may notes may notes matured result included impact periods outstanding net income per share calculations periods shown common stock resulting assumed settlement conversion spread may notes may notes dilutive effect average market price common stock period exceeded conversion price may notes may notes warrants related may notes may notes settled result included impact period outstanding net income per share calculations related warrants dilutive effect average market price common stock period exceeded warrants ' exercise price may notes may notes excluded stock options purchase approximately million weightedaverage shares common stock outstanding less million weightedaverage shares million weightedaverage shares computation diluted net income per share attributable gilead common stockholders effect antidilutive following table reconciliation numerator denominator used calculation basic diluted net income per share attributable gilead common stockholders millions year ended december net income attributable gilead shares used per share calculation basic effect dilutive securities stock options equivalents conversion spread related may notes conversion spread related may notes conversion spread related may notes warrants related may notes shares used per share calculation diluted net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders diluted segment information product sales operate one business segment primarily focuses discovery development commercialization innovative medicines areas unmet medical need products included one segment majority products similar economic characteristics including nature products production processes type customers distribution methods regulatory environment product sales consist following millions year ended december antiviral products sovaldi atripla truvada harvoni compleraeviplera stribild viread antiviral total antiviral products products letairis ranexa ambisome zydelig total product sales following table summarizes total revenues external customers collaboration partners geographic region millions product sales productrelated contract revenue attributed regions based shipto location royalty nonproduct related contract revenue attributed regions based location collaboration partner year ended december revenues united states europe countries total revenues following table summarizes revenues customers individually accounted total revenues percentage total revenues year ended december amerisourcebergen corp mckesson corp cardinal health inc longlived assets december net book value property plant equipment less office computer equipment united states ireland canada billion million million respectively december net book value property plant equipment less office computer equipment united states ireland canada million million million respectively income taxes provision income taxes consists following millions year ended december federal current deferred state current deferred foreign current deferred provision income taxes foreign pretax income billion million million cumulative unremitted foreign earnings considered indefinitely reinvested foreign subsidiaries us taxes provided approximately billion december billion december residual us tax liability amounts remitted would approximately billion december billion december reconciliation federal statutory tax rate applied income taxes effective tax rate summarized follows year ended december federal statutory rate state taxes net federal benefit foreign earnings different rates research credits net unbenefitted stock compensation effective tax rate deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows millions december deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible deferred revenue depreciation related research credit carryforwards net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities intangibles unremitted foreign earnings total deferred tax liabilities net deferred tax assets valuation allowance million december december december concluded based standard set forth financial accounting standards board accounting standards codification related income taxes likely realize benefit deferred tax assets related certain state net operating loss credit carryforwards december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards start expire utilized also federal tax credit carryforwards approximately million start expire utilized addition state net operating loss tax credit carryforwards approximately billion million respectively state net operating loss tax credit carryforwards start expire utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization file federal state foreign income tax returns many jurisdictions united states abroad federal income tax purposes statute limitations open onwards certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years california income tax purposes statute limitations open onwards income tax returns audited federal state foreign tax authorities currently examination irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions total federal state foreign unrecognized tax benefits million december million december total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements income accrued interest penalties related unrecognized tax benefits million december december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs tax authorities regarding uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities following rollforward total gross unrecognized tax benefit liabilities years ended december millions december balance beginning period tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance end period subsequent events february announced board directors authorized new billion fiveyear share repurchase program initiate completion program february also announced initiation quarterly dividend per share begin second quarter subject declaration board directors quarterly dividend equivalent per share annual basis selected quarterly financial information unaudited following amounts millions except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted gilead sciences inc schedule ii valuation qualifying accounts millions balance additionscharged balance end beginning period expense deductions period year ended december accounts receivable allowances sales return allowance valuation allowances deferred tax assets year ended december accounts receivable allowances sales return allowance valuation allowances deferred tax assets year ended december accounts receivable allowances sales return allowance valuation allowances deferred tax assets allowances doubtful accounts cash discounts chargebacks valuation allowance deferred tax assets includes million million december respectively related acquisitions item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae securities exchange act amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commission 's rules forms information accumulated communicated company 's management including chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective december b management 's report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included annual report issued report internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting report independent registered public accounting firm board directors stockholders gilead sciences inc audited gilead sciences inc 's internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission framework coso criteria gilead sciences inc 's management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinion company 's internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion gilead sciences inc maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated financial statements gilead sciences inc report dated february expressed unqualified opinion thereon ernst young llp redwood city california february item b information applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings nominees board committees meetings executive officers section beneficial ownership reporting compliance written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwgileadcom investors section corporate governance changes waivers code ethics disclosed website intend satisfy disclosure requirement item form k regarding amendment waiver provision code ethics disclosing information website item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee interlocks insider participation compensation committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference sections proxy statement headings security ownership certain beneficial owners management securities authorized issuance equity compensation plans item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings nominees certain relationships related party transactions item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services part iv item